WO2005027978A2 - Albumin-binding derivatives of therapeutic peptides - Google Patents

Albumin-binding derivatives of therapeutic peptides Download PDF

Info

Publication number
WO2005027978A2
WO2005027978A2 PCT/DK2004/000624 DK2004000624W WO2005027978A2 WO 2005027978 A2 WO2005027978 A2 WO 2005027978A2 DK 2004000624 W DK2004000624 W DK 2004000624W WO 2005027978 A2 WO2005027978 A2 WO 2005027978A2
Authority
WO
WIPO (PCT)
Prior art keywords
ethoxy
glp
lys
xaa
acetyl
Prior art date
Application number
PCT/DK2004/000624
Other languages
French (fr)
Other versions
WO2005027978A3 (en
Inventor
Jesper Lau
Thomas Kruse Hansen
Kjeld Madsen
Paw Bloch
Florencio Zaragoza DÖRWALD
Nils Langeland Johansen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP15152442.8A priority Critical patent/EP2932981B1/en
Priority to US10/572,348 priority patent/US20070203058A1/en
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to JP2006526519A priority patent/JP4949838B2/en
Priority to KR1020067005530A priority patent/KR101241862B1/en
Priority to CA002539253A priority patent/CA2539253A1/en
Priority to BR122019021416A priority patent/BR122019021416A2/pt
Priority to BRPI0414539A priority patent/BRPI0414539B8/en
Priority to EP04762844A priority patent/EP1670515A2/en
Priority to MXPA06002941A priority patent/MXPA06002941A/en
Priority to AU2004273573A priority patent/AU2004273573B2/en
Publication of WO2005027978A2 publication Critical patent/WO2005027978A2/en
Publication of WO2005027978A3 publication Critical patent/WO2005027978A3/en
Priority to IL174154A priority patent/IL174154A/en
Priority to NO20061722A priority patent/NO343825B1/en
Priority to US12/774,131 priority patent/US20100305032A1/en
Priority to AU2010203063A priority patent/AU2010203063B2/en
Priority to US13/427,791 priority patent/US20130053315A1/en
Priority to US13/427,667 priority patent/US20130040884A1/en
Priority to US13/903,662 priority patent/US20130244931A1/en
Priority to US14/750,095 priority patent/US20160108102A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to novel derivatives of glucagon-like-peptide-1 (GLP-1 ) and fragments thereof and analogues of such fragments which have a protracted profile of action and methods of making and using them.
  • the invention furthermore relates to novel derivatives of exendin and the use of such derivatives.
  • Peptides are widely used in medical practice, and since they can be produced by recombinant DNA technology it can be expected that their importance will increase also in the years to come. When native peptides or analogues thereof are used in therapy it is generally found that they have a high clearance. A high clearance of a therapeutic agent is inconvenient in cases where it is desired to maintain a high blood level thereof over a prolonged period of time since repeated administrations will then be necessary.
  • Examples of peptides which have a high clearance are: ACTH, corticotropin-releasing factor, angiotensin, calcitonin, insulin, glucagon, glucagon-like peptide-1 , glucagon-like peptide-2, insulin-like growth factor-1 , insulin-like growth factor-2, gastric inhibitory peptide, growth hormone-releasing factor, pituitary adenylate cyclase activating peptide, secretin, enterogastrin, somatostatin, somatotropin, somatomedin, parathyroid hormone, thrombopoietin, erythropoietin, hypothalamic releasing factors, prolactin, thyroid stimulating hormones, endorphins, enkephalins, vasopressin, oxytocin, opiods and analogues thereof, superoxide dismutase, interferon, asparaginase, arginase, arginine deamina
  • Endogenous peptides and proteins with interesting biological activities is growing rapidly, also as a result of the ongoing exploration of the human genome. Due to their biological activities, many of these polypeptides could in principle be used as therapeutic agents. Endogenous peptides are, however, not always suitable as drug candidates because these peptides often have half-lives of few minutes due to rapid degradation by pepti- dases and/or due to renal filtration and excretion in the urine. The half-life of polypeptides in human plasma varies strongly (from a few minutes to more than one week). Similarly, the half-life of small molecule drugs is also highly variable.
  • Serum albumin has a half-life of more than one week, and one approach to increasing the plasma half-life of peptides has been to derivatize the peptides with a chemical entity that binds to serum albumin.
  • the present invention relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer.
  • the present invention also relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer that separates the polypeptide and the albumin binding residue with a chemical moiety comprising at least 5 non-hydrogen atoms where 30-50% of these atoms are either N or O.
  • the spacer is defined as -(CH 2 )
  • Q is -Z-(CH 2 ),D[(CH 2 ) n G] ⁇ (CH 2 )p- I q is an integer in the range from 0 to 5, each D, E, and G independently are selected from -O-, -NR 3 -, -N(COR 4 )-, -PR 5 (O)-, and -P(OR 6 )(O)-, wherein R 3 , R 4 , R 5 , and R 6 independently represent hydrogen or d- ⁇ -alkyl,
  • Z is selected from -C(O)NH-, -C(O)NHCH 2 -, -OC(O)NH -, -C(O)NHCH 2 CH 2 -,
  • the present invention also relates to a compound which has the formula (I) A— W — B — Y— therapeutic polypeptide (I) wherein
  • A is an albumin binding residue
  • B is a hydrophilic spacer being -(CH 2 ) ⁇ D[(CH 2 ) n E] m (CH 2 )pQq-, wherein I, m and n independently are 1-20 and p is 0-10,
  • Q is -Z-(CH 2 ) l D[(CH 2 ) n G] m (CH 2 )p-, q is an integer in the range from 0 to 5, each D, E, and G independently are selected from -O-, -NR 3 -, -N(COR 4 )-, -PR 5 (O)-, and -P(OR 6 )(O)-, wherein R 3 , R 4 , R 5 , and R 6 independently represent hydrogen or Ci- ⁇ -alkyl,
  • Z is selected from -C(O)NH-, -C(O)NHCH 2 -, -OC(O)NH -, -C(O)NHCH 2 CH 2 -,
  • Y is a chemical group linking B and the therapeutic agent
  • W is a chemical group linking A and B.
  • the present invention also relates to a compound which has the formula (II) A-W— B— Y-therapeutic polypeptide — Y'-B'-W — A' (II) wherein A and A ' are albumin binding residues,
  • B and B ' are hydrophilic spacers independently selected from -(CH 2 ) ⁇ D [(CH 2 ) n E] m (CH 2 )p-Qq-, wherein
  • I, m and n independently are 1-20 and p is 0-10, Q is -Z-(CH2)
  • Y is a chemical group linking B and the therapeutic agent
  • Y ' is a chemical group linking B ' and the therapeutic agent
  • W is a chemical group linking A and B
  • W " is a chemical group linking A ' and B'.
  • a and A ' are albumin binding residues
  • B is a hydrophilic spacer selected from -(CH2) ⁇ D[(CH 2 )nE] m (CH 2 )p-Qq- wherein I, m and n independently are 1-20 and p is 0-10, Q is -Z-(CH 2 ),D[(CH 2 ) n G] m (CH 2 ) p -, q is an integer in the range from 0 to 5, each D, E, and G are independently selected from -O-, -NR 3 -, -N(COR 4 )-, -PR 5 (O)-, and -P(OR 6 )(O)-, wherein R 3 , R 4 , R 5 , and R 6 independently represent hydrogen or Ci- ⁇ -alkyl, Z is selected from -C(O)NH-, -C(O)NHCH 2 -, -OC(O)NH -, -C(O)NHCH 2 CH 2 -,
  • Y is a chemical group linking B and the therapeutic agent
  • W" is a chemical group linking B with A and A'.
  • the present invention relates to a compound comprising a hydrophilic spacer between a therapeutic peptide and one or more albumin binding residue(s), said compound having a protracted profile of action relative to the therapeutic polypeptide, where the albumin binding fraction as well as the free fraction of said compound are both able to bind to the receptor mediating the effect of the therapeutic polypeptide.
  • the hydrophilic spacer is an unbranched oligo ethylene glycol moiety with appropiate funtional groups at both terminals that forms a bridge between an amino group of the therapeutic polypeptide and a funtional group of the albumin binding residue.
  • the therapeutic polypeptide is a GLP-1 peptide.
  • albumin binding residue means a residue which binds non- covalently to human serum albumin.
  • the albumin binding residue attached to the therapeutic polypeptide typically has an affinity below 10 ⁇ M to human serum albumin and preferably below 1 ⁇ M.
  • a range of albumin binding residues are known among linear and branched lipoho- phillic moieties containing 4-40 carbon atoms, compounds with a cyclopentanophenanthrene skeleton, peptides having 10-30 amino acid residues etc.
  • hydrophilic spacer as used herein means a spacer that separates a peptide and an albumin binding residue with a chemical moiety which comprises at least 5 non- hydrogen atoms where 30-50% of these are either N or O.
  • therapeutic polypeptide as used herein means a polypeptide which is being developed for therapeutic use, or which has been developed for therapeutic use.
  • polypeptide and peptide as used herein means a compound composed of at least five constituent amino acids connected by peptide bonds.
  • the constituent amino acids may be from the group of the amino acids encoded by the genetic code and they may be natural amino acids which are not encoded by the genetic code, as well as synthetic amino acids.
  • Natural amino acids which are not encoded by the genetic code are e.g. hydroxyproline, y- carboxyglutamate, ornithine, phosphoserine, D-alanine and D-glutamine.
  • Synthetic amino ac- ids comprise amino acids manufactured by chemical synthesis, i.e.
  • D-isomers of the amino acids encoded by the genetic code such as D-alanine and D-leucine, Aib ( ⁇ -aminoisobutyric acid), Abu ( ⁇ -aminobutyric acid), Tie (tert-butylglycine), ⁇ -alanine, 3-aminomethy! benzoic acid, anthranilic acid.
  • analogue as used herein referring to a polypeptide means a modified pep- tide wherein one or more amino acid residues of the peptide have been substituted by other amino acid residues and/or wherein one or more amino acid residues have been deleted from the peptide and/or wherein one or more amino acid residues have been deleted from the peptide and or wherein one or more amino acid residues have been added to the peptide.
  • Such addition or deletion of amino acid residues can take place at the N-terminal of the peptide and/or at the C-terminal of the peptide.
  • [Arg 34 ]GLP-1 (7-37)Lys designates a GLP-1 analogue wherein the naturally occuring lysine at position 34 has been substituted with arginine and a lysine residue has been added to the C-terminal (position 38).
  • Formulae of peptide analogs and derivatives thereof are drawn using standard single letter abbreviation for amino acids used according to IUPAC-IUB no- menclature.
  • the term "derivative" as used herein in relation to a peptide means a chemically modified peptide or an analogue thereof, wherein at least one substituent is not present in the unmodified peptide or an analogue thereof, i.e.
  • GLP-1 (7-37) N ⁇ 26 -( ⁇ -Glu(N ⁇ -hexadecanoyl)))- [Arg 34 , Lys 26 ])GLP-1 (7- 37).
  • GLP-1 peptide as used herein means GLP-1 (7-37) (SEQ ID No. 1), a GLP-1 analogue, a GLP-1 derivative or a derivative of a GLP-1 analogue.
  • the GLP-1 peptide is an insulinotropic agent.
  • insulinotropic agent as used herein means a compound which is an agonist of the human GLP-1 receptor, i.e. a compound which stimulates the formation of cAMP in a suitable medium containing the human GLP-1 receptor. The potency of an insulinotropic agent is determined by calculating the EC 50 value from the dose-response curve as described below.
  • Purified plasma membranes from a stable transfected cell line, BHK467-12A (tk-ts13), expressing the human GLP-1 receptor was stimulated with GLP-1 and peptide analogues, and the potency of cAMP production was measured using the AlphaScreenTM cAMP Assay Kit from Perkin Elmer Life Sciences.
  • a stable transfected cell line has been prepared at NN and a high expressing clone was se- lected for screening. The cells were grown at 5% CO 2 in DMEM, 5% FCS, 1% Pen/Strep and 0.5 mg/ml G418.
  • Cells at approximate 80% confluence were washed 2X with PBS and harvested with Versene, centrifuged 5 min at 1000 rpm and the supernatant removed. The additional steps were all made on ice.
  • the suspension was homogenized for 20-30 sec and centrifuged 15 min at 20.000 rpm.
  • GLP-2 peptide as used herein means GLP-2(1-33), a GLP-2 analogue, a GLP-2 derivative or a derivative of a GLP-2 analogue.
  • exendin-4 peptide means exendin-4(1-39), an exendin-4 analogue, an exendin-4 derivative or a derivative of an exendin-4 analogue.
  • ex- endin-4 peptide is an insulinotropic agent.
  • stable exendin-4 peptide and "stable GLP-1 peptides” as used herein means chemically modified peptides derived from exendin-4(1-39) or GLP-1 (7-37), i.e. an analogue or a derivative which exhibits an in vivo plasma elimination half-life of at least 10 hours in man, as determined by the following method.
  • the method for determination of plasma elimination half- life of an exendin-4 peptide or a GLP-1 peptide in man is :
  • the peptide is dissolved in an isotonic buffer, pH 7.4, PBS or any other suitable buffer.
  • the dose is injected peripherally, preferably in the abdominal or upper thigh.
  • Blood samples for determination of active peptide are taken at frequent intervals, and for a sufficient duration to cover the terminal elimination part (e.g. Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 (day 2), 36 (day 2), 48 (day 3), 60 (day 3), 72 (day 4) and 84 (day 4) hours post dose).
  • Determination of the concentration of active peptide is performed as described in Wilken et al., Diabetologia 43(51 ):A143, 2000.
  • Derived pharmacoki- netic parameteres are calculated from the concentration-time data for each individual subject by use of non-compartmenta! methods, using the commercially available software WinNonlin Version 2.1 (Pharsight, Cary, NC, USA).
  • the terminal elimination rate constant is estimated by log-linear regression on the terminal log-linear part of the concentration-time curve, and used for calculating the elimination half-life.
  • DPP-IV protected as used herein referring to a polypeptide means a polypeptide which has been chemically modified in order to render said compound resistant to the plasma peptidase dipeptidyl aminopeptidase-4 (DPP-IV).
  • the DPP-IV enzyme in plasma is known to be involved in the degradation of several peptide hormones, e.g. GLP-1 , GLP-2, Exendin-4 etc.
  • GLP-1 peptide hormones
  • GLP-2 e.g. GLP-2
  • Exendin-4 e.g. GLP-1 , GLP-2, Exendin-4 etc.
  • Resistance of a peptide to degradation by dipeptidyl aminopeptidase IV is determined by the following degradation assay :
  • One method for performing this analysis is: The mixtures are applied onto a Zorbax 300SB-C18 (30 nm pores, 5 ⁇ m particles) 150 x 2.1 mm column and eluted at a flow rate of 0.5 ml/min with a linear gradient of acetonitrile in 0.1% trifluoroacetic acid (0% -100% acetonitrile over 30 min). Peptides and their degradation products may be monitored by their absorbance at 214 nm (peptide bonds) or 280 nm (aromatic amino acids), and are quantified by integration of their peak areas. The degradation pattern can be determined by using LC-MS where MS spectra of the separated peak can be determined.
  • Percentage intact/degraded compound at a given time is used for estimation of the peptides DPPIV stability.
  • a peptide is defined as DPPIV stabilised when it is 10 times more stable than the natural peptide based on percentage intact compound at a given time.
  • a DPPIV stabilised GLP-1 compound is at least 10 times more stable than GLP-1 (7-37).
  • C 1-6 -alkyl as used herein means a saturated, branched, straight or cyclic hydrocarbon group having from 1 to 6 carbon atoms. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, te/t-butyl, n- pentyl, isopentyl, neopentyl, fe/if-pentyl, n-hexyl, isohexyl, cyclohexane and the like.
  • the present invention relates to a compound which comprises a therapeutic polypep- tide linked to an albumin binding residue via a hydrophilic spacer.
  • the present invention also relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer that separates the polypeptide and the albumin binding residue with a chemical moiety comprising at least 5 non-hydrogen atoms where 30-50% of these atoms are either N or O.
  • the spacer is defined as -(CH 2 )
  • I, m and n independently are 1-20 and p is 0-10,
  • Q is -Z-(CH 2 ),D[(CH2)nG] m (CH 2 )p-, q is an integer in the range from 0 to 5, each D, E, and G independently are selected from -O-, -NR 3 -, -N(COR 4 )-, -PR 5 (O)-, and -P(OR 6 )(O)-, wherein R 3 , R 4 , R 5 , and R 6 independently represent hydrogen or
  • the present invention also relates to a compound which has the formula (I) : A— W — B — Y— therapeutic polypeptide (I) wherein
  • A is an albumin binding residue
  • B is a hydrophilic spacer being -(CH 2 )
  • Y is a chemical group linking B and the therapeutic agent
  • W is a chemical group linking A and B.
  • the present invention also relates to a compound which has the formula (II)
  • a and A ' are albumin binding residues
  • B and B ' are hydrophilic spacers independently selected from -(CH 2 )
  • I, m and n independently are 1-20 and p is 0-10, Q is -Z-(CH2) ⁇ D[(CH 2 )nG] m (CH2) P -, q is an integer in the range from 0 to 5, each D, E, and G independently are selected from -O-, -NR 3 -, -N(COR 4 )-, -PR 5 (O)-, and -P(OR 6 )(O)-, wherein R 3 , R 4 , R 5 , and R 6 independently represent hydrogen or
  • Z is selected from -C(O)NH-, -C(O)NHCH 2 -, -OC(O)NH -, -C(O)NHCH 2 CH 2 -,
  • Y is a chemical group linking B and the therapeutic agent
  • Y ' is a chemical group linking B ' and the therapeutic agent
  • W is a chemical group linking A and B
  • W is a chemical group linking A ' and B'.
  • the present invention relates to a compound which has the formula
  • a and A ' are albumin binding residues
  • B is a hydrophilic spacer selected from -(CH 2 )
  • I, m and n independently are 1-20 and p is 0-10,
  • Q is -Z-(CH 2 )iD[(CH 2 ) n G] m (CH 2 ) p -, q is an integer in the range from 0 to 5, each D, E, and G are independently selected from -O-, -NR 3 -, -N(COR 4 )-, -PR 5 (O)-, and -P(OR 6 )(O)-, wherein R 3 , R 4 , R 5 , and R 6 independently represent hydrogen or
  • Z is selected from -C(O)NH-, -C(O)NHCH 2 -, -OC(O)NH -, -C(O)NHCH 2 CH 2 -,
  • Y is a chemical group linking B and the therapeutic agent
  • W " is a chemical group linking B with A and A ' .
  • the present invention relates to a compound comprising a hydrophilic spacer between a therapeutic peptide and one or more albumin binding residue(s), said compound having a protracted profile of action relative to the therapeutic polypeptide, where the albumin binding fraction as well as the free fraction of said compound are both able to bind to the receptor mediating the effect of the therapeutic polypeptide.
  • the hydrophilic spacer is an unbranched oligo ethylene glycol moiety with appropiate funtional groups at both terminals that forms a bridge between an amino group of the therapeutic polypeptide and a funtional group of the albumin binding residue.
  • W " is selected from the group consisting of -C(0)NHCH- , -C(0)CH- , -(CH 2 ) S CH- , and -NHC(0)CNHC(O)CH 2 0(CH 2 ) 2 O(CH 2 ) 2 NH-
  • I is 1 or 2
  • n and m are independently 1-10 and p is 0-10.
  • D is -O-.
  • E is -O-.
  • the hydrophilic spacer is -CH 2 O[(CH 2 ) 2 O] m (CH 2 ) p Q q -, where m is 1-10, p is 1-3, and Q is -Z-CH 2 O[(CH 2 ) 2 O] m (CH 2 ) p -.
  • q is 1.
  • G is -O-.
  • Z is selected from the group consisting of • C(O)NH-, -C(O)NHCH 2 -, and -OC(O)NH-.
  • q is 0.
  • I is 2.
  • n is 2.
  • the hydrophilic spacer B is -[CH 2 CH 2 O] m+ ⁇ (CH 2 ) p Q q -.
  • the hydrophilic spacer B is -(CH 2 )rO-[(CH 2 ) ⁇ -O] ⁇ r(CH 2 )p-[C(O)NH-(CH 2 ) r O-[(CH 2 )n-O] m -(CH 2 )p] ⁇ r , where I, m, n, and p independently are 1-5, and q is 0-5.
  • the molar weight of the hydrophilic spacer is in the range from 80D to 1000D or in the range from 80D to 300D.
  • the albumin binding residue is a lipophilic residue.
  • albumin binding residue is negatively charged at physiological pH.
  • albumin binding residue comprises a group which can be negatively charged.
  • One preferred group which can be negatively charged is a carboxylic acid group.
  • the albumin binding residue binds non- covalently to albumin.
  • the albumin binding residue has a binding affinity towards human serum albumin that is below about 10 ⁇ M or below about 1 ⁇ M.
  • the albumin binding residue is selected from a straight chain alkyl group, a branched alkyl group, a group which has an ⁇ -carboxylic acid group, a partially or completely hydrogenated cyclopentanophenanthrene skeleton.
  • the albumin binding residue is a cibacronyl residue.
  • the albumin binding residue has from 6 to 40 carbon atoms, from 8 to 26 carbon atoms or from 8 to 20 carbon atoms.
  • the albumin binding residue is an acyl group selected from the group comprising CH 3 (CH 2 ) r CO-, wherein r is an integer from 4 to 38, preferably an integer from 4 to 24, more preferred selected from the group comprising CH 3 (CH 2 ) 6 CO-, CH 3 (CH 2 ) 8 CO-, CH 3 (CH 2 ) 10 CO-, CH 3 (CH 2 ) 12 CO-, CH 3 (CH 2 ) ⁇ 4 CO-, CH 3 (CH 2 ) 16 CO-, CH 3 (CH 2 ) ⁇ 8 CO-, CH 3 (CH 2 ) 20 CO- and CH 3 (CH 2 ) 22 CO-.
  • r is an integer from 4 to 38, preferably an integer from 4 to 24, more preferred selected from the group comprising CH 3 (CH 2 ) 6 CO-, CH 3 (CH 2 ) 8 CO-, CH 3 (CH 2 ) 10 CO-, CH 3 (CH 2 ) 12 CO-, CH 3 (CH 2 ) ⁇ 4 CO-, CH 3 (CH 2 ) 16 CO-, CH
  • albumin binding residue is an acyl group of a straight-chain or branched alkane ⁇ , ⁇ -dicarboxylic acid.
  • the albumin binding residue is an acyl group selected from the group comprising HOOC(CH 2 ) s CO-, wherein s is an integer from 4 to 38, preferably an integer from 4 to 24, more preferred selected from the group comprising HOOC(CH 2 ) ⁇ CO-, HOOC(CH 2 ) ⁇ 6 CO-, HOOC(CH 2 ) ⁇ 8 CO-, HOOC(CH 2 ) 20 CO- and HOOC(CH 2 ) 22 CO-.
  • albumin binding residue is a group of the formula CH 3 (CH 2 ) v CO-NHCH(COOH)(CH 2 ) 2 CO-, wherein v is an integer of from 10 to 24.
  • albumin binding residue is a group of the formula CH 3 (CH 2 ) w CO-NHCH((CH 2 ) 2 COOH)CO-, wherein w is an integer of from 8 to 24.
  • albumin binding residue is a group of the formula COOH(CH 2 ) x CO- wherein x is an integer of from 8 to 24. In another embodiment the albumin binding residue is a group of the formula
  • the albumin binding residue is a peptide, such as a peptide comprising less than 40 amino acid residues.
  • a number of small peptides which are albumin binding residues as well as a method for their identification is found in J. Biol Chem. 277, 38 (2002) 35035-35043.
  • albumin binding residue via spacer and linkers is attached to said therapeutic polypeptide via the ⁇ -amino group of a lysine residue.
  • albumin binding residue via spacer and linkers is attached to said therapeutic polypeptide via an amino acid residue selected from cysteine, glutamate and aspartate.
  • the therapeutic polypeptide is a GLP-1 peptide.
  • the therapeutic polypeptide is a GLP-1 pep- tide comprising the amino acid sequence of the formula (IV):
  • Xaa 7 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, ⁇ -hydroxy-histidine, homohistidine, N ⁇ -acetyl-histidine, ⁇ -fluoromethyl-histidine, ⁇ -methyl-histidine, 3- pyridylalanine, 2-pyridylalanine or 4-pyridylalanine;
  • Xaa 8 is Ala, Gly, Val, Leu, lie, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1- aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid;
  • Xaa ⁇ 6 is Val or Leu
  • Xaa 18 is Ser, Lys or Arg
  • Xaa 19 is Tyr or Gin; Xaa 20 is Leu or Met;
  • Xaa 22 is Gly, Glu or Aib;
  • Xaa 23 is Gin, Glu, Lys or Arg;
  • Xaa 25 is Ala or Val
  • Xaa 26 is Lys, Glu or Arg
  • Xaa 27 is Glu or Leu;
  • Xaa 30 is Ala, Glu or Arg;
  • Xaa 33 is Val or Lys
  • Xaa 34 is Lys, Glu, Asn or Arg;
  • Xaa 35 is Gly or Aib
  • Xaa 36 is Arg, Gly or Lys
  • Xaa 37 is Gly, Ala, Glu, Pro, Lys, amide or is absent;
  • Xaa 38 is Lys, Ser, amide or is absent.
  • Xaa 39 is Ser, Lys, amide or is absent;
  • Xaa 40 is Gly, amide or is absent
  • Xaa 4 ⁇ is Ala, amide or is absent;
  • Xaa 2 is Pro, amide or is absent;
  • Xaa 43 is Pro, amide or is absent;
  • Xaa 44 is Pro, amide or is absent;
  • Xaa 5 is Ser, amide or is absent
  • Xaa 6 is amide or is absent ; provided that if Xaa 38 , Xaa 39 , Xaa 40 , Xaa 4 ⁇ , Xaa 42 , Xaa 43 , Xaa 44 , Xaa 45 or Xaa 46 is absent then each amino acid residue downstream is also absent.
  • polypeptide is a GLP-1 peptide comprising the amino acid sequence of formula (V): Xaa 7 -Xaa 8 -Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Xaa ⁇ 8 -Tyr-Leu-Glu-Xaa 22 -Xaa 23 -Ala-Ala- Xaa 26 -Glu-Phe-lle-Xaa 3 o-Trp-Leu-Val-Xaa 34 -Xaa 3 5-Xaa 36 -Xaa 37 -Xaa 38
  • Formula (V) (SEQ ID No: 3) wherein Xaa 7 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, ⁇ -hydroxy-histidine, homohistidine, N ⁇ -acetyl-histidine, ⁇ -fluoromethyl-histidine, ⁇ -methyl-histidine, 3- pyridylalanine, 2-pyridylalanine or 4-pyridylalanine;
  • Xaa 8 is Ala, Gly, Val, Leu, lie, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1- aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid; Xaa 8 is Ser, Lys or Arg; Xaa 22 is Gly, Glu or Aib; Xaa 23 s Gin, Glu, Lys or Arg;
  • the GLP-1 peptide is selected from GLP-
  • the GLP-1 peptide is a fragment of a peptide selected from the group comprising GLP-1 (7-35), GLP-1 (7-36), GLP-1 (7-36)amide, GLP-1 (7-37), GLP-1 (7-38), GLP-1 (7-39), GLP-1 (7-40) and GLP-1 (7-41 ) or an analogue thereof.
  • the GLP-1 peptide is GLP-1 (A-B) wherein A is an integer from 1 to 7 and B is an integer from 38 to 45 or an analogue thereof comprising one albumin binding residue attached via a hydrophilic spacer to the C-terminal amino acid residue and, optionally, a second albumin binding residue attached to one of the other amino acid resi- dues.
  • the GLP-1 peptide comprises no more than fifteen amino acid residues which have been exchanged, added or deleted as compared to GLP-1 (7-37) (SEQ ID No. 1), or no more than ten amino acid residues which have been exchanged, added or deleted as compared to GLP-1 (7-37) (SEQ ID No. 1). In another embodiment the GLP-1 peptide comprises no more than six amino acid residues which have been exchanged, added or deleted as compared to GLP-1 (7-37) (SEQ ID No. 1).
  • the GLP-1 peptide comprises no more than 4 amino acid residues which are not encoded by the genetic code. In another embodiment the GLP-1 peptide is a DPPIV protected GLP-1 peptide.
  • the compound according to this invention is DPPIV stabilised.
  • the GLP-1 peptide comprises an Aib residue in position 8.
  • the amino acid residue in position 7 of said GLP-1 peptide is selected from the group consisting of D-histidine, desamino-histidine, 2-amino-histidine, ⁇ - hydroxy-histidine, homohistidine, N ⁇ -acetyl-histidine , ⁇ -fluoromethyl-histidine, ⁇ -methyl- histidine, 3-pyridylalanine, 2-pyridylalanine and 4-pyridylalanine.
  • the GLP-1 peptide is selected from the group consisting of Arg 34 GLP-1 (7-37),
  • the GLP-1 peptide is attached to said hydrophilic spacer via the amino acid residue in position 23, 26, 34, 36 or 38 relative to the amino acid sequence SEQ ID No: 1.
  • the GLP-1 peptide is Arg 18 , Leu 20 , Gin 34 , Lys 33 (N ⁇ -( ⁇ -aminobutyroyl(N ⁇ -hexadecanoyl))) Exendin-4-(7-45)-amide or Arg 33 , Leu 20 , Gin 34 , Lys 18 (N ⁇ -( ⁇ -aminobutyroyl(N ⁇ -hexadecanoyl))) Exendin-4-(7-45)-amide.
  • one albumin binding residue is attached to the C-terminal amino acid residue of the GLP-1 peptide via the hydrophilic spacer.
  • a second albumin binding residue is attached to an amino acid residue which is not the C-terminal amino acid residue of the GLP-1 peptide.
  • the lipophilic substituent is attached to the GLP-1 peptide by means of a hydrophilic spacer in such a way that a carboxyl group of the spacer forms an amide bond with an amino group of the GLP-1 peptide.
  • the compound is selected from the group consisting of N ⁇ 37 -(2-(2-(2-(dodecylamino)ethoxy)ethoxy)acetyl)-[Aib 8 ' 22,35 Lys 37 ]GLP-1 (7-37)amide
  • GLP-1 H-(7-37)Lys(2-(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetyl)ethoxy)ethoxy)acetyl)-OH
  • the therapeutic polypeptide is a GLP-2 peptide.
  • the GLP-2 peptide is a DPPIV-protected GLP-2 peptide.
  • the GLP-2 peptide is Gly 2 -GLP-2(1-33).
  • the GLP-2 peptide is Lys 17 Arg 30 -GLP ⁇ 2(1-33).
  • the therapeutic polypeptide is human insulin or an analogue thereof.
  • the therapeutic polypeptide is selected from the group consisting of Asp B 8 -human insulin, Lys B28 ,Pro B29 -human insulin, Lys B3 ,Glu B29 -human insulin, Gly A21 ,Arg B31 ,Arg B32 -human insulin and des(B30) human insulin.
  • the therapeutic polypeptide is human growth hormone or an analogue thereof.
  • the therapeutic polypeptide is parathyroid hormone or an analogue thereof.
  • the therapeutic polypeptide is human follicle stimulating hormone or an analogue thereof. In another embodiment of the invention the therapeutic polypeptide has a molar weight of less than 100 kDa, less than 50 kDa, or less than 10 kDa.
  • the therapeutic polypeptide is selected from the group consisting of a growth factor such as platelet-derived growth factor (PDGF), transforming growth factor ⁇ (TGF- ⁇ ), transforming growth factor ⁇ (TGF- ⁇ ), epidermal growth fac- tor (EGF), vascular endothelial growth factor (VEGF), a somatomedin such as insulin growth factor I (IGF-I), insulin growth factor II (IFG-II), erythropoietin (EPO), thrombopoietin (TPO) or angiopoietin, interferon, pro-urokinase, urokinase, tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1 , plasminogen activator inhibitor 2, von Willebrandt factor, a cytokine, e.g.
  • a growth factor such as platelet-derived growth factor (PDGF), transforming growth factor ⁇ (TGF- ⁇ ), transforming growth factor ⁇ (TGF-
  • interleukin such as interleukin (IL) 1, IL-1 Ra, IL-2, IL-4, IL-5, IL-6, IL-9, IL-11 , IL-12, IL- 13, IL-15, IL-16, IL-17, IL-18, IL-20 or IL-21
  • IL interleukin
  • CFS colony stimulating factor
  • stem cell factor such as GM- CSF
  • tumor necrosis factor such as TNF- ⁇ , lymphotoxin- ⁇ , lymphotoxin- ⁇ , CD40L, or CD30L
  • protease inhibitor e.g.
  • aprotinin an enzyme such as superoxide dismu- tase, asparaginase, arginase, arginine deaminase, adenosine deaminase, ribonuclease, cata- lase, uricase, bilirubin oxidase, trypsin, papain, alkaline phosphatase, ⁇ -glucoronidase, purine nucleoside phosphorylase or batroxobin, an opioid, e.g. endorphins, enkephalins or non-natural opioids, a hormone or neuropeptide, e.g.
  • an opioid e.g. endorphins, enkephalins or non-natural opioids
  • a hormone or neuropeptide e.g.
  • calcitonin glucagon, gastrins, adrenocorticotropic hormone (ACTH), cholecystokinins, lutenizing hormone, gonadotropin-releassing hormone, chorionic gonadotropin, corticotrophin-releasing factor, vasopressin, oxytocin, antidiuretic hormones, thyroid-stimulating hormone, thyrotropin-releasing hormone, relaxin, prolactin, peptide YY, neuropeptide Y, pancreastic polypeptide, leptin, CART (cocaine and amphetamine regu- lated transcript), a CART related peptide, perilipin, melanocortins (melanocyte-stimulating hormones) such as MC-4, melanin-concentrating hormones, natriuretic peptides, adrenomedullin, endothelin, secretin, amylin, vasoactive intestinal peptide (
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound according to the invention, and a pharmaceutically acceptable excipient.
  • the pharmaceutical composition is suited for parenteral administration.
  • the present invention relates to the use of a compound according to the invention for the preparation of a medicament.
  • a compound according to the invention wherein the therapeutic polypeptide is a GLP-1 peptide is used for the preparation of a medicament for the treatment or prevention of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, cognitive disorders, athero- schlerosis, myocardial infarction, coronary heart disease and other cardiovascular disorders, stroke, inflammatory bowel syndrome, dyspepsia and gastric ulcers.
  • a compound according to the invention wherein the therapeutic polypeptide is a GLP-1 peptide is used for the preparation of a medicament for delaying or preventing disease progression in type 2 diabetes.
  • a compound according to the invention wherein the therapeutic polypeptide is a GLP-1 peptide is used for the preparation of a medicament for decreasing food intake, decreasing ⁇ -cell apoptosis, increasing ⁇ -cell funtion and ⁇ -cell mass, and/or for restoring glucose sensitivity to ⁇ -cells.
  • a compound according to the invention wherein the therapeutic polypeptide is a GLP-2 peptide is used for the preparation of a medicament for the treatment of small bowel syndrome, inflammatory bowel syndrome or Crohns disease.
  • a compound according to the invention wherein the therapeutic polypeptide is an insulin peptide is used for the preparation of a medicament for the treatment or prevention of hyperglycemia, type 1 diabetes, type 2 diabetes or ⁇ -cell deficiency.
  • the therapeutic polypeptide can be produced by a method which comprises culturing a host cell containing a DNA sequence encoding the polypeptide and capable of expressing the polypeptide in a suitable nutrient medium under conditions permitting the expression of the peptide, after which the resulting peptide is recovered from the culture.
  • the medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection).
  • the peptide produced by the cells may then be recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the pro- teinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like, dependent on the type of peptide in question.
  • a salt e.g. ammonium sulphate
  • the DNA sequence encoding the therapeutic polypeptide may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the polypeptide by hybridisation using synthetic oligonucleotide probes in accordance with standard techniques (see, for example, Sambrook, J, Fritsch, EF and Maniatis, T, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1989).
  • the DNA sequence encoding the polypeptide may also be prepared synthetically by established standard methods, e.g.
  • the DNA sequence may also be prepared by polymerase chain reaction using specific primers, for instance as described in US 4,683,202 or Saiki et al. , Science 239 (1988), 487 - 491.
  • the DNA sequence may be inserted into any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced.
  • the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid.
  • the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.
  • the vector is preferably an expression vector in which the DNA sequence encoding the peptide is operably linked to additional segments required for transcription of the DNA, such as a promoter.
  • the promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA encoding the peptide of the invention in a variety of host cells are well known in the art, cf. for instance Sambrook et al., supra.
  • the DNA sequence encoding the peptide may also, if necessary, be operably connected to a suitable terminator, polyadenylation signals, transcriptional enhancer sequences, and transla- tional enhancer sequences.
  • the recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.
  • the vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell or one which confers resistance to a drug, e.g. ampicillin, kana- mycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.
  • a selectable marker e.g. a gene the product of which complements a defect in the host cell or one which confers resistance to a drug, e.g. ampicillin, kana- mycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.
  • a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector.
  • the secretory signal sequence is joined to the DNA sequence encoding the peptide in the correct reading frame.
  • Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the peptide.
  • the secre- tory signal sequence may be that normally associated with the peptide or may be from a gene encoding another secreted protein.
  • the host cell into which the DNA sequence or the recombinant vector is introduced may be any cell which is capable of producing the present peptide and includes bacteria, yeast, fungi and higher eukaryotic cells.
  • suitable host cells well known and used in the art are, without limitation, E. coli, Saccharomyces cerevisiae, or mammalian BHK or CHO cell lines.
  • GLP-1 analogues are described in International Patent Application No. 90/11296 (The General Hospital Corporation) which relates to peptide fragments which comprise GLP-1 (7-36) and functional derivatives thereof and have an insulinotropic activity which exceeds the insulinotropic activity of GLP-1 (1-36) or GLP-1 (1-37) and to their use as insulinotropic agents.
  • compositions containing a compound according to the present invention may be prepared by conventional techniques, e.g. as described in Remington's Pharmaceutical Sciences, 1985 or in Remington: The Science and Practice of Pharmacy, 19 th edition, 1995.
  • One object of the present invention is to provide a pharmaceutical formulation comprising a compound according to the present invention which is present in a concentration from about 0.1 mg/ml to about 25 mg/ml, and wherein said formulation has a pH from 2.0 to 10.0.
  • the pharmaceutical formulation may comprise a compound according to the present invention which is present in a concentration from about 0.1 mg/ml to about 50 mg/ml, and wherein said formulation has a pH from 2.0 to 10.0.
  • the formulation may further comprise a buffer system, preservative(s), isotonicity agent(s), chelating agent(s), stabilizers and surfactants.
  • the pharmaceutical formulation is an aqueous formulation, i.e. formulation comprising water. Such formulation is typically a solution or a suspension.
  • the pharmaceutical formulation is an aqueous solution.
  • aqueous formulation is defined as a formulation comprising at least 50 %w/w water.
  • aqueous solution is defined as a solution comprising at least 50 %w/w water, and the term “aqueous suspension” is defined as a suspension comprising at least 50 %w/w water.
  • the pharmaceutical formulation is a freeze-dried formulation, whereto the physician or the patient adds solvents and/or diluents prior to use.
  • the pharmaceutical formulation is a dried formulation (e.g. freeze-dried or spray-dried) ready for use without any prior dissolution.
  • the invention relates to a pharmaceutical formulation comprising an aqueous solution of a compound according to the present invention, and a buffer, wherein said compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from about 2.0 to about 10.0.
  • a pharmaceutical formulation comprising an aqueous solution of a compound according to the present invention, and a buffer, wherein said compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from about 7.0 to about 8.5.
  • the pH of the formulation is selected from the list consisting of 2.0, 2.1 , 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1 , 3.2, 3.3, 3.4, 3.5,
  • the pH of the formulation is at least 1 pH unit from the isoelectric point of the compound according to the present invention, even more preferable the pH of the formulation is at least 2 pH unit from the isoelectric point of the compound according to the present invention.
  • the buffer is selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethane, hepes, bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid or mixtures thereof.
  • Each one of these specific buffers constitutes an alternative embodiment of the invention.
  • the formulation further comprises a pharmaceutically acceptable preservative.
  • the preservative is selected from the group consisting of phenol, o-cresol, m-cresol, p-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p- hydroxybenzoate, 2-phenylethanol, benzyl alcohol, ethanol, chlorobutanol, and thiomerosal, bronopol, benzoic acid, imidurea, chlorohexidine, sodium dehydroacetate, chlorocresol, ethyl p-hydroxybenzoate, benzethonium chloride, chlorphenesine (3p-chlorphenoxypropane-1 ,2- diol) or mixtures thereof.
  • the preservative is present in a concentration from 0.1 mg/ml to 30 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 20 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 5 mg/ml to 10 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 10 mg/ml to 20 mg/ml. Each one of these specific preservatives constitutes an alternative embodiment of the invention.
  • the use of a preservative in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 19 th edition, 1995.
  • the formulation further comprises an isotonic agent.
  • the isotonic agent is selected from the group consisting of a salt (e.g. sodium chloride), a sugar or sugar alcohol, an amino acid (e.g. L- glycine, L-histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine), an alditol (e.g. glycerol (glycerine), 1 ,2-propanediol (propyleneglycol), 1 ,3-propanediol, 1 ,3- butanediol) polyethyleneglycol (e.g.
  • Any sugar such as mono- , di-, or polysaccharides, or water-soluble glucans, including for example fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch and carboxymethylcellulose-Na may be used.
  • the sugar additive is sucrose.
  • Sugar alcohol is defined as a C4-C8 hydrocarbon having at least one —OH group and includes, for example, mannitol, sorbitol, inositol, galacititol, dulcitol, xylitol, and arabitol.
  • the sugar alcohol additive is mannitol.
  • the sugars or sugar alcohols mentioned above may be used individually or in combination. There is no fixed limit to the amount used, as long as the sugar or sugar alcohol is soluble in the liquid preparation and does not adversely effect the stabilizing effects achieved using the methods of the invention.
  • the sugar or sugar alcohol concentration is between about 1 mg/ml and about 150 mg/ml.
  • the isotonic agent is present in a concentration from 1 mg/ml to 50 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 1 mg/ml to 7 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 8 mg/ml to 24 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 25 mg/ml to 50 mg/ml. Each one of these specific isotonic agents constitutes an alternative embodiment of the invention.
  • the use of an isotonic agent in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 19 th edition, 1995.
  • the formulation further comprises a chelating agent.
  • the chelating agent is selected from salts of ethylenediaminetetraacetic acid (EDTA), citric acid, and aspartic acid, and mixtures thereof.
  • the chelating agent is present in a concentration from 0.1 mg/ml to 5mg/ml.
  • the chelating agent is present in a concentration from 0.1 mg/ml to 2mg/ml.
  • the chelating agent is present in a concentration from 2mg/ml to 5mg/ml.
  • Each one of these specific chelating agents constitutes an alternative embodiment of the invention.
  • the use of a chelating agent in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 19 th edition, 1995.
  • the formulation further comprises a stabiliser.
  • a stabilizer in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Phar- macy, 19 th edition, 1995.
  • compositions of the invention are stabilized liquid pharmaceutical compositions whose therapeutically active components include a polypeptide that possibly exhibits aggregate formation during storage in liquid pharmaceutical formulations.
  • aggregate formation is intended a physical interaction between the polypeptide molecules that results in formation of oligomers, which may remain soluble, or large visible aggregates that precipitate from the solution.
  • during storage is intended a liquid pharmaceutical compo- sition or formulation once prepared, is not immediately administered to a subject. Rather, following preparation, it is packaged for storage, either in a liquid form, in a frozen state, or in a dried form for later reconstitution into a liquid form or other form suitable for administration to a subject.
  • liquid pharmaceutical composition or formulation is dried either by freeze drying (i.e., lyophilization; see, for example, Williams and Polli (1984) J. Parenteral Sci. Technol. 38:48-59), spray drying (see Masters (1991 ) in Spray- Drying Handbook (5th ed; Longman Scientific and Technical, Essez, U.K.), pp. 491-676; Broadhead et al. (1992) Drug Devel. Ind. Pharm. 18:1169-1206; and Mumenthaler et al. (1994) Pharm. Res. 11 :12-20), or air drying (Carpenter and Crowe (1988) Cryobiology 25:459-470; and Roser (1991) Biopharm.
  • Aggregate formation by a polypeptide during storage of a liquid pharmaceutical composition can adversely affect biological activity of that polypeptide, resulting in loss of therapeutic efficacy of the pharmaceutical composition. Furthermore, aggregate formation may cause other problems such as blockage of tubing, membranes, or pumps when the polypeptide-containing pharmaceutical composition is administered using an infusion system.
  • compositions of the invention may further comprise an amount of an amino acid base sufficient to decrease aggregate formation by the polypeptide during storage of the composition.
  • amino acid base is intended an amino acid or a combination of amino acids, where any given amino acid is present either in its free base form or in its salt form. Where a combination of amino acids is used, all of the amino acids may be present in their free base forms, all may be present in their salt forms, or some may be present in their free base forms while others are present in their salt forms.
  • amino acids used for preparing the compositions of the invention are those carrying a charged side chain, such as arginine, lysine, aspartic acid, and glutamic acid.
  • the amino acid used for preparing the compositions of the invention is glycine.
  • Any stereoisomer (i.e. L or D) of a particular amino acid e.g. methionine, histidine, imidazole, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine and mixtures thereof
  • a particular amino acid e.g. methionine, histidine, imidazole, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine and mixtures thereof
  • the L-stereoisomer is used.
  • Compositions of the invention may also be formulated with analogues of these amino acids.
  • amino acid analogue is intended a derivative of the naturally occurring amino acid that brings about the desired effect of decreasing aggregate formation by the polypeptide during storage of the liquid pharmaceutical compositions of the invention.
  • Suitable arginine analogues include, for example, aminoguanidine, ornithine and N-monoethyl L-arginine
  • suitable methionine analogues include ethionine and buthionine
  • suitable cystein analogues include S-methyl-L cystein.
  • the amino acid analogues are incorporated into the compositions in either their free base form or their salt form.
  • the amino acids or amino acid analogues are used in a concentration, which is sufficient to prevent or delay aggregation of the protein.
  • methionine or other sulphuric amino acids or amino acid analogous
  • methionine may be added to inhibit oxidation of methionine residues to methionine sulfoxide when the polypeptide acting as the therapeutic agent is a polypeptide comprising at least one methionine residue susceptible to such oxidation.
  • inhibit is intended minimal accumulation of methionine oxidized species over time. Inhibiting methionine oxidation results in greater retention of the polypeptide in its proper molecular form.
  • Any stereoisomer of methionine (L, D or a mixture thereof) can be used.
  • the amount to be added should be an amount sufficient to inhibit oxidation of the methionine residues such that the amount of methionine sulfoxide is acceptable to regulatory agencies. Typically, this means that the composition contains no more than about 10% to about 30% methionine sulfoxide. Generally, this can be achieved by adding methionine such that the ratio of methionine added to methionine residues ranges from about 1 :1 to about 1000:1 , such as 10:1 to about 100:1.
  • the formulation further comprises a stabiliser selected from the group of high molecular weight polymers or low molecular compounds.
  • the stabilizer is selected from polyethylene glycol (e.g. PEG 3350), polyvinylalcohol (PVA), polyvinylpyrrolidone, carboxy-/hydroxycellulose or derivates thereof (e.g. HPC, HPC-SL, HPC-L and HPMC), cyclodextrins, sulphur-containing substances as monothioglycerol, thioglycolic acid and 2-methylthioethanol, and different salts (e.g. sodium chloride).
  • PEG 3350 polyethylene glycol
  • PVA polyvinylalcohol
  • PVpyrrolidone polyvinylpyrrolidone
  • carboxy-/hydroxycellulose or derivates thereof e.g. HPC, HPC-SL, HPC-L and HPMC
  • cyclodextrins e.g. sulphur-containing substances as monothiogly
  • compositions may also comprise additional stabilizing agents, which further enhance stability of a therapeutically active polypeptide therein.
  • Stabilizing agents of particular interest to the present invention include, but are not limited to, methionine and EDTA, which protect the polypeptide against methionine oxidation, and a nonionic surfactant, which protects the polypeptide against aggregation associated with freeze-thawing or mechanical shearing.
  • the formulation further comprises a surfactant.
  • the surfactant is selected from a detergent, ethoxylated castor oil, polyglycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, polyoxypropylene-polyoxyethylene block polymers (eg. poloxamers such as Pluronic ® F68, poloxamer 188 and 407, Triton X-100 ), polyoxyethylene sorbitan fatty acid esters, starshaped PEO, polyoxyethylene and polyethylene derivatives such as alkylated and alkoxylated derivatives (tweens, e.g.
  • Tween-20, Tween-40, Tween-80 and Brij- 35 polyoxyethylene hydroxystearate, monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, alcohols, glycerol, lecitins and phospholipids (eg. phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, diphosphatidyl glycerol and sphingomyelin), derivates of phospholipids (eg. dipalmitoyl phosphatidic acid) and lysophospholipids (eg.
  • phospholipids eg. dipalmitoyl phosphatidic acid
  • lysophospholipids eg.
  • ceramides e.g. sodium tauro- dihydrofusidate etc.
  • C6-C12 long-chain fatty acids and salts thereof
  • acylcarnitines and derivatives N ⁇ -acylated derivatives of lysine, arginine or histidine, or side-chain acylated derivatives of lysine or arginine, N ⁇ -acylated derivatives of dipeptides comprising any combination of lysine, arginine or histidine and a neutral or acidic amino acid, N -acylated derivative of a tripeptide comprising any combination of a neutral amino acid and two charged amino acids, DSS (docusate sodium, CAS registry no [577-11- 7]), docusate calcium, CAS registry no [128-49-4]), docusate potassium, CAS registry no [7491-09-0]), SDS (sodium dodecyl sulfate or sodium lauryl sulfate), sodium caprylate, cholic acid or derivatives thereof, bile acids and salts thereof and glycine or taurine conjug
  • N-alkyl-N,N- dimethylammonio-1 -propanesulfonates 3-cholamido-1 -propyldimethylammonio-1 - propanesulfonate
  • cationic surfactants quarternary ammonium bases
  • cetyl- trimethylammonium bromide cetylpyridinium chloride
  • non-ionic surfactants eg. Dodecyl ⁇ - D-glucopyranoside
  • poloxamines eg.
  • Tetronic's which are tetrafunctional block copolymers derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine, or the surfactant may be selected from the group of imidazoline derivatives, or mixtures thereof. Each one of these specific surfactants constitutes an alternative embodiment of the invention.
  • a composition for parenteral administration of GLP-1 compounds may, for example, be prepared as described in WO 03/002136.
  • Such additional ingredients may include wetting agents, emulsifiers, antioxidants, bulking agents, tonicity modifiers, chelating agents, metal ions, oleaginous vehicles, proteins (e.g., human serum albumin, gelatin or proteins) and a zwit- terion (e.g., an amino acid such as betaine, taurine, arginine, glycine, lysine and histidine).
  • additional ingredients should not adversely affect the overall stability of the pharmaceutical formulation of the present invention.
  • compositions containing a compound according to the present invention may be administered to a patient in need of such treatment at several sites, for example, at topical sites, for example, skin and mucosal sites, at sites which bypass absorption, for example, administration in an artery, in a vein, in the heart, and at sites which in- volve absorption, for example, administration in the skin, under the skin, in a muscle or in the abdomen.
  • topical sites for example, skin and mucosal sites
  • sites which bypass absorption for example, administration in an artery, in a vein, in the heart
  • sites which in- volve absorption for example, administration in the skin, under the skin, in a muscle or in the abdomen.
  • Administration of pharmaceutical compositions according to the invention may be through several routes of administration, for example, lingual, sublingual, buccal, in the mouth, oral, in the stomach and intestine, nasal, pulmonary, for example, through the bron- chioles and alveoli or a combination thereof, epidermal, dermal, transdermal, vaginal, rectal, ocular, for examples through the conjunctiva, uretal, and parenteral to patients in need of such a treatment.
  • routes of administration for example, lingual, sublingual, buccal, in the mouth, oral, in the stomach and intestine, nasal, pulmonary, for example, through the bron- chioles and alveoli or a combination thereof, epidermal, dermal, transdermal, vaginal, rectal, ocular, for examples through the conjunctiva, uretal, and parenteral to patients in need of such a treatment.
  • compositions of the current invention may be administered in several dosage forms, for example, as solutions, suspensions, emulsions, microemulsions, multiple emul- sion, foams, salves, pastes, plasters, ointments, tablets, coated tablets, rinses, capsules, for example, hard gelatine capsules and soft gelatine capsules, suppositories, rectal capsules, drops, gels, sprays, powder, aerosols, inhalants, eye drops, ophthalmic ointments, ophthalmic rinses, vaginal pessaries, vaginal rings, vaginal ointments, injection solution, in situ transforming solutions, for example in situ gelling, in situ setting, in situ precipitating, in situ crystallization, infusion solution, and implants.
  • solutions for example, suspensions, emulsions, microemulsions, multiple emul- sion, foams, salves, pastes, plasters, ointments, tablets, coated tablets
  • compositions of the invention may further be compounded in, or attached to, for example through covalent, hydrophobic and electrostatic interactions, a drug carrier, drug delivery system and advanced drug delivery system in order to further enhance stability of the compound, increase bioavailability, increase solubility, decrease adverse effects, achieve chronotherapy well known to those skilled in the art, and increase patient compliance or any combination thereof.
  • carriers, drug delivery systems and advanced drug delivery systems include, but are not limited to, polymers, for example cellulose and derivatives, polysaccharides, for example dextran and derivatives, starch and derivatives, poly(vinyl alcohol), acrylate and methacrylate polymers, polylactic and polyglycolic acid and block co- polymers thereof, polyethylene glycols, carrier proteins, for example albumin, gels, for example, thermogelling systems, for example block co-polymeric systems well known to those skilled in the art, micelles, liposomes, microspheres, nanoparticulates, liquid crystals and dispersions thereof, L2 phase and dispersions there of, well known to those skilled in the art of phase behaviour in lipid-water systems, polymeric micelles, multiple emulsions, self- emulsifying, self-microemulsifying, cyclodextrins and derivatives thereof, and dendrimers.
  • polymers for example cellulose and derivatives, polysaccharides, for example dextran and derivative
  • compositions of the current invention are useful in the formulation of solids, semi- solids, powder and solutions for pulmonary administration of the compound, using, for example a metered dose inhaler, dry powder inhaler and a nebulizer, all being devices well known to those skilled in the art.
  • Compositions of the current invention are specifically useful in the formulation of controlled, sustained, protracting, retarded, and slow release drug delivery systems. More specifically, but not limited to, compositions are useful in formulation of parenteral controlled release and sustained release systems (both systems leading to a many-fold reduction in number of administrations), well known to those skilled in the art. Even more preferably, are controlled release and sustained release systems administered subcutaneous.
  • examples of useful controlled release system and compositions are hydrogels, oleaginous gels, liquid crystals, polymeric micelles, microspheres, nanoparticles,
  • Methods to produce controlled release systems useful for compositions of the cur- rent invention include, but are not limited to, crystallization, condensation, co-cystallization, precipitation, co-precipitation, emulsification, dispersion, high pressure homogenization, encapsulation, spray drying, microencapsulation, coacervation, phase separation, solvent evaporation to produce microspheres, extrusion and supercritical fluid processes.
  • General reference is made to Handbook of Pharmaceutical Controlled Release (Wise, D.L., ed. Mar- eel Dekker, New York, 2000) and Drug and the Pharmaceutical Sciences vol. 99: Protein Formulation and Delivery (MacNally, E.J., ed. Marcel Dekker, New York, 2000).
  • Parenteral administration may be performed by subcutaneous, intramuscular, intraperitoneal or intravenous injection by means of a syringe, optionally a pen-like syringe.
  • parenteral administration can be performed by means of an infusion pump.
  • a further option is a composition which may be a solution or suspension for the administration of the compound according to the present invention in the form of a nasal or pulmonal spray.
  • the pharmaceutical compositions containing the compound of the invention can also be adapted to transdermal administration, e.g. by needle-free injection or from a patch, optionally an iontophoretic patch, or transmucosal, e.g. buccal, administration.
  • stabilized formulation refers to a formulation with increased physical stabil- ity, increased chemical stability or increased physical and chemical stability.
  • physical stability of the protein formulation as used herein refers to the tendency of the protein to form biologically inactive and/or insoluble aggregates of the protein as a result of exposure of the protein to thermo-mechanical stresses and/or interaction with interfaces and surfaces that are destabilizing, such as hydrophobic surfaces and interfaces.
  • Physical stability of the aqueous protein formulations is evaluated by means of visual inspection and/or turbidity measurements after exposing the formulation filled in suitable containers (e.g. cartridges or vials) to mechanical/physical stress (e.g. agitation) at different temperatures for various time periods. Visual inspection of the formulations is performed in a sharp focused light with a dark background.
  • the turbidity of the formulation is characterized by a visual score ranking the degree of turbidity for instance on a scale from 0 to 3 (a formulation showing no turbidity corresponds to a visual score 0, and a formulation showing visual turbidity in daylight corresponds to visual score 3).
  • a formulation is classified physical unstable with respect to protein aggregation, when it shows visual turbidity in daylight.
  • the turbidity of the for- mulation can be evaluated by simple turbidity measurements well-known to the skilled person. Physical stability of the aqueous protein formulations can also be evaluated by using a spec- troscopic agent or probe of the conformational status of the protein.
  • the probe is preferably a small molecule that preferentially binds to a non-native conformer of the protein.
  • a small molecular spectroscopic probe of protein structure is Thioflavin T.
  • Thioflavin T is a fluorescent dye that has been widely used for the detection of amyloid fibrils. In the presence of fibrils, and perhaps other protein configurations as well, Thioflavin T gives rise to a new excitation maximum at about 450 nm and enhanced emission at about 482 nm when bound to a fibril protein form. Unbound Thioflavin T is essentially non-fluorescent at the wavelengths.
  • hydrophobic patch probes that bind pref- erentially to exposed hydrophobic patches of a protein.
  • the hydrophobic patches are generally buried within the tertiary structure of a protein in its native state, but become exposed as a protein begins to unfold or denature.
  • these small molecular, spectroscopic probes are aromatic, hydrophobic dyes, such as antrhacene, acridine, phenanthroline or the like.
  • spectroscopic probes are metal-amino acid complexes, such as cobalt metal complexes of hydrophobic amino acids, such as phenylalanine, leucine, isoleucine, methionine, and valine, or the like.
  • chemical stability of the protein formulation refers to chemical covalent changes in the protein structure leading to formation of chemical degradation products with potential less biological potency and/or potential increased immunogenic properties compared to the native protein structure.
  • chemical degradation products can be formed depending on the type and nature of the native protein and the environment to which the protein is exposed. Elimination of chemical degradation can most probably not be completely avoided and increasing amounts of chemical degradation products is often seen during storage and use of the protein formulation as well-known by the person skilled in the art.
  • Most proteins are prone to deamidation, a process in which the side chain amide group in glutaminyl or asparaginyl residues is hydrolysed to form a free carboxylic acid.
  • a “stabilized formulation” refers to a formulation with increased physical stability, increased chemical stability or increased physical and chemical stability.
  • a formulation must be stable during use and storage (in compliance with recommended use and storage conditions) until the expiration date is reached.
  • the pharmaceutical formulation comprising the compound according to the present invention is stable for more than 6 weeks of usage and for more than 3 years of storage.
  • the pharmaceutical formulation comprising the compound according to the present invention is stable for more than 4 weeks of usage and for more than 3 years of storage.
  • the pharmaceutical formulation comprising the compound according to the present invention is stable for more than 4 weeks of usage and for more than two years of storage. In an even further embodiment of the invention the pharmaceutical formulation comprising the compound is stable for more than 2 weeks of usage and for more than two years of storage.
  • compositions containing a GLP-1 derivative according to the present invention may be administered parenterally to patients in need of such a treatment.
  • Parenteral administration may be performed by subcutaneous, intramuscular or intravenous injection by means of a syringe, optionally a pen-like syringe.
  • parenteral administration can be performed by means of an infusion pump.
  • a further option is a composition which may be a powder or a liquid for the administration of the GLP-1 derivative in the form of a nasal or pul- monal spray.
  • the GLP-1 derivatives of the invention can also be administered transdermally, e.g. from a patch, optionally a iontophoretic patch, or transmucosally, e.g. bucally.
  • the injectable compositions of the GLP-1 derivative of the invention can be pre- pared using the conventional techniques of the pharmaceutical industry which involves dissolving and mixing the ingredients as appropriate to give the desired end product.
  • the GLP-1 derivative is dissolved in an amount of water which is somewhat less than the final volume of the composition to be prepared.
  • An isotonic agent, a preservative and a buffer is added as required and the pH value of the solution is adjusted - if necessary - using an acid, e.g. hydrochloric acid, or a base, e.g. aqueous sodium hydroxide as needed.
  • the volume of the solution is adjusted with water to give the desired concentration of the ingredients.
  • solutions containing a GLP-1 derivative according to the present invention may also contain a surfactant in order to improve the solubility and/or the stability of the GLP-1 derivative.
  • composition for nasal administration of certain peptides may, for example, be prepared as described in European Patent No. 272097 (to Novo Nordisk A/S) or in WO 93/18785.
  • the GLP-1 derivative is provided in the form of a composition suitable for administration by injection.
  • a compo- sition can either be an injectable solution ready for use or it can be an amount of a solid composition, e.g. a lyophilised product, which has to be dissolved in a solvent before it can be injected.
  • the injectable solution preferably contains not less than about 2 mg/ml, preferably not less than about 5 mg/ml, more preferred not less than about 10 mg/ml of the GLP-1 derivative and, preferably, not more than about 100 mg/ml of the GLP-1 derivative.
  • the GLP-1 derivatives of this invention can be used in the treatment of various diseases.
  • the particular GLP-1 derivative to be used and the optimal dose level for any patient will depend on the disease to be treated and on a variety of factors including the efficacy of the specific peptide derivative employed, the age, body weight, physical activity, and diet of the pa- tient, on a possible combination with other drugs, and on the severity of the case. It is recommended that the dosage of the GLP-1 derivative of this invention be determined for each individual patient by those skilled in the art.
  • the GLP-1 derivative will be useful for the preparation of a medicament with a protracted profile of action for the treatment of non-insulin dependent diabetes mellitus and/or for the treatment of obesity.
  • the present invention relates to the use of a compound according to the invention for the preparation of a medicament.
  • the present invention relates to the use of a compound according to the invention for the preparation of a medicament for the treatment of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, ⁇ -cell apoptosis, ⁇ -cell deficiency, myocardial infarction, inflammatory bowel syndrome, dyspepsia, cognitive disorders, e.g. cognitive enhancing, neuroprotection, atheroschlerosis, coronary heart disease and other cardiovascular disorders.
  • the present invention relates to the use of a compound according to the invention for the preparation of a medicament for the treatment of small bowel syndrome, inflammatory bowel syndrome or Crohns disease.
  • the present invention relates to the use of a compound ac- cording to the invention for the preparation of a medicament for the treatment of hypergly- cemia, type 1 diabetes, type 2 diabetes or ⁇ -cell deficiency.
  • the treatment with a compound according to the present invention may also be combined with combined with a second or more pharmacologically active substances, e.g. selected from antidiabetic agents, antiobesity agents, appetite regulating agents, antihypertensive agents, agents for the treatment and/or prevention of complications resulting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity.
  • antidiabetic agent includes compounds for the treatment and/or prophylaxis of insulin resis- tance and diseases wherein insulin resistance is the pathophysiological mechanism.
  • Examples of these pharmacologically active substances are : Insulin, GLP-1 agonists, sulphonylureas (e.g. tolbutamide, glibenclamide, glipizide and gliclazide), biguanides e.g. metformin, meglitinides, glucosidase inhibitors (e.g.
  • acorbose glucagon antagonists
  • DPP-IV dipeptidyl peptidase-IV
  • inhibitors of hepatic enzymes involved in stimula- tion of gluconeogenesis and/or glycogenolysis glucose uptake modulators
  • thiazolidinediones such as troglitazone and ciglitazone
  • compounds modifying the lipid metabolism such as antihyperlipidemic agents as HMG CoA inhibitors (statins), compounds lowering food intake, RXR agonists and agents acting on the ATP-dependent potassium channel of the ⁇ -cells, e.g.
  • glibenclamide glipizide, gliclazide and repaglinide
  • Cholestyramine colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol, dextrothyroxine, neteglinide, repaglinide
  • ⁇ -blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol
  • ACE angiotensin converting enzyme
  • benazepril captopril, enalapril, fosinopril, lisinopril, alatriopril, quinapril and ramipril
  • calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and
  • H-Glu(OH)-OBu f L-Glutamic acid ⁇ -tert-butyl ester
  • HOOC-(CH 2 ) ⁇ 4 -COONSu ⁇ -Carboxypentadecanoic acid 2,5-dioxopyrrolidin-1-yl ester.
  • HOOC-(CH 2 )i 6 -COONSu ⁇ -Carboxyheptadecanoic acid 2,5-dioxopyrrolidin-1-yl ester.
  • HOOC-(CH 2 ) 18 -COONSu ⁇ -Carboxynonadecanoic acid 2,5-dioxopyrrolidin-1-yl ester. Abbreviations: r.t Room temperature
  • MALDI-MS Matrix Assisted Laser Desorption/lonisation Mass Spectrometry
  • HPLC High Performance Liquid Chromatography amu: atomic mass units
  • One method for performing this analysis is: The mixtures are applied onto a Zorbax 300SB-C18 (30 nm pores, 5 ⁇ m particles) 150 x 2.1 mm column and eluted at a flow rate of 0.5 ml/min with a linear gradient of acetonitrile in 0.1% trifluoroacetic acid (0% -100% acetonitrile over 30 min). Peptides and their degradation products may be monitored by their absorbance at 214 nm (peptide bonds) or 280 nm (aromatic amino acids), and are quantified by integration of their peak areas. The degradation pattern can be determined by using LC-MS where MS spectra of the separated peak can be determined.
  • Percentage intact/degraded compound at a given time is used for estimation of the peptides DPPIV stability.
  • a peptide is defined as DPPIV stabilised when it is 10 times more stable than the natural peptide based on percentage intact compound at a given time.
  • a DPPIV stabilised GLP-1 compound is at least 10 times more stable than GLP-1 (7-37).
  • the peptides may be synthesized on Fmoc protected Rink amide resin (Novabiochem) or chlorotrityl resin or a similar resin suitable for solid phase peptide synthesis. Boc chemistry may be used but more conveinient is using Fmoc strategy eventually on an Applied Biosys- tems 433A peptide synthesizer in 0.25 mmol scale using the FastMoc UV protocols which employ HBTU (2-(1 H-Benzotriazol-1-yl)-1 , 1 ,3,3 tetramethyluronium hexafluorophosphate) mediated couplings in N-methyl pyrrolidone (N-methyl pyrrolidone) (HATU is better suited for hindered couplings) and UV monitoring of the deprotection of the Fmoc protection group.
  • Boc chemistry may be used but more conveinient is using Fmoc strategy eventually on an Applied Biosys- tems 433A peptide synth
  • the protected amino acid derivatives used may be standard Fmoc-amino acids supplied in preweighed cartridges (Applied Biosystems) suitable for the ABI433A synthesizer with the exception of unnatural aminoacids such as Fmoc-Aib-OH (Fmoc-aminoisobutyric acid) which are purchased from a supplier such as Bachem and transferred to empty cartridges.
  • the last amino acid coupled may be Boc protected.
  • the resin (0.25 mmol) may be placed placed in a manual shaker/filtration apparatus and treated with 2% hydrazine in N-methyl pyrrolidone (20 ml, 2x12 min) to remove the DDE group and subsequently washed with N-methyl pyrrolidone (4x20 ml).
  • the amino acid (4 molar equivalents relative to resin) may be dissolved in N-methyl pyrroli- done/methylene chloride (1 :1 , 10 ml). Hydroxybenzotriazole (HOBt) (4 molar equivalents relative to resin) and diisopropylcarbodiimide (4 molar equivalents relative to resin) is added and the solution was stirred for 15 min. The solution is added to the resin and diisopro- pyethylamine (4 molar equivalents relative to resin) is added. The resin is shaken 24 hours at room temperature.
  • HOBt Hydroxybenzotriazole
  • diisopropylcarbodiimide (4 molar equivalents relative to resin)
  • the resin is washed with N-methyl pyrrolidone (2x20 ml), N-methyl pyr- rolidone/Methylene chloride (1 :1 ) (2x20ml) and methylene chloride (2x20 ml).
  • the peptide is cleaved from the resin by stirring for 180 min at room temperature with a mix- ture of trifluoroacetic acid, water and triisopropylsilane (95:2.5:2.5).
  • the cleavage mixture is filtered and the filtrate is concentrated to an oil by a stream of nitrogen.
  • the crude peptide is precipitated from this oil with 45 ml diethyl ether and washed 3 times with 45 ml diethyl ether.
  • the crude peptide may be purified by semipreparative HPLC on a 20 mm x 250 mm column packed with 7 ⁇ C-18 silica. Depending on the peptide one or two purification systems may used:
  • Ammonium sulphate The column is equilibrated with 40% CH 3 CN in 0.05M (NH 4 ) 2 SO 4 , which is adjusted to pH 2.5 with concentrated H 2 SO 4 . After drying the crude peptide is dissolved in 5 ml 50% acetic acid H 2 O and diluted to 20 ml with H O and injected on the column which then is eluted with a gradient of 40% - 60% CH 3 CN in 0.05M (NH 4 ) 2 SO 4 , pH 2.5 at 10 ml/min during 50 min at 40 °C. The peptide containing fractions is collected and diluted with 3 volumes of H 2 O and passed through a Sep-Pak ® C18 cartridge (Waters part.
  • TFA After drying the crude peptide is dissolved in 5 ml 50% acetic acid H 2 O and diluted to 20 ml with H 2 O and injected on the column which then is eluted with a gradient of 40-60 % CH 3 CN in 0.1 % TFA 10 ml/min during 50 min at 40 °C. The peptide containing fractions is collected. The purified peptide is lyophilized after dilution of the eluate with water. The final product obtained may be characterised by analytical RP-HPLC (retention time) and by LCMS .
  • the RP-HPLC analysis performed in these in the experimental section was performed using UV detection at 214 nm and a Vydac 218TP54 4.6mm x 250mm 5 ⁇ C-18 silica column (The Separations Group, Hesperia, USA) which was eluted at 1 ml/min at 42 °C.
  • the different elution conditions were:
  • Hewlett Packard series 1100 Column compartment, Hewlett Packard series 1100 G1315A DAD diode array detector, Hewlett Packard series 1100 MSD and Sedere 75
  • HPLC pump Evaporative Light Scattering detectorcontrolled by HP Chemstation software.
  • HPLC pump is connected to two eluent reservoirs containing:
  • the analysis was performed at 23° C by injecting an appropriate volume of the sample (pref- erably 20 ⁇ l) onto the column which is eluted with a gradient of A and B.
  • HPLC conditions, detector settings and mass spectrometer settings used are giving in the following table.
  • ELS analogue output from ELS
  • LC-MS analysis could be performed on a PE-Sciex API 100 mass spectrometer equipped with two Perkin Elmer Series 200 Micropumps, a Perkin Elmer Series 200 autosampler, a Applied Biosystems 785A UV detector and a Sedex 75 Evaporative Light scattering detector.
  • a Waters Xterra 3.0 mm x 50 mm 5 ⁇ C-18 silica column was eluted at 1.5 ml/min at room temperature.
  • MALDI-TOF MS analysis was carried out using a Voyager RP instrument (PerSeptive Bio- systems Inc., Framingham, MA) equipped with delayed extraction and operated in linear mode. Alpha-cyano-4-hydroxy-cinnamic acid was used as matrix, and mass assignments were based on external calibration.
  • a resin (Rink amide, 0.68 mmol/g Novabiochem 0.25 mmole) was used to produce the pri- mary sequence on an ABI433A machine according to manufacturers guidelines. All protecting groups were acid labile with the exception of the residue used in position 37 (Fmo- cLys(ivDde)-OH, Novabiochem) allowing specific deprotection of this lysine rather than any other lysine.
  • Dodecanoic acid (4 molar equivalents relative to resin) was dissolved in N-methyl pyrrolidone/methylene chloride (1 :1 , 20 ml). Hydroxybenzotriazole hydrate (HOBt; H 2 O) (4 molar equivalents relative to resin) and diisopropylcarbodiimide (4 molar equivalents relative to resin) were added and the solution was stirred for 15 min. The solution was added to the resin and diisopropylethylamine (4 molar equivalents relative to resin) was added. The resin was shaken 24 hours at room temperature.
  • HOBt Hydroxybenzotriazole hydrate
  • the resin was washed with N-methyl pyrrolidone (2x20 ml), N-methyl pyrrolidone/methylene chloride (1 :1 ) (2x20ml) and methylene chloride (2x20 ml).
  • the peptide was cleaved from the resin by stirring for 180 min at room temperature with a mixture of trifluoroacetic acid, water and triisopropylsilane (95:2.5:2.5 15 ml).
  • the cleavage mixture was filtered and the filtrate was concentrated to an oil in vaccuum.
  • the crude peptide was precipitated from this oil with 45 ml diethyl ether and washed 3 times with 45 ml diethyl ether.
  • the crude peptide was purified by preparative HPLC on a 20 mm x 250 mm column packed with 7 ⁇ C-18 silica.
  • the crude peptide was dissolved in 5 ml 50% acetic acid in water and diluted to 20 ml with H 2 O and injected on the column which then was eluted with a gradient of 40-60 % (CH 3 CN in water with 0.1% TFA) 10 ml/min during 50 min at 40 °C.
  • the peptide containing fractions were collected.
  • the purified peptide was lyophi- lized after dilution of the eluate with water.
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Syn- thetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Syn- thetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • GLP-1 H-(7-37)Lys(2-(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetyl)ethoxy)ethoxy)acetyl)-OH
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic meth-ods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Syn- thetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Syn- thetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Syn- thetic methods".
  • the peptide was synthesized on a chlorotrityl resin (Novabiochem) using the Fmoc strategy on an Advanced Chemtech 348 peptide synthesizer (0.5 mmol/g, 100 mg resin/hole and 10 holes were used).
  • the couplings were mediated in Diisopropylcarbodiimide (DIC) (Fluka) and 1-hydroxybenzothazol (HOBt)/1-hydroxy-7-aza-benzotriazole (HOAt) (2:1 ) (Senn Chemicals) in 1-methyl-pyrrolidin-2-one (NMP) and 10 molar equivalents of amino acids and coupling reagents were applied.
  • DI Diisopropylcarbodiimide
  • HOBt 1-hydroxybenzothazol
  • HOAt 1-hydroxy-7-aza-benzotriazole
  • NMP 1-methyl-pyrrolidin-2-one
  • the used protected amino acid derivatives were standard Fmoc-amino acids (Advanced Chemtech) with the exception of the amino acids Fmoc- Lys(ivDde) (Novabiochem) and Fmoc-Glu-OtBu (Bachem).
  • the resin was afterwards divided into 5 portions (0.1 mmol) and the N-terminal was then treated with (Boc) 2 O and DIEA (5 molar equivalent) in NMP.
  • the peptide was cleaved from the resin by stirring for 120 min at room temperature with a mixture of trifluoroacetic acid, water and triisopropylsilane (94:3:3).
  • the cleavage mixture was filtered and the filtrate was concentrated to an oil by a stream of nitrogen.
  • the crude peptide was precipitated from this oil with 10 ml diethyl ether and washed 2 times with 10 ml diethyl ether.
  • a chlorotrityl resin (0.5 mmol/g Novabiochem, 0.1 mmole) was used to produce the primary sequence on an Advanced Chemtech 348 machine. All protecting groups were acid labile with the exception of the residue used in position 37 (FmocLys(ivDde)-OH, Novabiochem) allowing specific deprotection of this lysine rather than any other lysine.
  • the solution was then added to the resin.
  • the resin was shaken overnight at room temperature.
  • the resin was washed with NMP (4x5 ml).
  • a solution of 30% piperidine in NMP (5 ml, 20min) was added to the resin.
  • the resin was washed with NMP (4x5 ml).
  • the N-hydroxysuccinimide ester of C20 (6 molar equivalents relative to resin, KJ. Ross-Petersen A/S) and DIEA was dissolved in NMP and added to the resin.
  • the resin was shaken overnight at room temperature.
  • the resin was washed with NMP (3x5 ml) and methylene chloride (2x5 ml).
  • the peptide was cleaved from the resin by stirring for 120 min at room temperature with a mixture of trifluoroacetic acid, water and triisopropylsilane (94:3:3, 3 ml). The cleavage mixture was filtered and the filtrate was concentrated to an oil in vacuum. The crude peptide was precipitated from this oil with 10 ml diethyl ether and washed 2 times with 10 ml diethyl ether.
  • the eluate was aliquotted into vials containing the desired amount and dried by vacuum centrifugation.
  • the compound was prepared as in previous example and according to "Synthetic methods" except that octadecanedioic acid C18 was attached as a monoprotected tert-butyl ester (3 molar equivalents relative to resin) and the coupling was mediated with HOAt and DIC (also 3 molar equivalents relative to resin) in NMP.
  • the crude peptide was dissolved in 22.5% CH 3 CN, 0.1 N NaOH for purification.
  • the compound was prepared as in the two previous examples and according to "Synthetic methods".
  • the amino acid Fmoc-Glu(OtBu) (6 molar equivalents relative to resin) was coupled to the resin with HOAt and DIC (6 molar equivalents relative to resin).
  • the crude peptide was dissolved in 22.5% CH 3 CN, 0.1 N NaOH for purification.
  • the compound was prepared as in the three previous examples and according to "Synthetic methods" except that additional two OEG was coupled to the side chain of Lys.
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic meth-ods".
  • the compound was prepared according to the methods in Example 1 and in "General Syn- thetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
  • the protraction of a number GLP-1 derivatives of the invention was determined by monitor- ing the concentration thereof in plasma after sc administration to healthy pigs, using the methods described below. For comparison also the concentration in plasma of GLP-1 (7-37) after sc. administration was followed. The protraction of other GLP-1 derivatives of the invention can be determined in the same way.
  • test substances were dissolved in a vehicle suitable for subcutaneous or intravenous administration.
  • concentration was adjusted so the dosing volume was approximately 1 ml.
  • the animals were housed in pens with straw as bedding, six together in each pen.
  • the animals had free access to domestic quality drinking water during the study, but were fasted from approximately 4 pm the day before dosing until approximately 12 hours after dosing.
  • the animals were weighed on arrival and on the days of dosing.
  • the subcutaneous injection was given on the right side of the neck, approximately 5-7 cm from the ear and 7-9 cm from the middle of the neck.
  • the injections were given with a stopper on the needle, allowing 0.5 cm of the needle to be introduced.
  • Each test substance was given to three animals. Each animal received a dose of 2 nmol/kg body weight. Six animals were dosed per week while the remaining six were rested.
  • a full plasma concentration-time profile was obtained from each animal. Blood samples were collected according to the following schedule:
  • Predose (0) 0.17 (10 minutes), 0.5, 1 , 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after injection.
  • the blood samples were collected into test tubes containing a buffer for stabilisation in order to prevent enzymatic degradation of the GLP-1 analogues.
  • Plasma was immediately transferred to Micronic-tubes. Approximately 200 ⁇ l plasma was transferred to each Micronic-tube. The plasma was stored at -20°C until assayed. The plasma samples were assayed for the content of GLP-1 analogues using a immunoassay.
  • the plasma concentration-time profiles were analysed by a non-compartmental pharmacoki- netic analysis.
  • the following pharmacokinetic parameters were calculated at each occasion: AUC, AUC/Dose, AUC %Extrap , C max , t max , ⁇ z , t ⁇ > CL, CL/f, V z , V z /f and MRT.
  • the plasma concentrations of the peptides were determined in a sandwich ELISA or by RIA using different mono- or polyclonal antibodies. Choice of antibodies depends of the GLP-1 derivatives. The time at which the peak concentration in plasma is achieved varies within wide limits, depending on the particular GLP-1 derivative selected.
  • Wash-buffer Phosphate buffered saline, 0.05 % v/v Tween 20, pH 7.2
  • Assay-buffer BSA-buffer
  • BSA-buffer Phosphate buffered saline, 10 g/l Bovin Serum Albumin
  • A-TNP Nonsens antibody
  • AMDEX Streptavin-horseradish-peroxodase (Amersham RPN4401V)
  • TMB-substrate 3,3',5,5'tetramethylbenzidine ( ⁇ 0.02 %), hydrogen peroxide
  • the assay was carried out as follows (volumen/well):
  • the concentration in the samples was calculated from standard curves.
  • DB-buffer 80 mM phosphate buffer, 0.1 % Human serum albumin, 10 mM EDTA,
  • the assay was carried out in minisorp tubes 12x75 mm (volumen/tube) as follows:
  • RRA radio receptor assay
  • the method is a radiometric-ligand binding assay using LEADsee/cer imaging particles.
  • the assay is composed of membrane fragments containing the GLP-1 receptor, unlabeled GLP-1 analogues, human GLP-1 labelled with 125 l and PS LEADsee/cer particles coated with wheat germ agglutinin (WGA). Cold and 125 l-labelled GLP-1 will compete for the binding to the receptor.
  • WGA wheat germ agglutinin
  • the proximity between the 125 l-molecules and the LEADsee cer particles causes light emission from the particles.
  • the LEADseeker will image the emitted light and it will be reversibly correlated to the amount of GLP-1 analogue present in the sample.
  • GLP-1 analogues calibrators GLP-1 analogues were spiked into heat-treated plasma to produce dilution lines ranging from approximately 1 ⁇ M to 1 pM.
  • GLP-1 receptor suspension GLP-1 receptor membrane fragments were purified from baby hamster kidney (BHK) cells expressing the human pancreatic GLP-1 receptor. Stored ⁇ - 80°C until use.
  • WGA-coupled polystyrene LEADseeker imaging beads RPNQ0260, Amersham: The beads were reconstituted with GLP-1 RRA assay buffer to a concentration of 13.3 mg/mL. The GLP-1 receptor membrane suspension was then added and incubated cold (2-8°C) at end- over-end for at least 1 hr prior to use.
  • Multiscreen® Solvinert filter plate mounted on a chemical-comparable receiver plate (i.e. poly propylene plates) to collect the filtrate.
  • a chemical-comparable receiver plate i.e. poly propylene plates
  • GLP-1 radio receptor assay Use the following pipetting scheme and white polystyrene 384-well plates:
  • the light emission from each wells are detected by using the LEADseekerTM Multimodality Imaging System for duration of 10 minutes.
  • Purified plasma membranes from a stable transfected cell line, BHK467-12A (tk-ts13), expressing the human GLP-1 receptor was stimulated with GLP-1 and peptide analogues, and the potency of cAMP production was measured using the AlphaScreenTM cAMP Assay Kit from Perkin Elmer Life Sciences.
  • a stable transfected cell line has been prepared at NN and a high expressing clone was selected for screening.
  • the cells were grown at 5% CO 2 in DMEM, 5% FCS, 1% Pen/Strep and 0.5 mg/ml G418.
  • Cells at approximate 80% confluence were washed 2X with PBS and harvested with Versene, centrifuged 5 min at 1000 rpm and the supernatant removed. The additional steps were all made on ice.
  • the suspension was homogenized for 20-30 sec and centrifuged 15 min at 20.000 rpm.
  • the functional receptor assay was carried out by measurering the peptide induced cAMP production by The AlphaScreen Technology.
  • the basic principle of The AlphaScreen Technology is a competition between endogenous cAMP and exogenously added biotin-cAMP.
  • the capture of cAMP is achieved by using a specific antibody conjugated to acceptor beads.
  • Formed cAMP was counted and measured at a AlphaFusion Microplate Analyzer.
  • the EC 50 values was calculated using the Graph-Pad Prisme software.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Novel polypeptide derivatives having protracted profile of action. The present invention relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer. The present invention also relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer that separates the polypeptide and the albumin binding residue with a chemical moiety comprising at least 5 non-hydrogen atoms where 30-50% of these atoms are either N or O. In one embodiment of this invention the spacer is defined as -(CH2)lD[(CH2)nE]m(CH2)pQq-, wherein l, m and n independently are 1-20 and p is 0-10, Q is -Z-(CH2)lD[(CH2)nG]m(CH2)p-, q is an integer in the range from 0 to 5, each D, E and G independently are selected from -O-, NR3-, -N(COR4)-, -PR5(O)-, and -P(OR6)(O)-, wherein R3, R4, R5, and R6 independently represent hydrogen or C1-6-alky, Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH-, -C(O)NHCH2CH2-, -C(O)CH2-, -C(O)CH=CH-, -(CH2)s-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or 1.

Description

Novel GLP-1 derivatives
FIELD OF THE INVENTION
The present invention relates to novel derivatives of glucagon-like-peptide-1 (GLP-1 ) and fragments thereof and analogues of such fragments which have a protracted profile of action and methods of making and using them. The invention furthermore relates to novel derivatives of exendin and the use of such derivatives.
BACKGROUND OF THE INVENTION
Peptides are widely used in medical practice, and since they can be produced by recombinant DNA technology it can be expected that their importance will increase also in the years to come. When native peptides or analogues thereof are used in therapy it is generally found that they have a high clearance. A high clearance of a therapeutic agent is inconvenient in cases where it is desired to maintain a high blood level thereof over a prolonged period of time since repeated administrations will then be necessary. Examples of peptides which have a high clearance are: ACTH, corticotropin-releasing factor, angiotensin, calcitonin, insulin, glucagon, glucagon-like peptide-1 , glucagon-like peptide-2, insulin-like growth factor-1 , insulin-like growth factor-2, gastric inhibitory peptide, growth hormone-releasing factor, pituitary adenylate cyclase activating peptide, secretin, enterogastrin, somatostatin, somatotropin, somatomedin, parathyroid hormone, thrombopoietin, erythropoietin, hypothalamic releasing factors, prolactin, thyroid stimulating hormones, endorphins, enkephalins, vasopressin, oxytocin, opiods and analogues thereof, superoxide dismutase, interferon, asparaginase, arginase, arginine deaminase, adenosine deaminase and ribonuclease. In some cases it is possible to influence the release profile of peptides by applying suitable pharmaceutical compositions, but this approach has various shortcomings and is not generally applicable.
The number of known endogenous peptides and proteins with interesting biological activities is growing rapidly, also as a result of the ongoing exploration of the human genome. Due to their biological activities, many of these polypeptides could in principle be used as therapeutic agents. Endogenous peptides are, however, not always suitable as drug candidates because these peptides often have half-lives of few minutes due to rapid degradation by pepti- dases and/or due to renal filtration and excretion in the urine. The half-life of polypeptides in human plasma varies strongly (from a few minutes to more than one week). Similarly, the half-life of small molecule drugs is also highly variable. The reason for this strong variability of plasma half-lives of peptides, proteins, or other compounds is, however, not well understood. Thus, there is a need to modify therapeutic compounds to provide longer duration of action in vivo while maintaining low toxicity and therapeutic advantages. Serum albumin has a half-life of more than one week, and one approach to increasing the plasma half-life of peptides has been to derivatize the peptides with a chemical entity that binds to serum albumin.
Knudsen et al. (J. Med. Chem. 2000, 43, 1664-1669) have shown that acylated GLP-1 peptides exhibit high receptor potency and a tenfold increase of plasma half-life in pigs. Zobel et al. (Bioorg. Med. Chem. Lett 2003, 13, 1513-1515) have shown that the plasma half-life of an anticoagulant peptide in rabbits increased by 10-50 fold on derivatization of the amino terminus with phosphate ester based small molecules binding to serum albumin.
SUMMARY OF THE INVENTION
The present invention relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer.
The present invention also relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer that separates the polypeptide and the albumin binding residue with a chemical moiety comprising at least 5 non-hydrogen atoms where 30-50% of these atoms are either N or O. In one embodiment of this invention the spacer is defined as -(CH2)|D[(CH2)nE]m(CH2)pQq-, wherein I, m and n independently are 1-20 and p is 0-10,
Q is -Z-(CH2),D[(CH2)nG]πι(CH2)p-I q is an integer in the range from 0 to 5, each D, E, and G independently are selected from -O-, -NR3-, -N(COR4)-, -PR5(O)-, and -P(OR6)(O)-, wherein R3, R4, R5, and R6 independently represent hydrogen or d-β-alkyl,
Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH -, -C(O)NHCH2CH2-,
-C(O)CH2-, -C(O)CH=CH-, -(CH2)s-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or
1 or a pharmaceutically acceptable salt or prodrug thereof.
The present invention also relates to a compound which has the formula (I) A— W — B — Y— therapeutic polypeptide (I) wherein
A is an albumin binding residue,
B is a hydrophilic spacer being -(CH2)ιD[(CH2)nE]m(CH2)pQq-, wherein I, m and n independently are 1-20 and p is 0-10,
Q is -Z-(CH2)lD[(CH2)nG]m(CH2)p-, q is an integer in the range from 0 to 5, each D, E, and G independently are selected from -O-, -NR3-, -N(COR4)-, -PR5(O)-, and -P(OR6)(O)-, wherein R3, R4, R5, and R6 independently represent hydrogen or Ci-β-alkyl,
Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH -, -C(O)NHCH2CH2-,
-C(O)CH2-, -C(O)CH=CH-, -(CH2)S-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or
1 ,
Y is a chemical group linking B and the therapeutic agent, and W is a chemical group linking A and B.
The present invention also relates to a compound which has the formula (II) A-W— B— Y-therapeutic polypeptide — Y'-B'-W — A' (II) wherein A and A' are albumin binding residues,
B and B' are hydrophilic spacers independently selected from -(CH2)ιD [(CH2)nE]m(CH2)p-Qq-, wherein
I, m and n independently are 1-20 and p is 0-10, Q is -Z-(CH2)|D[(CH2)nG]m(CH2)P-, q is an integer in the range from 0 to 5, each D, E, and G independently are selected from -O-, -NR3-, -N(COR4)-, -PR5(O)-, and -P(OR6)(O)-, wherein R3, R4, R5, and R6 independently represent hydrogen or C1-6-alkyl,
Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH -, -C(O)NHCH2CH2-, -C(O)CH2-, -C(O)CH=CH-, -(CH2)S-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or
1 ,
Y is a chemical group linking B and the therapeutic agent, and Y' is a chemical group linking B' and the therapeutic agent, and W is a chemical group linking A and B, and W" is a chemical group linking A' and B'. In another aspect the present invention relates to a compound which has the formula (III)
A-W'-B — Y-therapeutic polypeptide (III) A' wherein
A and A' are albumin binding residues,
B is a hydrophilic spacer selected from -(CH2)ιD[(CH2)nE]m(CH2)p-Qq- wherein I, m and n independently are 1-20 and p is 0-10, Q is -Z-(CH2),D[(CH2)nG]m(CH2)p-, q is an integer in the range from 0 to 5, each D, E, and G are independently selected from -O-, -NR3-, -N(COR4)-, -PR5(O)-, and -P(OR6)(O)-, wherein R3, R4, R5, and R6 independently represent hydrogen or Ci-β-alkyl, Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH -, -C(O)NHCH2CH2-,
-C(O)CH2-, -C(O)CH=CH-, -(CH2)β-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or
1 , Y is a chemical group linking B and the therapeutic agent, and W" is a chemical group linking B with A and A'.
In another aspect the present invention relates to a compound comprising a hydrophilic spacer between a therapeutic peptide and one or more albumin binding residue(s), said compound having a protracted profile of action relative to the therapeutic polypeptide, where the albumin binding fraction as well as the free fraction of said compound are both able to bind to the receptor mediating the effect of the therapeutic polypeptide.
In one embodiment the hydrophilic spacer is an unbranched oligo ethylene glycol moiety with appropiate funtional groups at both terminals that forms a bridge between an amino group of the therapeutic polypeptide and a funtional group of the albumin binding residue.
In another aspect of the present invention the therapeutic polypeptide is a GLP-1 peptide. DEFINITIONS
In the present specification, the following terms have the indicated meaning : The term "albumin binding residue" as used herein means a residue which binds non- covalently to human serum albumin. The albumin binding residue attached to the therapeutic polypeptide typically has an affinity below 10 μM to human serum albumin and preferably below 1 μM. A range of albumin binding residues are known among linear and branched lipoho- phillic moieties containing 4-40 carbon atoms, compounds with a cyclopentanophenanthrene skeleton, peptides having 10-30 amino acid residues etc.
The term "hydrophilic spacer" as used herein means a spacer that separates a peptide and an albumin binding residue with a chemical moiety which comprises at least 5 non- hydrogen atoms where 30-50% of these are either N or O.
The term "therapeutic polypeptide" as used herein means a polypeptide which is being developed for therapeutic use, or which has been developed for therapeutic use.
The term "polypeptide" and "peptide" as used herein means a compound composed of at least five constituent amino acids connected by peptide bonds. The constituent amino acids may be from the group of the amino acids encoded by the genetic code and they may be natural amino acids which are not encoded by the genetic code, as well as synthetic amino acids. Natural amino acids which are not encoded by the genetic code are e.g. hydroxyproline, y- carboxyglutamate, ornithine, phosphoserine, D-alanine and D-glutamine. Synthetic amino ac- ids comprise amino acids manufactured by chemical synthesis, i.e. D-isomers of the amino acids encoded by the genetic code such as D-alanine and D-leucine, Aib (α-aminoisobutyric acid), Abu (α-aminobutyric acid), Tie (tert-butylglycine), β-alanine, 3-aminomethy! benzoic acid, anthranilic acid.
The term "analogue" as used herein referring to a polypeptide means a modified pep- tide wherein one or more amino acid residues of the peptide have been substituted by other amino acid residues and/or wherein one or more amino acid residues have been deleted from the peptide and/or wherein one or more amino acid residues have been deleted from the peptide and or wherein one or more amino acid residues have been added to the peptide. Such addition or deletion of amino acid residues can take place at the N-terminal of the peptide and/or at the C-terminal of the peptide. A simple system is used to describe analogues : For example [Arg34]GLP-1 (7-37)Lys designates a GLP-1 analogue wherein the naturally occuring lysine at position 34 has been substituted with arginine and a lysine residue has been added to the C-terminal (position 38). Formulae of peptide analogs and derivatives thereof are drawn using standard single letter abbreviation for amino acids used according to IUPAC-IUB no- menclature. The term "derivative" as used herein in relation to a peptide means a chemically modified peptide or an analogue thereof, wherein at least one substituent is not present in the unmodified peptide or an analogue thereof, i.e. a peptide which has been covalently modified. Typical modifications are amides, carbohydrates, alkyl groups, acyl groups, esters and the like. An ex- ample of a derivative of GLP-1 (7-37) is Nε26-(γ-Glu(Nα-hexadecanoyl)))- [Arg34, Lys26])GLP-1 (7- 37).
The term "GLP-1 peptide" as used herein means GLP-1 (7-37) (SEQ ID No. 1), a GLP-1 analogue, a GLP-1 derivative or a derivative of a GLP-1 analogue. In one embodiment the GLP-1 peptide is an insulinotropic agent. The term "insulinotropic agent" as used herein means a compound which is an agonist of the human GLP-1 receptor, i.e. a compound which stimulates the formation of cAMP in a suitable medium containing the human GLP-1 receptor. The potency of an insulinotropic agent is determined by calculating the EC50 value from the dose-response curve as described below. Purified plasma membranes from a stable transfected cell line, BHK467-12A (tk-ts13), expressing the human GLP-1 receptor was stimulated with GLP-1 and peptide analogues, and the potency of cAMP production was measured using the AlphaScreen™ cAMP Assay Kit from Perkin Elmer Life Sciences. A stable transfected cell line has been prepared at NN and a high expressing clone was se- lected for screening. The cells were grown at 5% CO2 in DMEM, 5% FCS, 1% Pen/Strep and 0.5 mg/ml G418.
Cells at approximate 80% confluence were washed 2X with PBS and harvested with Versene, centrifuged 5 min at 1000 rpm and the supernatant removed. The additional steps were all made on ice. The cell pellet was homogenized by the Ultrathurax for 20-30 sec. in 10 ml of Buffer 1 (20 mM Na-HEPES, 10 mM EDTA, pH=7.4), centrifuged 15 min at 20.000 rpm and the pellet resuspended in 10 ml of Buffer 2 (20 mM Na-HEPES, 0.1 mM EDTA, pH=7.4). The suspension was homogenized for 20-30 sec and centrifuged 15 min at 20.000 rpm. Suspension in Buffer 2, homogenization and centrifugation was repeated once and the membranes were resuspended in Buffer 2 and ready for further analysis or stored at -80°C. The functional receptor assay was carried out by measurering the peptide induced cAMP production by The AlphaScreen Technology. The basic principle of The AlphaScreen Technology is a competition between endogenous cAMP and exogenously added biotin-cAMP. The capture of cAMP is achieved by using a specific antibody conjugated to acceptor beads. Formed cAMP was counted and measured at a AlphaFusion Microplate Analyzer. The EC50 values was calculated using the Graph-Pad Prisme software. The term "GLP-2 peptide" as used herein means GLP-2(1-33), a GLP-2 analogue, a GLP-2 derivative or a derivative of a GLP-2 analogue.
The term "exendin-4 peptide" as used herein means exendin-4(1-39), an exendin-4 analogue, an exendin-4 derivative or a derivative of an exendin-4 analogue. In one embodiment the ex- endin-4 peptide is an insulinotropic agent.
The terms "stable exendin-4 peptide" and "stable GLP-1 peptides" as used herein means chemically modified peptides derived from exendin-4(1-39) or GLP-1 (7-37), i.e. an analogue or a derivative which exhibits an in vivo plasma elimination half-life of at least 10 hours in man, as determined by the following method. The method for determination of plasma elimination half- life of an exendin-4 peptide or a GLP-1 peptide in man is : The peptide is dissolved in an isotonic buffer, pH 7.4, PBS or any other suitable buffer. The dose is injected peripherally, preferably in the abdominal or upper thigh. Blood samples for determination of active peptide are taken at frequent intervals, and for a sufficient duration to cover the terminal elimination part (e.g. Pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 (day 2), 36 (day 2), 48 (day 3), 60 (day 3), 72 (day 4) and 84 (day 4) hours post dose). Determination of the concentration of active peptide is performed as described in Wilken et al., Diabetologia 43(51 ):A143, 2000. Derived pharmacoki- netic parameteres are calculated from the concentration-time data for each individual subject by use of non-compartmenta! methods, using the commercially available software WinNonlin Version 2.1 (Pharsight, Cary, NC, USA). The terminal elimination rate constant is estimated by log-linear regression on the terminal log-linear part of the concentration-time curve, and used for calculating the elimination half-life.
The term "DPP-IV protected" as used herein referring to a polypeptide means a polypeptide which has been chemically modified in order to render said compound resistant to the plasma peptidase dipeptidyl aminopeptidase-4 (DPP-IV). The DPP-IV enzyme in plasma is known to be involved in the degradation of several peptide hormones, e.g. GLP-1 , GLP-2, Exendin-4 etc. Thus, a considerable effort is being made to develop analogues and derivatives of the polypeptides susceptible to DPP-IV mediated hydrolysis in order to reduce the rate of degradation by DPP-IV. Resistance of a peptide to degradation by dipeptidyl aminopeptidase IV is determined by the following degradation assay :
Aliquots of the peptides are incubated at 37 °C with an aliquot of purified dipeptidyl aminopeptidase IV for 4-22 hours in an appropriate buffer at pH 7-8 (buffer not being albumin). Enzymatic reactions are terminated by the addition of trifluoroacetic acid, and the peptide degradation products are separated and quantified using HPLC or LC-MS analysis. One method for performing this analysis is: The mixtures are applied onto a Zorbax 300SB-C18 (30 nm pores, 5 μm particles) 150 x 2.1 mm column and eluted at a flow rate of 0.5 ml/min with a linear gradient of acetonitrile in 0.1% trifluoroacetic acid (0% -100% acetonitrile over 30 min). Peptides and their degradation products may be monitored by their absorbance at 214 nm (peptide bonds) or 280 nm (aromatic amino acids), and are quantified by integration of their peak areas. The degradation pattern can be determined by using LC-MS where MS spectra of the separated peak can be determined. Percentage intact/degraded compound at a given time is used for estimation of the peptides DPPIV stability. A peptide is defined as DPPIV stabilised when it is 10 times more stable than the natural peptide based on percentage intact compound at a given time. Thus, a DPPIV stabilised GLP-1 compound is at least 10 times more stable than GLP-1 (7-37).
The term "C1-6-alkyl" as used herein means a saturated, branched, straight or cyclic hydrocarbon group having from 1 to 6 carbon atoms. Representative examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, te/t-butyl, n- pentyl, isopentyl, neopentyl, fe/if-pentyl, n-hexyl, isohexyl, cyclohexane and the like.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a compound which comprises a therapeutic polypep- tide linked to an albumin binding residue via a hydrophilic spacer.
The present invention also relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer that separates the polypeptide and the albumin binding residue with a chemical moiety comprising at least 5 non-hydrogen atoms where 30-50% of these atoms are either N or O. In one embodiment of this invention the spacer is defined as -(CH2)|D[(CH2)nE]m(CH2)pQq-, wherein
I, m and n independently are 1-20 and p is 0-10,
Q is -Z-(CH2),D[(CH2)nG]m(CH2)p-, q is an integer in the range from 0 to 5, each D, E, and G independently are selected from -O-, -NR3-, -N(COR4)-, -PR5(O)-, and -P(OR6)(O)-, wherein R3, R4, R5, and R6 independently represent hydrogen or
C1-6-alkyl,
Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH -, -C(O)NHCH2CH2-, -C(O)CH2-, -C(O)CH=CH-, -(CH2)S-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or
1 or a pharmaceutically acceptable salt or prodrug thereof.
The present invention also relates to a compound which has the formula (I) : A— W — B — Y— therapeutic polypeptide (I) wherein
A is an albumin binding residue,
B is a hydrophilic spacer being -(CH2)|D[(CH2)nE]m(CH2)pQq-, wherein I, m and n independently are 1-20 and p is 0-10, Q is -Z-(CH2)ιD[(CH2)nG]m(CH2)p-, q is an integer in the range from 0 to 5, each D, E, and G independently are selected from -O-, -NR3-, -N(COR4)-, -PR5(O)-, and -P(OR6)(O)-, wherein R3, R4, R5, and R6 independently represent hydrogen or Ci-β-alkyl,
Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH -, -C(O)NHCH2CH2-, -C(O)CH2-, -C(O)CH=CH-, -(CH2)β-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or
1 , Y is a chemical group linking B and the therapeutic agent, and W is a chemical group linking A and B.
The present invention also relates to a compound which has the formula (II)
A-W— B— Y-therapeutic polypeptide — Y'-B'-W — A' (II) wherein
A and A' are albumin binding residues,
B and B' are hydrophilic spacers independently selected from -(CH2)|D [(CH2)nE]m(CH2)p-Qq-, wherein
I, m and n independently are 1-20 and p is 0-10, Q is -Z-(CH2)ιD[(CH2)nG]m(CH2)P-, q is an integer in the range from 0 to 5, each D, E, and G independently are selected from -O-, -NR3-, -N(COR4)-, -PR5(O)-, and -P(OR6)(O)-, wherein R3, R4, R5, and R6 independently represent hydrogen or
Ci-β-alkyl,
Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH -, -C(O)NHCH2CH2-,
-C(O)CH2-, -C(O)CH=CH-, -(CH2)S-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or
1 , Y is a chemical group linking B and the therapeutic agent, and Y' is a chemical group linking B' and the therapeutic agent, and W is a chemical group linking A and B, and W is a chemical group linking A' and B'.
In one embodiment of the invention Y' is selected from the group consisting of -C(0)NH-, - NHC(O)-, -C(O)NHCH2-, -CH2NHC(O)-, -OC(O)NH -, -NHC(O)O-, -C(O)NHCH2-, CH2NHC(O)-, -C(O)CH2-, -CH2C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -(CH2)S-, -C(O)-, -C(O)0-, -OC(O)-, -NHC(O)- and -C(0)NH-, wherein s is 0 or 1.
In a further embodiment of the invention W is selected from the group consisting of -
C(0)NH-, -NHC(O)-, -C(O)NHCH2-, -CH2NHC(O)-, -OC(O)NH -, -NHC(O)O-, -C(O)CH2-, - CH2C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -(CH2)S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and -C(O)NH-, wherein s is 0 or 1.
In another aspect the present invention relates to a compound which has the formula
(III)
A-W"-B— Y-therapeutic polypeptide (III) A' wherein
A and A' are albumin binding residues, B is a hydrophilic spacer selected from -(CH2)|D[(CH2)nE]m(CH2)p-Qq- wherein
I, m and n independently are 1-20 and p is 0-10,
Q is -Z-(CH2)iD[(CH2)nG]m(CH2)p-, q is an integer in the range from 0 to 5, each D, E, and G are independently selected from -O-, -NR3-, -N(COR4)-, -PR5(O)-, and -P(OR6)(O)-, wherein R3, R4, R5, and R6 independently represent hydrogen or
C-i-e-alkyl,
Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH -, -C(O)NHCH2CH2-,
-C(O)CH2-, -C(O)CH=CH-, -(CH2)S-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or
1 , Y is a chemical group linking B and the therapeutic agent, and W" is a chemical group linking B with A and A'.
In another aspect the present invention relates to a compound comprising a hydrophilic spacer between a therapeutic peptide and one or more albumin binding residue(s), said compound having a protracted profile of action relative to the therapeutic polypeptide, where the albumin binding fraction as well as the free fraction of said compound are both able to bind to the receptor mediating the effect of the therapeutic polypeptide.
In one embodiment the hydrophilic spacer is an unbranched oligo ethylene glycol moiety with appropiate funtional groups at both terminals that forms a bridge between an amino group of the therapeutic polypeptide and a funtional group of the albumin binding residue.
In one embodiment Y is selected from the group consisting of -C(0)NH-, -NHC(O)-, -C(0)NHCH2-, -CH2NHC(0)-, -OC(0)NH -, -NHC(O)O-, -C(O)NHCH2-, CH2NHC(O)-, -C(O)CH2-, -CH2C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -(CH2)S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and -C(O)NH-, wherein s is 0 or 1.
In another embodiment W is selected from the group consisting of of -C(O)NH-, - NHC(O)-, -C(O)NHCH2-, -CH2NHC(O)-, -OC(O)NH -, -NHC(O)O-, -C(O)CH2-, -CH2C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -(CH2)S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and -C(O)NH-, wherein s is 0 or 1.
In another embodiment W" is selected from the group consisting of -C(0)NHCH- , -C(0)CH- , -(CH2)SCH- , and -NHC(0)CNHC(O)CH20(CH2)2O(CH2)2NH-
wherein s is 0, 1 or 2.
In another embodiment I is 1 or 2, n and m are independently 1-10 and p is 0-10.
In another embodiment D is -O-.
In another embodiment of the invention E is -O-.
In yet another embodiment of the invention the hydrophilic spacer is -CH2O[(CH2)2O]m(CH2)pQq-, where m is 1-10, p is 1-3, and Q is -Z-CH2O[(CH2)2O]m(CH2)p-.
In another embodiment q is 1.
In another embodiment G is -O-.
In yet another embodiment of the invention Z is selected from the group consisting of • C(O)NH-, -C(O)NHCH2-, and -OC(O)NH-. In yet another embodiment q is 0.
In another embodiment I is 2.
In another embodiment n is 2.
In yet another embodiment the hydrophilic spacer B is -[CH2CH2O]m+ι(CH2)pQq-.
In yet another embodiment the hydrophilic spacer B is -(CH2)rO-[(CH2)π-O]πr(CH2)p-[C(O)NH-(CH2)rO-[(CH2)n-O]m-(CH2)p]ιr, where I, m, n, and p independently are 1-5, and q is 0-5.
In yet another embodiment -W-B-Y- is selected from the group consisting of
Figure imgf000013_0001
W Y
Figure imgf000013_0002
In yet another embodiment >W"-B-Y- is
Figure imgf000014_0001
In yet another embodiment the albumin binding residue A is selected from the group consisting of
Figure imgf000014_0002
Figure imgf000014_0003
Figure imgf000014_0004
where the chiral carbon atom is either R or S,
Figure imgf000014_0005
where the chiral carbon atom is either R or S,
Figure imgf000015_0001
where the chiral carbon atom is either R or S,
Figure imgf000015_0002
where the two chiral carbon atoms independently are either R or S,
Figure imgf000015_0003
where the two chiral carbon atoms independently are either R or S,
Figure imgf000015_0004
where the two chiral carbon atoms independently are either L or D,
Figure imgf000015_0005
where the chiral carbon atom is either R or S,
Figure imgf000015_0006
where the chiral carbon atom is either R or S,
Figure imgf000015_0007
where the two chiral carbon atoms independently are either R or S,
Figure imgf000016_0001
where the two chiral carbon atoms independently are either R or S,
H3C
Figure imgf000016_0002
Figure imgf000016_0003
Figure imgf000017_0001
Figure imgf000017_0002
Figure imgf000017_0003
Figure imgf000017_0004
o
H0 WΛXX^
H0Λ
In yet another embodiment the molar weight of the hydrophilic spacer is in the range from 80D to 1000D or in the range from 80D to 300D.
In another embodiment of the invention, the albumin binding residue is a lipophilic residue.
In another embodiment the albumin binding residue is negatively charged at physiological pH. In another embodiment the albumin binding residue comprises a group which can be negatively charged. One preferred group which can be negatively charged is a carboxylic acid group.
In another embodiment of the invention, the albumin binding residue binds non- covalently to albumin. In another embodiment the albumin binding residue has a binding affinity towards human serum albumin that is below about 10 μM or below about 1 μM. In yet another embodiment of the invention the albumin binding residue is selected from a straight chain alkyl group, a branched alkyl group, a group which has an ω-carboxylic acid group, a partially or completely hydrogenated cyclopentanophenanthrene skeleton. In another embodiment the albumin binding residue is a cibacronyl residue. In another embodiment the albumin binding residue has from 6 to 40 carbon atoms, from 8 to 26 carbon atoms or from 8 to 20 carbon atoms.
In another embodiment the albumin binding residue is an acyl group selected from the group comprising CH3(CH2)rCO-, wherein r is an integer from 4 to 38, preferably an integer from 4 to 24, more preferred selected from the group comprising CH3(CH2)6CO-, CH3(CH2)8CO-, CH3(CH2)10CO-, CH3(CH2)12CO-, CH3(CH2)ι4CO-, CH3(CH2)16CO-, CH3(CH2)ι8CO-, CH3(CH2)20CO- and CH3(CH2)22CO-.
In another embodiment the albumin binding residue is an acyl group of a straight-chain or branched alkane α,ω-dicarboxylic acid.
In another embodiment the albumin binding residue is an acyl group selected from the group comprising HOOC(CH2)sCO-, wherein s is an integer from 4 to 38, preferably an integer from 4 to 24, more preferred selected from the group comprising HOOC(CH2)ι CO-, HOOC(CH2)ι6CO-, HOOC(CH2)ι8CO-, HOOC(CH2)20CO- and HOOC(CH2)22CO-.
In another embodiment the albumin binding residue is a group of the formula CH3(CH2)vCO-NHCH(COOH)(CH2)2CO-, wherein v is an integer of from 10 to 24. In another embodiment the albumin binding residue is a group of the formula CH3(CH2)wCO-NHCH((CH2)2COOH)CO-, wherein w is an integer of from 8 to 24.
In another embodiment the albumin binding residue is a group of the formula COOH(CH2)xCO- wherein x is an integer of from 8 to 24. In another embodiment the albumin binding residue is a group of the formula
-NHCH(COOH)(CH2)4NH-CO(CH2)yCH3, wherein y is an integer of from 8 to 18.
In another embodiment of the invention the albumin binding residue is a peptide, such as a peptide comprising less than 40 amino acid residues. A number of small peptides which are albumin binding residues as well as a method for their identification is found in J. Biol Chem. 277, 38 (2002) 35035-35043.
In another embodiment of the invention the albumin binding residue via spacer and linkers is attached to said therapeutic polypeptide via the ε-amino group of a lysine residue.
In another embodiment the albumin binding residue via spacer and linkers is attached to said therapeutic polypeptide via an amino acid residue selected from cysteine, glutamate and aspartate.
In one embodiment of the present invention the therapeutic polypeptide is a GLP-1 peptide.
In another embodiment of the invention the therapeutic polypeptide is a GLP-1 pep- tide comprising the amino acid sequence of the formula (IV):
Xaa7-Xaa8-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Xaa16-Ser-Xaa18-Xaa19-Xaa2o-Glu-Xaa22-Xaa23-Ala-
Xaa25-Xaa26-Xaa27-Phe-lle-Xaa3o-Trp-Leu-Xaa33-Xaa34-Xaa35-Xaa36-Xaa37-Xaa38-Xaa39-
Xaa40-Xaa41-Xaa42-Xaa 3-Xaa44-Xaa 5-Xaa46
Formula (IV) (SEQ ID No: 2) wherein
Xaa7 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, Nα-acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3- pyridylalanine, 2-pyridylalanine or 4-pyridylalanine;
Xaa8 is Ala, Gly, Val, Leu, lie, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1- aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid;
Xaaι6 is Val or Leu;
Xaa18 is Ser, Lys or Arg;
Xaa19 is Tyr or Gin; Xaa20 is Leu or Met;
Xaa22 is Gly, Glu or Aib; Xaa23 is Gin, Glu, Lys or Arg;
Xaa25 is Ala or Val;
Xaa26 is Lys, Glu or Arg;
Xaa27 is Glu or Leu; Xaa30 is Ala, Glu or Arg;
Xaa33 is Val or Lys;
Xaa34 is Lys, Glu, Asn or Arg;
Xaa35 is Gly or Aib;
Xaa36 is Arg, Gly or Lys; Xaa37 is Gly, Ala, Glu, Pro, Lys, amide or is absent;
Xaa38 is Lys, Ser, amide or is absent.
Xaa39 is Ser, Lys, amide or is absent;
Xaa40 is Gly, amide or is absent;
Xaa4ι is Ala, amide or is absent; Xaa 2 is Pro, amide or is absent;
Xaa43 is Pro, amide or is absent;
Xaa44 is Pro, amide or is absent;
Xaa 5 is Ser, amide or is absent;
Xaa 6 is amide or is absent ; provided that if Xaa38, Xaa39, Xaa40, Xaa4ι, Xaa42, Xaa43, Xaa44, Xaa45 or Xaa46 is absent then each amino acid residue downstream is also absent.
In another embodiment of the invention the polypeptide is a GLP-1 peptide comprising the amino acid sequence of formula (V): Xaa7-Xaa8-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Xaaι8-Tyr-Leu-Glu-Xaa22-Xaa23-Ala-Ala- Xaa26-Glu-Phe-lle-Xaa3o-Trp-Leu-Val-Xaa34-Xaa35-Xaa36-Xaa37-Xaa38
Formula (V) (SEQ ID No: 3) wherein Xaa7 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, Nα-acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3- pyridylalanine, 2-pyridylalanine or 4-pyridylalanine;
Xaa8 is Ala, Gly, Val, Leu, lie, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1- aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid; Xaa 8 is Ser, Lys or Arg; Xaa22 is Gly, Glu or Aib; Xaa23 s Gin, Glu, Lys or Arg;
X3326 s Lys, Glu or Arg;
Xaa3o s Ala, Glu or Arg; Xaa34 s Lys, Glu or Arg; Xaa35 s Gly or Aib;
Figure imgf000021_0001
Xaa3 s Gly, Ala, Glu or Lys; Xaa38 s Lys, amide or is absent.
In yet another embodiment of the invention the GLP-1 peptide is selected from GLP-
1 (7-35), GLP-1 (7-36), GLP-1 (7-36)-amide, GLP-1 (7-37), GLP-1 (7-38), GLP-1 (7-39), GLP-1 (7- 40), GLP-1 (7-41 ) or an analogue thereof.
In another embodiment the GLP-1 peptide is a fragment of a peptide selected from the group comprising GLP-1 (7-35), GLP-1 (7-36), GLP-1 (7-36)amide, GLP-1 (7-37), GLP-1 (7-38), GLP-1 (7-39), GLP-1 (7-40) and GLP-1 (7-41 ) or an analogue thereof.
In another embodiment of the invention the GLP-1 peptide is GLP-1 (A-B) wherein A is an integer from 1 to 7 and B is an integer from 38 to 45 or an analogue thereof comprising one albumin binding residue attached via a hydrophilic spacer to the C-terminal amino acid residue and, optionally, a second albumin binding residue attached to one of the other amino acid resi- dues.
In another embodiment the GLP-1 peptide comprises no more than fifteen amino acid residues which have been exchanged, added or deleted as compared to GLP-1 (7-37) (SEQ ID No. 1), or no more than ten amino acid residues which have been exchanged, added or deleted as compared to GLP-1 (7-37) (SEQ ID No. 1). In another embodiment the GLP-1 peptide comprises no more than six amino acid residues which have been exchanged, added or deleted as compared to GLP-1 (7-37) (SEQ ID No. 1).
In another embodiment the GLP-1 peptide comprises no more than 4 amino acid residues which are not encoded by the genetic code. In another embodiment the GLP-1 peptide is a DPPIV protected GLP-1 peptide.
In another embodiment the compound according to this invention is DPPIV stabilised. In another embodiment the GLP-1 peptide comprises an Aib residue in position 8. In another embodiment the amino acid residue in position 7 of said GLP-1 peptide is selected from the group consisting of D-histidine, desamino-histidine, 2-amino-histidine, β- hydroxy-histidine, homohistidine, Nα-acetyl-histidine , α-fluoromethyl-histidine, α-methyl- histidine, 3-pyridylalanine, 2-pyridylalanine and 4-pyridylalanine. In another embodiment the GLP-1 peptide is selected from the group consisting of Arg34GLP-1 (7-37),
Lys38Arg26'34GLP-1 (7-38), Lys38Arg26'34GLP-1 (7-38)-OH, Lys36Arg26'34GLP-1 (7-36), Aib8'22'35 GLP-1 (7-37), Aib8'35 GLP-1 (7-37), Aib8'22 GLP-1 (7-37), Aib 8,22,35 Arg26'34Lys38GLP-1 (7-38), Aib8'35 Arg26'34Lys38GLP-1 (7-38), Aib8'22 Arg26'34Lys38GLP-1 (7-38), Aib8'22'35 Arg26'34Lys38GLP-1 (7-38), Aib8'35 Arg26'34Lys38GLP-1 (7-38), Aib8'22'35 Arg26Lys38GLP-1 (7-38), Aib8'35λrg26Lys38GLP-1 (7-38), Aib8'22 Arg26Lys38GLP-1 (7-38),
Aib8'22'35 Arg34Lys38GLP-1 (7-38), Aib8'35Arg34Lys38GLP-1 (7-38), Aib8'22Arg34Lys38GLP-1 (7-38), Aib8'22'35Ala37Lys38GLP-1 (7-38), Aib8'35Ala37Lys38GLP-1 (7-38), Aib8'22Ala37Lys38GLP-1 (7-38), Aib8'22'35 Lys37GLP-1 (7-37), Aib8'35Lys37GLP-1(7-37) and Aib8'22Lys37GLP-1 (7-38).
In another embodiment the GLP-1 peptide is attached to said hydrophilic spacer via the amino acid residue in position 23, 26, 34, 36 or 38 relative to the amino acid sequence SEQ ID No: 1.
In another embodiment the GLP-1 peptide is exendin-4 (SEQ ID NO 4). In another embodiment the GLP-1 peptide is ZP-10, i.e. HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-amide (SEQ ID NO 5). In another embodiment the GLP-1 peptide is HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGX, wherein X = P or Y, or a fragment or an analogue thereof.
In another embodiment of the invention the GLP-1 peptide is Arg18, Leu20, Gin34, Lys33 (Nε-(γ-aminobutyroyl(Nα-hexadecanoyl))) Exendin-4-(7-45)-amide or Arg33, Leu20, Gin34, Lys18 (Nε-(γ-aminobutyroyl(Nα-hexadecanoyl))) Exendin-4-(7-45)-amide.
In another embodiment of the invention one albumin binding residue is attached to the C-terminal amino acid residue of the GLP-1 peptide via the hydrophilic spacer.
In another embodiment of the invention a second albumin binding residue is attached to an amino acid residue which is not the C-terminal amino acid residue of the GLP-1 peptide. In another embodiment, the lipophilic substituent is attached to the GLP-1 peptide by means of a hydrophilic spacer in such a way that a carboxyl group of the spacer forms an amide bond with an amino group of the GLP-1 peptide.
In another embodiment of the invention the compound is selected from the group consisting of Nε37-(2-(2-(2-(dodecylamino)ethoxy)ethoxy)acetyl)-[Aib8'22,35Lys37]GLP-1 (7-37)amide
Figure imgf000023_0001
Nε37-(2-(2-(2-(17-sulphohexadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib8'22'35,Lys37] GLP-1 (7- 37)amide
Figure imgf000023_0002
Nε37-{2-[2-(2-(15-carboxypentadecanoylamino)ethoxy)ethoxy]acetyl}-[Aib8'22'35,Lys37] GLP- 1 (7-37)amide
Figure imgf000023_0003
(7- 37)amide
Figure imgf000023_0004
8,22,35 i , ._37ι
NεJ7-(2-(2-(2-(19-carboxynonadecanoylamino)ethoxy)ethoxy)acetyl)[Aib°'^"30,Lys0,]GLP-1 (7- 37)amide
Figure imgf000024_0001
[AibB'ZAd&,Arg^HGLP-1-(7-37)Lys(4-(Hexadecanoylamino)-4(S)-carboxybutyryl)-OH
Figure imgf000024_0002
[Aib8,22'35,Arg26'34]GLP-1-(7-37)Lys(2-(2-(2-(hexadecanoylamino)ethoxy)ethoxy)acetyl)-OH
Figure imgf000024_0003
NεJ -(2-[2-(2,6-(S)-Bis-{2-[2-(2-
(dodecanoylamino)ethoxy)ethoxy]acetylamino}hexanoylamino)ethoxy]ethoxy}) acetyl-[Aib8'22,35]GLP-1 (7-37)amide
Figure imgf000024_0004
NεJ -(2-[2-(2,6-(S)-Bis-{2-[2-(2-
(tetradecanoylamino)ethoxy)ethoxy]acetylamino}hexanoylamino)ethoxy]ethoxy}) acetyl-[Aib8'22'35]GLP-1 (7-37)amide
Figure imgf000025_0001
[Aib8'22'35,Arg26'34]GLP-1-(7-37)Lys(2-(2-(2-(4-(Hexadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetyl)-OH
Figure imgf000025_0002
[Aib8'22'35]GLP-1 (7-37)Lys((2-{2-[4-[4-(4-Amino-9,10-dioxo-3-sulfo-9,10-dihydro-anthracen-1- ylamino)-2-sulfo-phenylamino]-6-(2-sulfo-phenylamino)-[1 ,3,5]triazin-2-ylamino]-ethoxy}- ethoxy)-acetyl))amide
Figure imgf000025_0003
,8,22,35,
[Aib0'^'όa]GLP-1 (7-37)Lys(({2-[2-(2-{2-[2-(2-{2-[2-(15-carboxypentadecanoylamino)- ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl amino)ethoxy]ethoxy}acetyl))amide
Figure imgf000026_0001
Nε37-([2-(2-{3-[2,5-dioxo-3-(15-carboxypentadecylsulfanyl)-pyrrolidin-1-yl]- pprrooppiioonnyyllεamino}ethoxy)ethoxy)acetyl]-[D-Ala8,Lys37]-GLP-1-[7-
37]amide
Figure imgf000026_0002
[Aib8'22'35Ala37]GLP-1 (7-37)Lys((2-(2-(2-(11- (oxalylamino)undecanoylamino)ethoxy)ethoxy)acetyl-)))amide
Figure imgf000026_0003
[Aib8'22'35,Ala37]-GLP-1 (7-37)Lys({2-[2-(2-{2-[2-(2-(15-carboxy-pentadecanoylamino)- ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl)amide
Figure imgf000027_0001
[Aib8'22' ,Ala37]-GLP-1 (7-37)Lys((2-{2-[11 -(5-Dimethylaminonaphthalene-1 - sulfonylamino)undecanoylamino]ethoxy}ethoxy)acetyl)amide
Figure imgf000027_0002
[Aib8'22'35,Ala37]-GLP-1 (7-37)Lys(([2-(2-{2-[1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1 H-indol- 3-yl]acetylamino}ethoxy)ethoxy]acetyl))amide
Figure imgf000027_0003
[Aib8,Arg26'34,Glu22'23'30]GLP-1 H(7-37)Lys(2-(2-(2- (octadecanoylamino)ethoxy)ethoxy)acetyl)amide
Figure imgf000028_0001
[Aib8,Arg26'34,Glu22'23'30]GLP-1 (7-37)Lys(2-(2-(2- (eicosanoylamino)ethoxy)ethoxy)acetyl)amide
Figure imgf000028_0002
[Gly8,Arg26'34] GLP-1 H-(7-37)Lys(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetyl)ethoxy)ethoxy)acetyl)-OH
Figure imgf000028_0003
[Aib8,Arg26'34]GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2- (octadecanoy!amino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000028_0004
[Aib8] -GLP-1 -(7-37)Lys (2-(2-(2-(4-(Hexadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetyl)-OH
Figure imgf000029_0001
[Aib8,Arg26'34] GLP-1 (7-37) Lys{2-(2-(2-(2-[2-(2-(4-(octadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000029_0002
[Aib8,Arg26'34] GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-(17- carboxyheptanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000029_0003
[Gly8, Arg26'34] GLP1-(7-37) Lys{2-(2-(2-(2-[2-(2-(17- carboxyheptadecanoylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000029_0004
[Aib8]GLP-1-(7-37)Lys(2-(2-(2-(2-(2-(2-(4-(Hexadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetylamino) ethoxy)ethoxy)acetyl)-OH
Figure imgf000030_0001
N" -(2-(2-(2-(dodecanoylamino)ethoxy)ethoxy)acetyl)-[AibB' 2/2,'3d50Lys ,307'η] GLP-1 H(7-37)-amide
Figure imgf000030_0002
Nε37-(2-(2-(2-(tetradecanoylamino)ethoxy)ethoxy)acetyl)-[Aib8'22'35Lys37] GLP-1 H(7-37)- amide
Figure imgf000030_0003
Figure imgf000030_0004
GLP-1 (7-37)-amide
Figure imgf000030_0005
Figure imgf000030_0006
GLP-1 (7-37)-amide
Figure imgf000031_0001
Figure imgf000031_0002
GLP-1 (7-37)-amide
Figure imgf000031_0003
N ,ε36 -(2-(2-(2-(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl))- 26,34 ,36'
[Aib°,Arg"D'XLysHGLP-1-(7-37)-OH
Figure imgf000031_0004
N -(2-(2-(2-(2-(2-(2-
(octadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl))[Arg26,34,Lys36]GLP- 1 (7-37)-OH
Figure imgf000031_0005
N -{2-(2-(2-(2-[2-(2-(octadecanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}- [Gly8,Arg26'34,Lys36]GLP-1-(7-37)-OH
Figure imgf000032_0001
N -(2-(2-(2-(4-4(4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluorononanoylsulfamoyl- butyrylamino)ethoxy)ethoxy)acetyl))[Aib8'2 '35,Lys37] GLP-1-(7-37)-OH
Figure imgf000032_0002
N |E"37-(2-(2-(2-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11 ,11 ,12,12,12-Heneicosafluoro- dodecyloxyacetylamino)ethoxy) ethoxy)acetyl)[Aib8'22'35,Lys37]GLP-1-(7-37)-OH
Figure imgf000032_0003
Nε37-(2-(2-(2-(4-(hexadecanoylsulfamoyl)butyrylamino)ethoxy)ethoxy)acetyl)[Aib8'22,35,Lys37] GLP-1 -(7-37)-OH
Figure imgf000032_0004
[Arg26'34]GLP-1(7-37)Lys({2-(2-(2-(2-[2-(2- (octadecanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)})-OH
Figure imgf000033_0001
[Arg26'34] GLP-1(7-37)Lys{2-(2-(2-(2-[2-(2-(4-(octadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000033_0002
Nε2ϋ-{2-(2-(2-(2-[2-(2-(4-(hexadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-exendin(1-39)
Figure imgf000033_0003
[Ala8, Arg26'34]GLP-1 (7-37)Lys((2-[2-((2-oxalyIamino-3-carboxy-2-4,5,6,7-tetrahydro- benzo[b]thiophen-6-yl-acetylamino))ethoxy]ethoxyacetyl) amide
Figure imgf000034_0001
[Aib8'22'35]GLP-1 (7-37)Lys((2-[2-((2-oxalylamino-3-carboxy-2-4,5,6,7-tetrahydro- benzo[b]thiophen-6-yl-acetylamino))ethoxy]ethoxyacetyl) amide
Figure imgf000034_0002
N"°-(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl)-
[Aib8,Arg26'34,Lys 6]GLP-1-(7-37)-OH
Figure imgf000034_0003
N ,ε36 -(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl)-
[Gly8,Arg26'34,Lys36]GLP-1-(7-37)-OH
Figure imgf000035_0001
N -2-(2-(2-(4-(4-(Heptadecanoylamino)-4-(S)-carboxybutyrylamino)-4-(S)- carboxybutyrylamino)ethoxy)ethoxy) acetyl-[Aib8'22'35,Lys37]GLP-1-(7-37)-NH2
Figure imgf000035_0002
N"'-2-(2-[2-(2-[2-(4-[4-(Heptadecanoylamino)-4-(S) carboxybutyrylamino]-4-(S)-carboxybutyrylamino)ethoxy] ethoxy)acetylamino)ethoxy]ethoxy)acetyl-[Aib8'22'35,Lys37]GLP-1-(7-37)-NH2
Figure imgf000035_0003
N -(2-(2-(2-(4-(Hexadecanoylamino)-4(S)-carboxybutyrylamino) ethoxy)ethoxy)acetyl)-[Aib8,Arg34]GLP-1-(7-37)-
-OH
Figure imgf000036_0001
Nεi6-2-(2-2-(2-(2-(2-(4-(Octadecanoylamino)-4(S)- carboxybutyrylamιno)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl- [Aib8, Arg34]GLP-1-(7-37)-OH
Figure imgf000036_0002
[Gly8,Arg2834]GLP-1 (7-37)Lys(2-(2-(19-(carboxy)nonadecanoylamιno)ethoxy)ethoxy)acetyl)
OH
Figure imgf000036_0003
[Gly8,Arg26'34]GLP-1 (7-37)Lys((2-(2-(17- (carboxy)heptadecanoylamino)ethoxy)ethoxy)acetyl))-OH
Figure imgf000036_0004
[Gly8,Arg26'34]GLP-1 (7-37)Lys(2-(2-(2-(4-(19-(carboxy)nonadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy)acetyl)-OH
Figure imgf000037_0001
[Gly8,Arg26'34]GLP-1 (7-37)Lys((2-(2-(2-(2-(2-(2-(2-(2-(2-
(hexadecanoylamino)ethoxy)ethoxy)acetyl)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)- acetyl)-OH
Figure imgf000037_0002
[Gly8, Arg26'34]GLP-1 (7-37)Lys (2-(2-(2-(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)- acetylamino)ethoxy)ethoxy)acetyl) NH2
Figure imgf000037_0003
N^(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(4-(17-(carboxy)heptadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetylamino) ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl) [Lys20]exendin-4 (1 -39)-NH2
Figure imgf000038_0001
N -(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy) acetylamino)ethoxy)ethoxy)acetyl) [Aib8,Arg26'34, Lys36] GLP-1 (7-37)
Figure imgf000038_0002
N- -(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy) acetylamino)ethoxy)ethoxy)acetyl) [Arg26'34, Lys36] GLP-1 (7-37)
Figure imgf000038_0003
N -(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy) acetylamino)ethoxy)ethoxy)acetyl) [Glyβ,Arg D LysH GLP-1 (7-37)
Figure imgf000039_0001
Nε20-(2-(2-(2-(2-(2-(2-(2-(2-(2-
(Octadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetylamino)ethoxy)- ethoxy)acetyl)[Lys20] Exendin-4 (1-39)amide
Figure imgf000039_0002
Nε36-(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl)-[Arg26,34,Lys36]GLP-1-
(7-37)
Figure imgf000039_0003
Nε -(2-[2-(2-[2-(2-[2-(17-Carboxyheptadecanoylamino)ethoxy]
34ι ethoxy)acetylamino]ethoxy)ethoxy]acetyl)[ArgπGLP-1-(7-37)-OH
Figure imgf000040_0001
Nε26-[2-(2-[2-(2-[2-(2-[4-(17-Carboxyheptadecanoylamino)-4(S)- carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Arg ,34, ]GLP-1-(7-37)- OH
Figure imgf000040_0002
N"υ-(2-(2-(2-(2-(2-(2-(2-(2-(2-(17-
Carboxyheptadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl- amino)ethoxy)ethoxy)acetyl)[Lys20] Exendin-4 (1-39) amide
Figure imgf000040_0003
[Gly8, Glu22'23'30, Arg18'26'34]GLP1 (7-37) Lys(2-(2-(2-(2-(2-(2-(17- carboxyheptadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy))ethoxy)acetyl)-NH2
Figure imgf000041_0001
[Imidazolylpropionic acid7, Asp16, Aib22'35 ]GLP1(7-37)Lys NH((2-{[4-(17- carboxyheptadecanoylamino)butylcarbamoyl]methoxy}ethoxy)ethoxy))
Figure imgf000041_0002
[Imidazolylpropionic acid7, Aib22'35 ]GLP1(7-37)Lys NH( (2-{[4-(17- carboxyheptadecanoylamino)butylcarbamoyl]methoxy}ethoxy)ethoxy))
Figure imgf000041_0003
, and [3-(5-lmidazoyl)propionyl7, Aib8, Arg26'34 ] GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-(17- carboxyheptanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000042_0001
In another embodiment the therapeutic polypeptide is a GLP-2 peptide.
In another embodiment the GLP-2 peptide is a DPPIV-protected GLP-2 peptide.
In another embodiment the GLP-2 peptide is Gly2-GLP-2(1-33).
In yet another embodiment the GLP-2 peptide is Lys17Arg30-GLP~2(1-33).
In another embodiment of the invention the therapeutic polypeptide is human insulin or an analogue thereof.
In another embodiment of the invention the therapeutic polypeptide is selected from the group consisting of AspB 8-human insulin, LysB28,ProB29-human insulin, LysB3,GluB29-human insulin, GlyA21,ArgB31,ArgB32-human insulin and des(B30) human insulin.
In another embodiment of the invention the therapeutic polypeptide is human growth hormone or an analogue thereof.
In another embodiment of the invention the therapeutic polypeptide is parathyroid hormone or an analogue thereof.
In another embodiment of the invention the therapeutic polypeptide is human follicle stimulating hormone or an analogue thereof. In another embodiment of the invention the therapeutic polypeptide has a molar weight of less than 100 kDa, less than 50 kDa, or less than 10 kDa.
In another embodiment of the invention the therapeutic polypeptide is selected from the group consisting of a growth factor such as platelet-derived growth factor (PDGF), transforming growth factor α (TGF-α), transforming growth factor β (TGF-β), epidermal growth fac- tor (EGF), vascular endothelial growth factor (VEGF), a somatomedin such as insulin growth factor I (IGF-I), insulin growth factor II (IFG-II), erythropoietin (EPO), thrombopoietin (TPO) or angiopoietin, interferon, pro-urokinase, urokinase, tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1 , plasminogen activator inhibitor 2, von Willebrandt factor, a cytokine, e.g. an interleukin such as interleukin (IL) 1, IL-1 Ra, IL-2, IL-4, IL-5, IL-6, IL-9, IL-11 , IL-12, IL- 13, IL-15, IL-16, IL-17, IL-18, IL-20 or IL-21 , a colony stimulating factor (CFS) such as GM- CSF, stem cell factor, a tumor necrosis factor such as TNF-α, lymphotoxin-α, lymphotoxin-β, CD40L, or CD30L, a protease inhibitor e.g. aprotinin, an enzyme such as superoxide dismu- tase, asparaginase, arginase, arginine deaminase, adenosine deaminase, ribonuclease, cata- lase, uricase, bilirubin oxidase, trypsin, papain, alkaline phosphatase, β-glucoronidase, purine nucleoside phosphorylase or batroxobin, an opioid, e.g. endorphins, enkephalins or non-natural opioids, a hormone or neuropeptide, e.g. calcitonin, glucagon, gastrins, adrenocorticotropic hormone (ACTH), cholecystokinins, lutenizing hormone, gonadotropin-releassing hormone, chorionic gonadotropin, corticotrophin-releasing factor, vasopressin, oxytocin, antidiuretic hormones, thyroid-stimulating hormone, thyrotropin-releasing hormone, relaxin, prolactin, peptide YY, neuropeptide Y, pancreastic polypeptide, leptin, CART (cocaine and amphetamine regu- lated transcript), a CART related peptide, perilipin, melanocortins (melanocyte-stimulating hormones) such as MC-4, melanin-concentrating hormones, natriuretic peptides, adrenomedullin, endothelin, secretin, amylin, vasoactive intestinal peptide (VIP), pituary adenylate cyclase activating polypeptide (PACAP), bombesin, bombesin-like peptides, thymosin, heparin-binding protein, soluble CD4, hypothalmic releasing factor, melanotonins and analogues thereof.
In another aspect the present invention relates to a pharmaceutical composition comprising a compound according to the invention, and a pharmaceutically acceptable excipient.
In one embodiment the pharmaceutical composition is suited for parenteral administration.
In another aspect the present invention relates to the use of a compound according to the invention for the preparation of a medicament.
In one embodiment of the invention a compound according to the invention wherein the therapeutic polypeptide is a GLP-1 peptide is used for the preparation of a medicament for the treatment or prevention of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, cognitive disorders, athero- schlerosis, myocardial infarction, coronary heart disease and other cardiovascular disorders, stroke, inflammatory bowel syndrome, dyspepsia and gastric ulcers.
In another embodiment of the invention a compound according to the invention wherein the therapeutic polypeptide is a GLP-1 peptide is used for the preparation of a medicament for delaying or preventing disease progression in type 2 diabetes. In another embodiment of the invention a compound according to the invention wherein the therapeutic polypeptide is a GLP-1 peptide is used for the preparation of a medicament for decreasing food intake, decreasing β-cell apoptosis, increasing β-cell funtion and β-cell mass, and/or for restoring glucose sensitivity to β-cells.
In another embodiment of the invention a compound according to the invention wherein the therapeutic polypeptide is a GLP-2 peptide is used for the preparation of a medicament for the treatment of small bowel syndrome, inflammatory bowel syndrome or Crohns disease. In another embodiment of the invention a compound according to the invention wherein the therapeutic polypeptide is an insulin peptide is used for the preparation of a medicament for the treatment or prevention of hyperglycemia, type 1 diabetes, type 2 diabetes or β-cell deficiency.
The therapeutic polypeptide can be produced by a method which comprises culturing a host cell containing a DNA sequence encoding the polypeptide and capable of expressing the polypeptide in a suitable nutrient medium under conditions permitting the expression of the peptide, after which the resulting peptide is recovered from the culture.
The medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection). The peptide produced by the cells may then be recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, precipitating the pro- teinaceous components of the supernatant or filtrate by means of a salt, e.g. ammonium sulphate, purification by a variety of chromatographic procedures, e.g. ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like, dependent on the type of peptide in question.
The DNA sequence encoding the therapeutic polypeptide may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the polypeptide by hybridisation using synthetic oligonucleotide probes in accordance with standard techniques (see, for example, Sambrook, J, Fritsch, EF and Maniatis, T, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1989). The DNA sequence encoding the polypeptide may also be prepared synthetically by established standard methods, e.g. the phosphoamidite method described by Beaucage and Caruthers, Tetrahedron Letters 22 (1981), 1859 - 1869, or the method described by Matthes et al., EMBO Journal 3 (1984), 801 - 805. The DNA sequence may also be prepared by polymerase chain reaction using specific primers, for instance as described in US 4,683,202 or Saiki et al. , Science 239 (1988), 487 - 491.
The DNA sequence may be inserted into any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.
The vector is preferably an expression vector in which the DNA sequence encoding the peptide is operably linked to additional segments required for transcription of the DNA, such as a promoter. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA encoding the peptide of the invention in a variety of host cells are well known in the art, cf. for instance Sambrook et al., supra.
The DNA sequence encoding the peptide may also, if necessary, be operably connected to a suitable terminator, polyadenylation signals, transcriptional enhancer sequences, and transla- tional enhancer sequences. The recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.
The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell or one which confers resistance to a drug, e.g. ampicillin, kana- mycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.
To direct a parent peptide of the present invention into the secretory pathway of the host cells, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector. The secretory signal sequence is joined to the DNA sequence encoding the peptide in the correct reading frame. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the peptide. The secre- tory signal sequence may be that normally associated with the peptide or may be from a gene encoding another secreted protein.
The procedures used to ligate the DNA sequences coding for the present peptide, the pro- moter and optionally the terminator and/or secretory signal sequence, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al.., supra).
The host cell into which the DNA sequence or the recombinant vector is introduced may be any cell which is capable of producing the present peptide and includes bacteria, yeast, fungi and higher eukaryotic cells. Examples of suitable host cells well known and used in the art are, without limitation, E. coli, Saccharomyces cerevisiae, or mammalian BHK or CHO cell lines.
Examples of compounds which can be useful as GLP-1 moieties according to the present in- vention are described in International Patent Application No. WO 87/06941 (The General Hospital Corporation) which relates to a peptide fragment which comprises GLP-1 (7-37) and functional derivatives thereof and to its use as an insulinotropic agent.
Further GLP-1 analogues are described in International Patent Application No. 90/11296 (The General Hospital Corporation) which relates to peptide fragments which comprise GLP-1 (7-36) and functional derivatives thereof and have an insulinotropic activity which exceeds the insulinotropic activity of GLP-1 (1-36) or GLP-1 (1-37) and to their use as insulinotropic agents.
International Patent Application No. 91/11457 (Buckley et al..) discloses analogues of the ac- tive GLP-1 peptides 7-34, 7-35, 7-36, and 7-37 which can also be useful as GLP-1 moieties according to the present invention.
Pharmaceutical compositions Pharmaceutical compositions containing a compound according to the present invention may be prepared by conventional techniques, e.g. as described in Remington's Pharmaceutical Sciences, 1985 or in Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
One object of the present invention is to provide a pharmaceutical formulation comprising a compound according to the present invention which is present in a concentration from about 0.1 mg/ml to about 25 mg/ml, and wherein said formulation has a pH from 2.0 to 10.0. The pharmaceutical formulation may comprise a compound according to the present invention which is present in a concentration from about 0.1 mg/ml to about 50 mg/ml, and wherein said formulation has a pH from 2.0 to 10.0. The formulation may further comprise a buffer system, preservative(s), isotonicity agent(s), chelating agent(s), stabilizers and surfactants. In one embodiment of the invention the pharmaceutical formulation is an aqueous formulation, i.e. formulation comprising water. Such formulation is typically a solution or a suspension. In a further embodiment of the invention the pharmaceutical formulation is an aqueous solution. The term "aqueous formulation" is defined as a formulation comprising at least 50 %w/w water. Likewise, the term "aqueous solution" is defined as a solution comprising at least 50 %w/w water, and the term "aqueous suspension" is defined as a suspension comprising at least 50 %w/w water.
In another embodiment the pharmaceutical formulation is a freeze-dried formulation, whereto the physician or the patient adds solvents and/or diluents prior to use.
In another embodiment the pharmaceutical formulation is a dried formulation (e.g. freeze-dried or spray-dried) ready for use without any prior dissolution.
In a further aspect the invention relates to a pharmaceutical formulation comprising an aqueous solution of a compound according to the present invention, and a buffer, wherein said compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from about 2.0 to about 10.0. In a further aspect the invention relates to a pharmaceutical formulation comprising an aqueous solution of a compound according to the present invention, and a buffer, wherein said compound is present in a concentration from 0.1 mg/ml or above, and wherein said formulation has a pH from about 7.0 to about 8.5.
In a another embodiment of the invention the pH of the formulation is selected from the list consisting of 2.0, 2.1 , 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1 , 3.2, 3.3, 3.4, 3.5,
3.6, 3.7, 3.8, 3.9, 4.0, 4.1 , 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1 , 5.2, 5.3, 5.4, 5.5, 5.6,
5.7, 5.8, 5.9, 6.0, 6.1 , 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1 , 7.2, 7.3, 7.4, 7.5, 7.6, 7.7,
7.8, 7.9, 8.0, 8.1 , 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1 , 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8,
9.9, and 10.0. Preferably, the pH of the formulation is at least 1 pH unit from the isoelectric point of the compound according to the present invention, even more preferable the pH of the formulation is at least 2 pH unit from the isoelectric point of the compound according to the present invention.
In a further embodiment of the invention the buffer is selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethane, hepes, bicine, tricine, malic acid, succinate, maleic acid, fumaric acid, tartaric acid, aspartic acid or mixtures thereof. Each one of these specific buffers constitutes an alternative embodiment of the invention.
In a further embodiment of the invention the formulation further comprises a pharmaceutically acceptable preservative. In a further embodiment of the invention the preservative is selected from the group consisting of phenol, o-cresol, m-cresol, p-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p- hydroxybenzoate, 2-phenylethanol, benzyl alcohol, ethanol, chlorobutanol, and thiomerosal, bronopol, benzoic acid, imidurea, chlorohexidine, sodium dehydroacetate, chlorocresol, ethyl p-hydroxybenzoate, benzethonium chloride, chlorphenesine (3p-chlorphenoxypropane-1 ,2- diol) or mixtures thereof. In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 30 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 20 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 5 mg/ml to 10 mg/ml. In a further embodiment of the invention the preservative is present in a concentration from 10 mg/ml to 20 mg/ml. Each one of these specific preservatives constitutes an alternative embodiment of the invention. The use of a preservative in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
In a further embodiment of the invention the formulation further comprises an isotonic agent. In a further embodiment of the invention the isotonic agent is selected from the group consisting of a salt (e.g. sodium chloride), a sugar or sugar alcohol, an amino acid (e.g. L- glycine, L-histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine), an alditol (e.g. glycerol (glycerine), 1 ,2-propanediol (propyleneglycol), 1 ,3-propanediol, 1 ,3- butanediol) polyethyleneglycol (e.g. PEG400), or mixtures thereof. Any sugar such as mono- , di-, or polysaccharides, or water-soluble glucans, including for example fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch and carboxymethylcellulose-Na may be used. In one embodiment the sugar additive is sucrose. Sugar alcohol is defined as a C4-C8 hydrocarbon having at least one —OH group and includes, for example, mannitol, sorbitol, inositol, galacititol, dulcitol, xylitol, and arabitol. In one embodiment the sugar alcohol additive is mannitol. The sugars or sugar alcohols mentioned above may be used individually or in combination. There is no fixed limit to the amount used, as long as the sugar or sugar alcohol is soluble in the liquid preparation and does not adversely effect the stabilizing effects achieved using the methods of the invention. In one embodiment, the sugar or sugar alcohol concentration is between about 1 mg/ml and about 150 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 1 mg/ml to 50 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 1 mg/ml to 7 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 8 mg/ml to 24 mg/ml. In a further embodiment of the invention the isotonic agent is present in a concentration from 25 mg/ml to 50 mg/ml. Each one of these specific isotonic agents constitutes an alternative embodiment of the invention. The use of an isotonic agent in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
In a further embodiment of the invention the formulation further comprises a chelating agent. In a further embodiment of the invention the chelating agent is selected from salts of ethylenediaminetetraacetic acid (EDTA), citric acid, and aspartic acid, and mixtures thereof. In a further embodiment of the invention the chelating agent is present in a concentration from 0.1 mg/ml to 5mg/ml. In a further embodiment of the invention the chelating agent is present in a concentration from 0.1 mg/ml to 2mg/ml. In a further embodiment of the invention the chelating agent is present in a concentration from 2mg/ml to 5mg/ml. Each one of these specific chelating agents constitutes an alternative embodiment of the invention. The use of a chelating agent in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
In a further embodiment of the invention the formulation further comprises a stabiliser. The use of a stabilizer in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Phar- macy, 19th edition, 1995.
More particularly, compositions of the invention are stabilized liquid pharmaceutical compositions whose therapeutically active components include a polypeptide that possibly exhibits aggregate formation during storage in liquid pharmaceutical formulations. By "aggregate formation" is intended a physical interaction between the polypeptide molecules that results in formation of oligomers, which may remain soluble, or large visible aggregates that precipitate from the solution. By "during storage" is intended a liquid pharmaceutical compo- sition or formulation once prepared, is not immediately administered to a subject. Rather, following preparation, it is packaged for storage, either in a liquid form, in a frozen state, or in a dried form for later reconstitution into a liquid form or other form suitable for administration to a subject. By "dried form" is intended the liquid pharmaceutical composition or formulation is dried either by freeze drying (i.e., lyophilization; see, for example, Williams and Polli (1984) J. Parenteral Sci. Technol. 38:48-59), spray drying (see Masters (1991 ) in Spray- Drying Handbook (5th ed; Longman Scientific and Technical, Essez, U.K.), pp. 491-676; Broadhead et al. (1992) Drug Devel. Ind. Pharm. 18:1169-1206; and Mumenthaler et al. (1994) Pharm. Res. 11 :12-20), or air drying (Carpenter and Crowe (1988) Cryobiology 25:459-470; and Roser (1991) Biopharm. 4:47-53). Aggregate formation by a polypeptide during storage of a liquid pharmaceutical composition can adversely affect biological activity of that polypeptide, resulting in loss of therapeutic efficacy of the pharmaceutical composition. Furthermore, aggregate formation may cause other problems such as blockage of tubing, membranes, or pumps when the polypeptide-containing pharmaceutical composition is administered using an infusion system.
The pharmaceutical compositions of the invention may further comprise an amount of an amino acid base sufficient to decrease aggregate formation by the polypeptide during storage of the composition. By "amino acid base" is intended an amino acid or a combination of amino acids, where any given amino acid is present either in its free base form or in its salt form. Where a combination of amino acids is used, all of the amino acids may be present in their free base forms, all may be present in their salt forms, or some may be present in their free base forms while others are present in their salt forms. In one embodiment, amino acids used for preparing the compositions of the invention are those carrying a charged side chain, such as arginine, lysine, aspartic acid, and glutamic acid. In one em- bodiment, the amino acid used for preparing the compositions of the invention is glycine. Any stereoisomer (i.e. L or D) of a particular amino acid (e.g. methionine, histidine, imidazole, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine and mixtures thereof) or combinations of these stereoisomers, may be present in the pharmaceutical compositions of the invention so long as the particular amino acid is present either in its free base form or its salt form. In one embodiment the L-stereoisomer is used. Compositions of the invention may also be formulated with analogues of these amino acids. By "amino acid analogue" is intended a derivative of the naturally occurring amino acid that brings about the desired effect of decreasing aggregate formation by the polypeptide during storage of the liquid pharmaceutical compositions of the invention. Suitable arginine analogues include, for example, aminoguanidine, ornithine and N-monoethyl L-arginine, suitable methionine analogues include ethionine and buthionine and suitable cystein analogues include S-methyl-L cystein. As with the other amino acids, the amino acid analogues are incorporated into the compositions in either their free base form or their salt form. In a further embodiment of the invention the amino acids or amino acid analogues are used in a concentration, which is sufficient to prevent or delay aggregation of the protein. In a further embodiment of the invention methionine (or other sulphuric amino acids or amino acid analogous) may be added to inhibit oxidation of methionine residues to methionine sulfoxide when the polypeptide acting as the therapeutic agent is a polypeptide comprising at least one methionine residue susceptible to such oxidation. By "inhibit" is intended minimal accumulation of methionine oxidized species over time. Inhibiting methionine oxidation results in greater retention of the polypeptide in its proper molecular form. Any stereoisomer of methionine (L, D or a mixture thereof) can be used. The amount to be added should be an amount sufficient to inhibit oxidation of the methionine residues such that the amount of methionine sulfoxide is acceptable to regulatory agencies. Typically, this means that the composition contains no more than about 10% to about 30% methionine sulfoxide. Generally, this can be achieved by adding methionine such that the ratio of methionine added to methionine residues ranges from about 1 :1 to about 1000:1 , such as 10:1 to about 100:1.
In a further embodiment of the invention the formulation further comprises a stabiliser selected from the group of high molecular weight polymers or low molecular compounds. In a further embodiment of the invention the stabilizer is selected from polyethylene glycol (e.g. PEG 3350), polyvinylalcohol (PVA), polyvinylpyrrolidone, carboxy-/hydroxycellulose or derivates thereof (e.g. HPC, HPC-SL, HPC-L and HPMC), cyclodextrins, sulphur-containing substances as monothioglycerol, thioglycolic acid and 2-methylthioethanol, and different salts (e.g. sodium chloride). Each one of these specific stabilizers constitutes an alternative embodiment of the invention.
The pharmaceutical compositions may also comprise additional stabilizing agents, which further enhance stability of a therapeutically active polypeptide therein. Stabilizing agents of particular interest to the present invention include, but are not limited to, methionine and EDTA, which protect the polypeptide against methionine oxidation, and a nonionic surfactant, which protects the polypeptide against aggregation associated with freeze-thawing or mechanical shearing.
In a further embodiment of the invention the formulation further comprises a surfactant. In a further embodiment of the invention the surfactant is selected from a detergent, ethoxylated castor oil, polyglycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, polyoxypropylene-polyoxyethylene block polymers (eg. poloxamers such as Pluronic® F68, poloxamer 188 and 407, Triton X-100 ), polyoxyethylene sorbitan fatty acid esters, starshaped PEO, polyoxyethylene and polyethylene derivatives such as alkylated and alkoxylated derivatives (tweens, e.g. Tween-20, Tween-40, Tween-80 and Brij- 35), polyoxyethylene hydroxystearate, monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, alcohols, glycerol, lecitins and phospholipids (eg. phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, diphosphatidyl glycerol and sphingomyelin), derivates of phospholipids (eg. dipalmitoyl phosphatidic acid) and lysophospholipids (eg. palmitoyl lysophosphatidyl-L- serine and 1-acyl-sn-glycero-3-phosphate esters of ethanolamine, choline, serine or threonine) and alkyl, alkoxyl (alkyl ester), alkoxy (alkyl ether)- derivatives of lysophosphatidyl and phosphatidylcholines, e.g. lauroyl and myristoyl derivatives of lysophosphatidylcholine, dipalmitoylphosphatidylcholine, and modifications of the polar head group, that is cholines, ethanolamines, phosphatidic acid, serines, threonines, glycerol, inositol, and the positively charged DODAC, DOTMA, DCP, BISHOP, lysophosphatidylserine and lysophosphatidylthreonine, and glycerophospholipids (eg. cephalins), glyceroglycolipids (eg. galactopyransoide), sphingoglycolipids (eg. ceramides, gangliosides), dodecylphosphocholine, hen egg lysolecithin, fusidic acid derivatives- (e.g. sodium tauro- dihydrofusidate etc.), long-chain fatty acids and salts thereof C6-C12 (eg. oleic acid and caprylic acid), acylcarnitines and derivatives, Nα-acylated derivatives of lysine, arginine or histidine, or side-chain acylated derivatives of lysine or arginine, Nα-acylated derivatives of dipeptides comprising any combination of lysine, arginine or histidine and a neutral or acidic amino acid, N -acylated derivative of a tripeptide comprising any combination of a neutral amino acid and two charged amino acids, DSS (docusate sodium, CAS registry no [577-11- 7]), docusate calcium, CAS registry no [128-49-4]), docusate potassium, CAS registry no [7491-09-0]), SDS (sodium dodecyl sulfate or sodium lauryl sulfate), sodium caprylate, cholic acid or derivatives thereof, bile acids and salts thereof and glycine or taurine conjugates, ursodeoxycholic acid, sodium cholate, sodium deoxycholate, sodium taurocholate, sodium glycocholate, N-Hexadecyi-N,N-dimethyl-3-ammonio-1-propanesulfonate, anionic (alkyl-aryl- sulphonates) monovalent surfactants, zwitterionic surfactants (e.g. N-alkyl-N,N- dimethylammonio-1 -propanesulfonates, 3-cholamido-1 -propyldimethylammonio-1 - propanesulfonate, cationic surfactants (quarternary ammonium bases) (e.g. cetyl- trimethylammonium bromide, cetylpyridinium chloride), non-ionic surfactants (eg. Dodecyl β- D-glucopyranoside), poloxamines (eg. Tetronic's), which are tetrafunctional block copolymers derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine, or the surfactant may be selected from the group of imidazoline derivatives, or mixtures thereof. Each one of these specific surfactants constitutes an alternative embodiment of the invention.
The use of a surfactant in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
A composition for parenteral administration of GLP-1 compounds may, for example, be prepared as described in WO 03/002136.
It is possible that other ingredients may be present in the peptide pharmaceutical formulation of the present invention. Such additional ingredients may include wetting agents, emulsifiers, antioxidants, bulking agents, tonicity modifiers, chelating agents, metal ions, oleaginous vehicles, proteins (e.g., human serum albumin, gelatin or proteins) and a zwit- terion (e.g., an amino acid such as betaine, taurine, arginine, glycine, lysine and histidine). Such additional ingredients, of course, should not adversely affect the overall stability of the pharmaceutical formulation of the present invention.
Pharmaceutical compositions containing a compound according to the present invention may be administered to a patient in need of such treatment at several sites, for example, at topical sites, for example, skin and mucosal sites, at sites which bypass absorption, for example, administration in an artery, in a vein, in the heart, and at sites which in- volve absorption, for example, administration in the skin, under the skin, in a muscle or in the abdomen.
Administration of pharmaceutical compositions according to the invention may be through several routes of administration, for example, lingual, sublingual, buccal, in the mouth, oral, in the stomach and intestine, nasal, pulmonary, for example, through the bron- chioles and alveoli or a combination thereof, epidermal, dermal, transdermal, vaginal, rectal, ocular, for examples through the conjunctiva, uretal, and parenteral to patients in need of such a treatment.
Compositions of the current invention may be administered in several dosage forms, for example, as solutions, suspensions, emulsions, microemulsions, multiple emul- sion, foams, salves, pastes, plasters, ointments, tablets, coated tablets, rinses, capsules, for example, hard gelatine capsules and soft gelatine capsules, suppositories, rectal capsules, drops, gels, sprays, powder, aerosols, inhalants, eye drops, ophthalmic ointments, ophthalmic rinses, vaginal pessaries, vaginal rings, vaginal ointments, injection solution, in situ transforming solutions, for example in situ gelling, in situ setting, in situ precipitating, in situ crystallization, infusion solution, and implants. Compositions of the invention may further be compounded in, or attached to, for example through covalent, hydrophobic and electrostatic interactions, a drug carrier, drug delivery system and advanced drug delivery system in order to further enhance stability of the compound, increase bioavailability, increase solubility, decrease adverse effects, achieve chronotherapy well known to those skilled in the art, and increase patient compliance or any combination thereof. Examples of carriers, drug delivery systems and advanced drug delivery systems include, but are not limited to, polymers, for example cellulose and derivatives, polysaccharides, for example dextran and derivatives, starch and derivatives, poly(vinyl alcohol), acrylate and methacrylate polymers, polylactic and polyglycolic acid and block co- polymers thereof, polyethylene glycols, carrier proteins, for example albumin, gels, for example, thermogelling systems, for example block co-polymeric systems well known to those skilled in the art, micelles, liposomes, microspheres, nanoparticulates, liquid crystals and dispersions thereof, L2 phase and dispersions there of, well known to those skilled in the art of phase behaviour in lipid-water systems, polymeric micelles, multiple emulsions, self- emulsifying, self-microemulsifying, cyclodextrins and derivatives thereof, and dendrimers. Compositions of the current invention are useful in the formulation of solids, semi- solids, powder and solutions for pulmonary administration of the compound, using, for example a metered dose inhaler, dry powder inhaler and a nebulizer, all being devices well known to those skilled in the art. Compositions of the current invention are specifically useful in the formulation of controlled, sustained, protracting, retarded, and slow release drug delivery systems. More specifically, but not limited to, compositions are useful in formulation of parenteral controlled release and sustained release systems (both systems leading to a many-fold reduction in number of administrations), well known to those skilled in the art. Even more preferably, are controlled release and sustained release systems administered subcutaneous. Without limiting the scope of the invention, examples of useful controlled release system and compositions are hydrogels, oleaginous gels, liquid crystals, polymeric micelles, microspheres, nanoparticles,
Methods to produce controlled release systems useful for compositions of the cur- rent invention include, but are not limited to, crystallization, condensation, co-cystallization, precipitation, co-precipitation, emulsification, dispersion, high pressure homogenization, encapsulation, spray drying, microencapsulation, coacervation, phase separation, solvent evaporation to produce microspheres, extrusion and supercritical fluid processes. General reference is made to Handbook of Pharmaceutical Controlled Release (Wise, D.L., ed. Mar- eel Dekker, New York, 2000) and Drug and the Pharmaceutical Sciences vol. 99: Protein Formulation and Delivery (MacNally, E.J., ed. Marcel Dekker, New York, 2000). Parenteral administration may be performed by subcutaneous, intramuscular, intraperitoneal or intravenous injection by means of a syringe, optionally a pen-like syringe. Alternatively, parenteral administration can be performed by means of an infusion pump. A further option is a composition which may be a solution or suspension for the administration of the compound according to the present invention in the form of a nasal or pulmonal spray. As a still further option, the pharmaceutical compositions containing the compound of the invention can also be adapted to transdermal administration, e.g. by needle-free injection or from a patch, optionally an iontophoretic patch, or transmucosal, e.g. buccal, administration.
The term "stabilized formulation" refers to a formulation with increased physical stabil- ity, increased chemical stability or increased physical and chemical stability.
The term "physical stability" of the protein formulation as used herein refers to the tendency of the protein to form biologically inactive and/or insoluble aggregates of the protein as a result of exposure of the protein to thermo-mechanical stresses and/or interaction with interfaces and surfaces that are destabilizing, such as hydrophobic surfaces and interfaces. Physical stability of the aqueous protein formulations is evaluated by means of visual inspection and/or turbidity measurements after exposing the formulation filled in suitable containers (e.g. cartridges or vials) to mechanical/physical stress (e.g. agitation) at different temperatures for various time periods. Visual inspection of the formulations is performed in a sharp focused light with a dark background. The turbidity of the formulation is characterized by a visual score ranking the degree of turbidity for instance on a scale from 0 to 3 (a formulation showing no turbidity corresponds to a visual score 0, and a formulation showing visual turbidity in daylight corresponds to visual score 3). A formulation is classified physical unstable with respect to protein aggregation, when it shows visual turbidity in daylight. Alternatively, the turbidity of the for- mulation can be evaluated by simple turbidity measurements well-known to the skilled person. Physical stability of the aqueous protein formulations can also be evaluated by using a spec- troscopic agent or probe of the conformational status of the protein. The probe is preferably a small molecule that preferentially binds to a non-native conformer of the protein. One example of a small molecular spectroscopic probe of protein structure is Thioflavin T. Thioflavin T is a fluorescent dye that has been widely used for the detection of amyloid fibrils. In the presence of fibrils, and perhaps other protein configurations as well, Thioflavin T gives rise to a new excitation maximum at about 450 nm and enhanced emission at about 482 nm when bound to a fibril protein form. Unbound Thioflavin T is essentially non-fluorescent at the wavelengths.
Other small molecules can be used as probes of the changes in protein structure from native to non-native states. For instance the "hydrophobic patch" probes that bind pref- erentially to exposed hydrophobic patches of a protein. The hydrophobic patches are generally buried within the tertiary structure of a protein in its native state, but become exposed as a protein begins to unfold or denature. Examples of these small molecular, spectroscopic probes are aromatic, hydrophobic dyes, such as antrhacene, acridine, phenanthroline or the like. Other spectroscopic probes are metal-amino acid complexes, such as cobalt metal complexes of hydrophobic amino acids, such as phenylalanine, leucine, isoleucine, methionine, and valine, or the like.
The term "chemical stability" of the protein formulation as used herein refers to chemical covalent changes in the protein structure leading to formation of chemical degradation products with potential less biological potency and/or potential increased immunogenic properties compared to the native protein structure. Various chemical degradation products can be formed depending on the type and nature of the native protein and the environment to which the protein is exposed. Elimination of chemical degradation can most probably not be completely avoided and increasing amounts of chemical degradation products is often seen during storage and use of the protein formulation as well-known by the person skilled in the art. Most proteins are prone to deamidation, a process in which the side chain amide group in glutaminyl or asparaginyl residues is hydrolysed to form a free carboxylic acid. Other degradations pathways involves formation of high molecular weight transformation products where two or more protein molecules are covalently bound to each other through transamidation and/or disulfide interactions leading to formation of covalently bound dimer, oligomer and polymer degradation products (Stability of Protein Pharmaceuticals, Ahem. T.J. & Manning M.C., Plenum Press, New York 1992). Oxidation (of for instance methionine residues) can be mentioned as another variant of chemical degradation. The chemical stabil- ity of the protein formulation can be evaluated by measuring the amount of the chemical degradation products at various time-points after exposure to different environmental conditions (the formation of degradation products can often be accelerated by for instance increasing temperature). The amount of each individual degradation product is often determined by separation of the degradation products depending on molecule size and/or charge using various chromatography techniques (e.g. SEC-HPLC and/or RP-HPLC).
Hence, as outlined above, a "stabilized formulation" refers to a formulation with increased physical stability, increased chemical stability or increased physical and chemical stability. In general, a formulation must be stable during use and storage (in compliance with recommended use and storage conditions) until the expiration date is reached. In one embodiment of the invention the pharmaceutical formulation comprising the compound according to the present invention is stable for more than 6 weeks of usage and for more than 3 years of storage.
In another embodiment of the invention the pharmaceutical formulation comprising the compound according to the present invention is stable for more than 4 weeks of usage and for more than 3 years of storage.
In a further embodiment of the invention the pharmaceutical formulation comprising the compound according to the present invention is stable for more than 4 weeks of usage and for more than two years of storage. In an even further embodiment of the invention the pharmaceutical formulation comprising the compound is stable for more than 2 weeks of usage and for more than two years of storage.
Pharmaceutical compositions containing a GLP-1 derivative according to the present invention may be administered parenterally to patients in need of such a treatment. Parenteral administration may be performed by subcutaneous, intramuscular or intravenous injection by means of a syringe, optionally a pen-like syringe. Alternatively, parenteral administration can be performed by means of an infusion pump. A further option is a composition which may be a powder or a liquid for the administration of the GLP-1 derivative in the form of a nasal or pul- monal spray. As a still further option, the GLP-1 derivatives of the invention can also be administered transdermally, e.g. from a patch, optionally a iontophoretic patch, or transmucosally, e.g. bucally.
Thus, the injectable compositions of the GLP-1 derivative of the invention can be pre- pared using the conventional techniques of the pharmaceutical industry which involves dissolving and mixing the ingredients as appropriate to give the desired end product.
According to one procedure, the GLP-1 derivative is dissolved in an amount of water which is somewhat less than the final volume of the composition to be prepared. An isotonic agent, a preservative and a buffer is added as required and the pH value of the solution is adjusted - if necessary - using an acid, e.g. hydrochloric acid, or a base, e.g. aqueous sodium hydroxide as needed. Finally, the volume of the solution is adjusted with water to give the desired concentration of the ingredients. Further to the above-mentioned components, solutions containing a GLP-1 derivative according to the present invention may also contain a surfactant in order to improve the solubility and/or the stability of the GLP-1 derivative.
A composition for nasal administration of certain peptides may, for example, be prepared as described in European Patent No. 272097 (to Novo Nordisk A/S) or in WO 93/18785.
According to one preferred embodiment of the present invention, the GLP-1 derivative is provided in the form of a composition suitable for administration by injection. Such a compo- sition can either be an injectable solution ready for use or it can be an amount of a solid composition, e.g. a lyophilised product, which has to be dissolved in a solvent before it can be injected. The injectable solution preferably contains not less than about 2 mg/ml, preferably not less than about 5 mg/ml, more preferred not less than about 10 mg/ml of the GLP-1 derivative and, preferably, not more than about 100 mg/ml of the GLP-1 derivative.
The GLP-1 derivatives of this invention can be used in the treatment of various diseases. The particular GLP-1 derivative to be used and the optimal dose level for any patient will depend on the disease to be treated and on a variety of factors including the efficacy of the specific peptide derivative employed, the age, body weight, physical activity, and diet of the pa- tient, on a possible combination with other drugs, and on the severity of the case. It is recommended that the dosage of the GLP-1 derivative of this invention be determined for each individual patient by those skilled in the art.
In particular, it is envisaged that the GLP-1 derivative will be useful for the preparation of a medicament with a protracted profile of action for the treatment of non-insulin dependent diabetes mellitus and/or for the treatment of obesity.
In another aspect the present invention relates to the use of a compound according to the invention for the preparation of a medicament. In one embodiment the present invention relates to the use of a compound according to the invention for the preparation of a medicament for the treatment of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, β-cell apoptosis, β-cell deficiency, myocardial infarction, inflammatory bowel syndrome, dyspepsia, cognitive disorders, e.g. cognitive enhancing, neuroprotection, atheroschlerosis, coronary heart disease and other cardiovascular disorders. In another embodiment the present invention relates to the use of a compound according to the invention for the preparation of a medicament for the treatment of small bowel syndrome, inflammatory bowel syndrome or Crohns disease.
In another embodiment the present invention relates to the use of a compound ac- cording to the invention for the preparation of a medicament for the treatment of hypergly- cemia, type 1 diabetes, type 2 diabetes or β-cell deficiency.
The treatment with a compound according to the present invention may also be combined with combined with a second or more pharmacologically active substances, e.g. selected from antidiabetic agents, antiobesity agents, appetite regulating agents, antihypertensive agents, agents for the treatment and/or prevention of complications resulting from or associated with diabetes and agents for the treatment and/or prevention of complications and disorders resulting from or associated with obesity. In the present context the expression "antidiabetic agent" includes compounds for the treatment and/or prophylaxis of insulin resis- tance and diseases wherein insulin resistance is the pathophysiological mechanism.
Examples of these pharmacologically active substances are : Insulin, GLP-1 agonists, sulphonylureas (e.g. tolbutamide, glibenclamide, glipizide and gliclazide), biguanides e.g. metformin, meglitinides, glucosidase inhibitors (e.g. acorbose), glucagon antagonists, DPP-IV (dipeptidyl peptidase-IV) inhibitors, inhibitors of hepatic enzymes involved in stimula- tion of gluconeogenesis and/or glycogenolysis, glucose uptake modulators, thiazolidinediones such as troglitazone and ciglitazone, compounds modifying the lipid metabolism such as antihyperlipidemic agents as HMG CoA inhibitors (statins), compounds lowering food intake, RXR agonists and agents acting on the ATP-dependent potassium channel of the β-cells, e.g. glibenclamide, glipizide, gliclazide and repaglinide; Cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol, dextrothyroxine, neteglinide, repaglinide; β-blockers such as alprenolol, atenolol, timolol, pindolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, alatriopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and α-blockers such as doxazosin, urapidil, prazosin and terazosin; CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC4 (melanocortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, β3 agonists, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin re-uptake inhibitors, serotonin and noradrenaline re-uptake inhibitors, mixed sero- tonin and noradrenergic compounds, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth hormone releasing compounds, TRH (thyreotropin releasing hormone) agonists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA agonists (bromocriptin, doprexin), lipase/amylase inhibitors, RXR (retinoid X receptor) modulators, TR β agonists; histamine H3 antagonists.
It should be understood that any suitable combination of the compounds according to the invention with one or more of the above-mentioned compounds and optionally one or more further pharmacologically active substances are considered to be within the scope of the present invention.
The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection. The features disclosed in the foregoing description and in the following examples may, both separately and in any combination thereof, be material for realising the invention in diverse forms thereof.
EXAMPLES
The following acronyms for commercially available chemicals are used:
DMF N,N-Dimethylformamide.
DCC N,N-Dicyclohexylcarbodiimide
NMP N-Methyl-2-pyrrolidone.
TFA Trifluoroacetic acid.
THF Tetrahydrofuran
DIEA diisopropylethylamine
H2O water
CH3CN acetonitrile
HBTU 2-(1 H-Benzotriazol-1-yl)-1 ,1 ,3,3 tetramethyluronium hexafluoro phosphate
Fmoc 9 H-fluoren-9-ylmethoxycarbonyl
Boc tert butyloxycarbonyl
OtBu tert butyl ester tBu tert butyl
Trt triphenylmethyl
Pmc 2,2,5,7, 8-Pentamethyl-chroman-6-sulfonyl
Dde 1-(4,4-Dimethyl-2,6-dioxocycIohexylidene)ethyl
DCM dichloromethane
TIS triisopropylsilane)
Et2O: diethylether
H-Glu(OH)-OBuf: : L-Glutamic acid α-tert-butyl ester
HOOC-(CH2)12 -COONSu : ω-Carboxytridecanoic acid 2,5-dioxopyrrolidin-1-yl est(
HOOC-(CH2)ι4 -COONSu : ω-Carboxypentadecanoic acid 2,5-dioxopyrrolidin-1-yl ester.
HOOC-(CH2)i6 -COONSu : ω-Carboxyheptadecanoic acid 2,5-dioxopyrrolidin-1-yl ester.
HOOC-(CH2)18 -COONSu : ω-Carboxynonadecanoic acid 2,5-dioxopyrrolidin-1-yl ester. Abbreviations: r.t Room temperature
PDMS: Plasma Desorption Mass Spectrometry
MALDI-MS: Matrix Assisted Laser Desorption/lonisation Mass Spectrometry HPLC: High Performance Liquid Chromatography amu: atomic mass units
Analytical:
Resistance of a peptide to degradation by dipeptidyl aminopeptidase IV is determined by the following degradation assay :
Aliquots of the peptides are incubated at 37 °C with an aliquot of purified dipeptidyl aminopeptidase IV for 4-22 hours in an appropriate buffer at pH 7-8 (buffer not being albumin). Enzymatic reactions are terminated by the addition of trifluoroacetic acid, and the peptide degradation products are separated and quantified using HPLC or LC-MS analysis. One method for performing this analysis is: The mixtures are applied onto a Zorbax 300SB-C18 (30 nm pores, 5 μm particles) 150 x 2.1 mm column and eluted at a flow rate of 0.5 ml/min with a linear gradient of acetonitrile in 0.1% trifluoroacetic acid (0% -100% acetonitrile over 30 min). Peptides and their degradation products may be monitored by their absorbance at 214 nm (peptide bonds) or 280 nm (aromatic amino acids), and are quantified by integration of their peak areas. The degradation pattern can be determined by using LC-MS where MS spectra of the separated peak can be determined. Percentage intact/degraded compound at a given time is used for estimation of the peptides DPPIV stability. A peptide is defined as DPPIV stabilised when it is 10 times more stable than the natural peptide based on percentage intact compound at a given time. Thus, a DPPIV stabilised GLP-1 compound is at least 10 times more stable than GLP-1 (7-37).
General Synthetic methods
The peptides may be synthesized on Fmoc protected Rink amide resin (Novabiochem) or chlorotrityl resin or a similar resin suitable for solid phase peptide synthesis. Boc chemistry may be used but more conveinient is using Fmoc strategy eventually on an Applied Biosys- tems 433A peptide synthesizer in 0.25 mmol scale using the FastMoc UV protocols which employ HBTU (2-(1 H-Benzotriazol-1-yl)-1 , 1 ,3,3 tetramethyluronium hexafluorophosphate) mediated couplings in N-methyl pyrrolidone (N-methyl pyrrolidone) (HATU is better suited for hindered couplings) and UV monitoring of the deprotection of the Fmoc protection group. Other coupling reagents besides from HBTU and HATU as described in e.g. Current Opinion in Chemical Biology, 2004, 8:211-221 may also be used. The protected amino acid derivatives used may be standard Fmoc-amino acids supplied in preweighed cartridges (Applied Biosystems) suitable for the ABI433A synthesizer with the exception of unnatural aminoacids such as Fmoc-Aib-OH (Fmoc-aminoisobutyric acid) which are purchased from a supplier such as Bachem and transferred to empty cartridges. The last amino acid coupled may be Boc protected.
The attachment of sidechains and linkers to specific lysine residues on the crude resin bound protected peptide may eventually beintroduced in a specific position by incorporation of Fmoc-Lys(Dde)-OH during automated synthesis followed by selective deprotection with hydrazine. Other orthogonal protecting groups may be used on Lysine.
Procedure for removal of Dde-protection. The resin (0.25 mmol) may be placed placed in a manual shaker/filtration apparatus and treated with 2% hydrazine in N-methyl pyrrolidone (20 ml, 2x12 min) to remove the DDE group and subsequently washed with N-methyl pyrrolidone (4x20 ml).
Procedure for attachment of sidechains to Lysine residues.
The amino acid (4 molar equivalents relative to resin) may be dissolved in N-methyl pyrroli- done/methylene chloride (1 :1 , 10 ml). Hydroxybenzotriazole (HOBt) (4 molar equivalents relative to resin) and diisopropylcarbodiimide (4 molar equivalents relative to resin) is added and the solution was stirred for 15 min. The solution is added to the resin and diisopro- pyethylamine (4 molar equivalents relative to resin) is added. The resin is shaken 24 hours at room temperature. The resin is washed with N-methyl pyrrolidone (2x20 ml), N-methyl pyr- rolidone/Methylene chloride (1 :1 ) (2x20ml) and methylene chloride (2x20 ml).
Procedure for removal of Fmoc-protection: The resin (0.25 mmol) is placed in a filter flask in a manual shaking apparatus and treated with N-methyl pyrrolidone/methylene chloride (1 :1 ) (2x20 ml) and with N-methyl pyrrolidone (1x20 ml), a solution of 20% piperidine in N-methyl pyrrolidone (3x20 ml, 10 min each). The resin is washed with N-methyl pyrrolidone (2x20 ml), N-methyl pyrrolidone/methylene chloride (1 :1 ) (2x20ml) and methylene chloride (2x20 ml).
Procedure for cleaving the peptide off the resin:
The peptide is cleaved from the resin by stirring for 180 min at room temperature with a mix- ture of trifluoroacetic acid, water and triisopropylsilane (95:2.5:2.5). The cleavage mixture is filtered and the filtrate is concentrated to an oil by a stream of nitrogen. The crude peptide is precipitated from this oil with 45 ml diethyl ether and washed 3 times with 45 ml diethyl ether.
Purification: The crude peptide may be purified by semipreparative HPLC on a 20 mm x 250 mm column packed with 7μ C-18 silica. Depending on the peptide one or two purification systems may used:
Ammonium sulphate: The column is equilibrated with 40% CH3CN in 0.05M (NH4)2SO4, which is adjusted to pH 2.5 with concentrated H2SO4. After drying the crude peptide is dissolved in 5 ml 50% acetic acid H2O and diluted to 20 ml with H O and injected on the column which then is eluted with a gradient of 40% - 60% CH3CN in 0.05M (NH4)2SO4, pH 2.5 at 10 ml/min during 50 min at 40 °C. The peptide containing fractions is collected and diluted with 3 volumes of H2O and passed through a Sep-Pak® C18 cartridge (Waters part. #:51910 ) which has been equilibrated with 0.1% TFA. It is then eluted with 70% CH3CN containing 0.1 % TFA and the purified peptide is isolated by lyophilisation after dilution of the eluate with water.
TFA: After drying the crude peptide is dissolved in 5 ml 50% acetic acid H2O and diluted to 20 ml with H2O and injected on the column which then is eluted with a gradient of 40-60 % CH3CN in 0.1 % TFA 10 ml/min during 50 min at 40 °C. The peptide containing fractions is collected. The purified peptide is lyophilized after dilution of the eluate with water. The final product obtained may be characterised by analytical RP-HPLC (retention time) and by LCMS .
The RP-HPLC analysis performed in these in the experimental section was performed using UV detection at 214 nm and a Vydac 218TP54 4.6mm x 250mm 5μ C-18 silica column (The Separations Group, Hesperia, USA) which was eluted at 1 ml/min at 42 °C. The different elution conditions were:
A1 : Equilibration of the column with in a buffer consisting of 0.1 M (NH4)2SO , which was adjusted to pH 2.5 with concentrated H2SO4 and elution by a gradient of
0% to 60% CH3CN in the same buffer during 50 min. B1 : Equilibration of the column with 0.1% TFA / H2O and elution by a gradient of
0% CH3CN / 0.1 % TFA / H2O to 60% CH3CN / 0.1 % TFA / H2O during 50 min.
B6: Equilibration of the column with 0.1 % TFA / H2O and elution by a gradient of
0% CH3CN / 0.1% TFA / H2O to 90% CH3CN / 0.1 % TFA / H2O during 50 min. An alternative system was: B4 : The RP-analyses was performed using a Alliance Waters 2695 system fitted with a Waters 2487 dualband detector. UV detections at 214nm and 254nm were col- lected using a Symmetry300 C18 , 5 urn, 3.9 mm x 150 mm column, 42 °C. Eluted with a linear gradient of 5-95% acetonitrile, 90-0% water, and 5% trifluoroacetic acid (1.0%) in water over 15 minutes at a flow-rate of 1.0 min/min.
LCMS was performed on a setup consisting of Hewlett Packard series 1100 G1312A Bin
Pump, Hewlett Packard series 1100 Column compartment, Hewlett Packard series 1100 G1315A DAD diode array detector, Hewlett Packard series 1100 MSD and Sedere 75
Evaporative Light Scattering detectorcontrolled by HP Chemstation software. The HPLC pump is connected to two eluent reservoirs containing:
A: 0.05% TFA/water
B: 0.05%TFA/acetonitrile Or alternatively the two systems may be:
A: 10mM NH4OH in water
B: 10mM NH4OH in 90% acetonitrile
The analysis was performed at 23° C by injecting an appropriate volume of the sample (pref- erably 20 μl) onto the column which is eluted with a gradient of A and B.
The HPLC conditions, detector settings and mass spectrometer settings used are giving in the following table.
Column Waters Xterra MS C-18 (50 X 3 mm id 5 μm)
Gradient 5% - 100% acetonitrile linear during 6.5 min at 1.5ml/min Detection 210 nm (analogue output from DAD)
ELS (analogue output from ELS)
MS ionisation mode API-ES. Scan 550-1500 amu step 0.1 amu
Alternatively, LC-MS analysis could be performed on a PE-Sciex API 100 mass spectrometer equipped with two Perkin Elmer Series 200 Micropumps, a Perkin Elmer Series 200 autosampler, a Applied Biosystems 785A UV detector and a Sedex 75 Evaporative Light scattering detector. A Waters Xterra 3.0 mm x 50 mm 5μ C-18 silica column was eluted at 1.5 ml/min at room temperature. It was equilibrated with 5 % CH3CN / 0.05% TFA / H2O and eluted for 1.0 min with 5% CH3CN / 0.05% TFA / H2O and then with a linear gradient to 90% CH3CN / 0.05% TFA / H2O over 7 min. Detection was by UV detection at 214nm and Evaporative light Scattering. A fraction of the column eluate was introduced into the ionspray inter- face of a PE-Sciex API 100 mass spectrometer. The mass range 300 - 2000 amu was scanned every 2 seconds during the run.
MALDI-TOF MS analysis was carried out using a Voyager RP instrument (PerSeptive Bio- systems Inc., Framingham, MA) equipped with delayed extraction and operated in linear mode. Alpha-cyano-4-hydroxy-cinnamic acid was used as matrix, and mass assignments were based on external calibration.
Example 1
Figure imgf000066_0001
A resin (Rink amide, 0.68 mmol/g Novabiochem 0.25 mmole) was used to produce the pri- mary sequence on an ABI433A machine according to manufacturers guidelines. All protecting groups were acid labile with the exception of the residue used in position 37 (Fmo- cLys(ivDde)-OH, Novabiochem) allowing specific deprotection of this lysine rather than any other lysine.
Procedure
The above prepared resin (0.25 mmole) containing the GLP-1 analogue amino acid sequence was placed in a manual shaker/filtration apparatus and treated with 2% hydrazine in N-methyl pyrrolidone in (2x12 min. 2x20 ml) to remove the Dde group. The resin was washed with N-methyl pyrrolidone (4x20 ml). Fmoc-8-amino-3,6-dioxaoctanoic acid (Neosys- tem FA03202) (4 molar equivalents relative to resin) was dissolved in N-methyl pyrrolidone/methylene chloride (1 :1 , 20 ml). Hydroxybenzotriazole (HOBt) (4 molar equivalents relative to resin) and diisopropylcarbodiimide (4 molar equivalents relative to resin) was added and the solution was stirred for 15 min. The solution was added to the resin and diisopropylethylamine (4 molar equivalents relative to resin) was added. The resin was shaken 24 hours at room temperature. The resin was washed with N-methyl pyrrolidone (4x20 ml). A solution of 20% piperidine in N-methyl pyrrolidone (3x20 ml, 10 min each) was added to the resin while shaking. The resin was washed with N-methyl pyrrolidone (4x20 ml). Dodecanoic acid (4 molar equivalents relative to resin) was dissolved in N-methyl pyrrolidone/methylene chloride (1 :1 , 20 ml). Hydroxybenzotriazole hydrate (HOBt; H2O) (4 molar equivalents relative to resin) and diisopropylcarbodiimide (4 molar equivalents relative to resin) were added and the solution was stirred for 15 min. The solution was added to the resin and diisopropylethylamine (4 molar equivalents relative to resin) was added. The resin was shaken 24 hours at room temperature. The resin was washed with N-methyl pyrrolidone (2x20 ml), N-methyl pyrrolidone/methylene chloride (1 :1 ) (2x20ml) and methylene chloride (2x20 ml). The peptide was cleaved from the resin by stirring for 180 min at room temperature with a mixture of trifluoroacetic acid, water and triisopropylsilane (95:2.5:2.5 15 ml). The cleavage mixture was filtered and the filtrate was concentrated to an oil in vaccuum. The crude peptide was precipitated from this oil with 45 ml diethyl ether and washed 3 times with 45 ml diethyl ether. The crude peptide was purified by preparative HPLC on a 20 mm x 250 mm column packed with 7μ C-18 silica. The crude peptide was dissolved in 5 ml 50% acetic acid in water and diluted to 20 ml with H2O and injected on the column which then was eluted with a gradient of 40-60 % (CH3CN in water with 0.1% TFA) 10 ml/min during 50 min at 40 °C. The peptide containing fractions were collected. The purified peptide was lyophi- lized after dilution of the eluate with water. HPLC: (method B6): RT=32.8 min HPLC: (method A1 ): RT=43.6 min LCMS: m/z = 765.0 (M+5H)5+, 957.0 (M+4H)4+, 1275.0 (M+3H)3+. Calculated (M+H)+ = 3825.0
Example 2
Nε37-(2-(2-(2-(17-sulphohexadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib8'22'35,Lys37] GLP-1 (7- 37)amide
Figure imgf000067_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods". HPLC: (method A1 ): RT=45.5 min
LCMS: m/z = 792.9 (M+5H)5+, 990.9 (M+4H)4+, 1320.9 (M+3H)3+ Calculated (M+H)+ = 3959.9 Example 3
Nε37-{2-[2-(2-(15-carboxypentadecanoylamino)ethoxy)ethoxy]acetyl}-[Aib8,22'35,Lys37] GLP-
1 (7-37)amide
Figure imgf000068_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods". HPLC: (method B1 ): RT=43.8 min HPLC: (method A1 ): RT=42.0 min LCMS: m/z = 978.3 (M+4H)4+, 1303.8 (M+3H)3+ Calculated (M+H)+ = 3909.6
Example 4 Nε37-(2-(2-(2-(17-carboxyheptadecanoylamino)ethoxy)ethoxy)acetyl)[Aib8'22'35,Lys37]GLP-1 (7- 37)amide
Figure imgf000068_0002
Prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B1 ): RT=46.4 min HPLC: (method A1 ): RT=44.4 min LCMS: m/z = 985.5 (M+4H)4+, 1313.4 (M+3H)3+ Calculated (M+H)+ = 3937.6
Example 5 Nε 7-(2-(2-(2-(19-carboxynonadecanoylamino)ethoxy)ethoxy)acetyl)[Aib8'22,35,Lys37]GLP-1 (7- 37)amide
Figure imgf000069_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B1): RT=49.5 min HPLC: (method A1 ): RT=47.1 min LCMS: m/z = 992.5 (M+4H)4+, 1322.6 (M+3H)3+ Calculated (M+H)+ = 3965.7
Example 6
[Aib8'22'35,Arg26'34]GLP-1-(7-37)Lys(4-(Hexadecanoylamino)-4(S)-carboxybutyryl)-OH
Figure imgf000069_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT= 36.28min LCMS: m/z = 995 (M+4H)4+, 1326 (M+3H)3+ Calculated (M+H)+ = 3977.6
Example 7
[Aib8'22'35,Arg26'34]GLP-1-(7-37)Lys(2-(2-(2-(hexadecanoylamino)ethoxy)ethoxy)acetyl)-OH
Figure imgf000070_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT=37.1min LCMS: m/z = 999 (M+4H)4+, 1332 (M+3H)3+ Calculated (M+H)+ = 3993.7
Example 8
Nε37-(2-[2-(2,6-(S)-Bis-{2-[2-(2-
(dodecanoylamino)ethoxy)ethoxy]acetylamino}hexanoylamino)ethoxy]ethoxy}) acetyI-[Aib8'22'35]GLP-1 (7-37)amide
Figure imgf000070_0002
The compound was prepared according to the methods in Example 1 and in "General Syn- thetic methods".
HPLC: (method B6): RT=38.2 min
LCMS: m/z = 1106.7 (M+4H)4+, 1475.3 (M+3H)3+ Calculated (M+H)+ = 4433.0
Example 9 Nε37-(2-[2-(2,6-(S)-Bis-{2-[2-(2-
(tetradecanoylamino)ethoxy)ethoxy]acetylamino}hexanoylamino)ethoxy]ethoxy}) acetyl-[Aib8'22'35]GLP-1 (7-37)amide
Figure imgf000071_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT=42.9 min LCMS: m/z = 1120.9 (M+4H)4+, 1494.2 (M+3H)3+ Calculated (M+H)+ = 4480.4
Example 10
[Aib8'22'35,Arg26'34]GLP-1-(7-37)Lys(2-(2-(2-(4-(Hexadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetyl)-OH
Figure imgf000071_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT=36.0 min LCMS: m/z = 1032.0 (M+4H)4+, 1374.0 (M+3H)3+ Calculated (M+H)+ = 4122.8
Example 11 [Aib8'22'35]GLP-1 (7-37)Lys((2-{2-[4-[4-(4-Amino-9,10-dioxo-3-sulfo-9,10-dihydro-anthracen-1- ylamino)-2-sulfo-phenylamino]-6-(2-sulfo-phenylamino)-[1 ,3,5]triazin-2-ylamino]-ethoxy}- ethoxy)-acetyl))amide
Figure imgf000072_0001
Prepared by loading DdeLys(Fmoc)-OH onto Rink resin. The resin was then treated with piperidine as in "Synthetic methods" to remove Fmoc selectively. 2-(2-(2-(Fmoc- amino)ethoxy)ethoxy)acetic acid was coupled onto the epsilon amingroup of lysine and Fmoc was removed. DMSO and Cibacron Blue 3GA (17 equivalents) (Sigma C-9534) was added and the mixture was heated at 60 °C for 15 hours, washed with water (3 times), methanol (2 times), THF (2 times) and diethyl ether (2 times). The Dde protecting group was removed and the remaining amino acids were added as in "Synthetic methods"
HPLC: (method A1 ): RT=38.1 min
LCMS: m/z = 1110.4 (M+4H)4+, 1436.4 (M+3H)3+ Calculated (M+H)+ = 4435.9
Example 12
[Aib8'22'35]GLP-1 (7-37)Lys(({2-[2-(2-{2-[2-(2-{2-[2-(15-carboxypentadecanoylamino)- ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl amino)ethoxy]ethoxy}acetyl))amide
Figure imgf000072_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method A1): RT=41.2 min HPLC: (method B6): RT=30.7 min
LCMS: m/z = 1069.1 (M+4H)4+, 1424.6 (M+3H)3+ Calculated (M+H)+ = 4271 Example 13
Nε37-([2-(2-{3-[2,5-dioxo-3-(15-carboxypentadecylsulfanyl)-pyrrolidin-1-yl]- propionylamino}ethoxy)ethoxy)acetyl]-[D-Ala8,Lys37]-GLP-1-[7-
37]amide
Figure imgf000073_0001
The compound was prepared according to the methods in Example 1 and in "General Syn- thetic methods".
HPLC: (method A1): RT=45.2 min
LCMS: m/z = 1004.0 (M+4H)4\ 1338.2 (M+3H)3+ Calculated (M+H)+ = 4010.7
Example 14 [Aib8'22'35Ala37]GLP-1 (7-37)Lys((2-(2-(2-(11 -
(oxalylamino)undecanoylamino)ethoxy)ethoxy)acetyl-)))amide
Figure imgf000073_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods". HPLC (method A1 ): RT=37.9 min HPLC (method B1): RT=39.5 min LCMS: m/z = 993.3 (M+4H)4+, 1323.9 (M+3H)3+ Calculated (M+H)+ = 3967.6
Example 15 [Aib8'22'35,Ala37]-GLP-1 (7-37)Lys({2-[2-(2-{2-[2-(2-(15-carboxy-pentadecanoylamino)- ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl)amide
Figure imgf000074_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC (method B6): RT=31.1 min HPLC (method A1): RT=41.9 min
LCMS: m/z = 1376.3 (M+3H)3+ Calculated (M+H)+ = 4125.8
Example 16
[Aib8'22'35,Ala37]-GLP-1 (7-37)Lys((2-{2-[11 -(5-Dimethylaminonaphthalene-1 - sulfonylamino)undecanoylamino]ethoxy}ethoxy)acetyl)amide
Figure imgf000074_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC (method A1 ): RT=42.6 min HPLC (method B6): RT=30.4 min LCMS: m/z = 1377.3 (M+3H)3+ Calculated (M+H)+ = 4128.8
Example 17 [Aib8'22'35,Ala37]-GLP-1 (7-37)Lys(([2-(2-{2-[1-(4-ChlorobenzoyI)-5-methoxy-2-methyl-1 H-indol- 3-yl]acetylamino}ethoxy)ethoxy]acetyl))amide
Figure imgf000075_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC (method A1 ): RT=41.1 min HPLC (method B6): RT=31.1 min LCMS: m/z = 1351.8 (M+3H)3+ Calculated (M+H)+ = 4052.0
Example 18
[Aib8,Arg26'34,Glu22'23'30]GLP-1 H(7-37)Lys(2-(2-(2- (octadecanoylamino)ethoxy)ethoxy)acetyl)amide
Figure imgf000075_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC (method B6): RT=39.3 min LCMS: m/z = 1366.6 (M+3H)3+ Calculated (M+H)+ = 4095.6
Example 19
[[AAiibb88,,AArrgg2266''33'4,Glu22'23'30]GLP-1 (7-37)Lys(2-(2-(2- (eicosanoylamino)ethoxy)ethoxy)acetyl)amide
Figure imgf000076_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods". HPLC (method B6): RT=42.6 min
LCMS: m/z = 1375.7 (M+3H)3+ Calculated (M+H)+ = 4123.7
Example 20
[Gly8,Arg26'34] GLP-1 H-(7-37)Lys(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetyl)ethoxy)ethoxy)acetyl)-OH
Figure imgf000076_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC (method B6): RT=38.0 min (99.9%) HPLC (method A1 ): RT=49.0 min LCMS: m/z = 1054.6 (M+4H)4+ 1405.3(M+3H)3+ Calculated (M+H)+ = 4211.8
Example 21
[Aib8,Arg26'3 ]GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-
(octadecanoylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000077_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC (method B6): RT=38.7 min LCMS: m/z = 1029.2 (M+4H)4+ 1371.4 (M+3H)3+ Calculated (M+H)+ = 4110.8
Example 22
[Aib8] -GLP-1 -(7-37)Lys (2-(2-(2-(4-(Hexadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetyl)-OH
Figure imgf000077_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC (method B6): RT= 34.7 min LCMS: m/z = 1000.3 (M+4H)4+ 1337.4 (M+3H)3+ Calculated (M+H)+ = 4110.8
Example 23
[Aib8,Arg26'34] GLP-1 (7-37) Lys{2-(2-(2-(2-[2-(2-(4-(octadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000078_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods". HPLC (method B6): RT= 37.5 min
3+
LCMS: m/z = 1414.9 (M+3Hr Calculated (M+Hf = 4239.8
Example 24
[Aib8,Arg26'34] GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-(17- carboxyheptanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000078_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC (method B6): RT= 32.4 min HPLC (method A1): RT= 43.8 min LCMS: m/z = 1381.3 (M+3H)3+ Calculated (M+H)+ = 4140.0
Example 25
[Gly8, Arg26'34] GLP1-(7-37) Lys{2-(2-(2-(2-[2-(2-(17- carboxyheptadecanoylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000079_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC (method A1 ): RT= 42.3 min LCMS: m/z = 1372.3 (M+3H)3+ Calculated (M+H)+ = 4112.7
Example 26
[Aib8]GLP-1-(7-37)Lys(2-(2-(2-(2-(2-(2-(4-(Hexadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetylamino) ethoxy)ethoxy)acetyl )-O H
Figure imgf000079_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC (method B6): RT= 33.5 min LCMS: m/z = 1040.3 (M+4H)4+ 1386.6 (M+3H)3+ Calculated (M+H)+ = 4155.8
Example 27
N" -(2-(2-(2-(dodecanoylamino)ethoxy)ethoxy)acetyl)-[Aib°^ 22,'3J5O,Lys ,3d7'n] GLP-1 H(7-37)-amide
Figure imgf000079_0003
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT=32.8 min
LC-MS: m/z = 765.7 (M+H)5+, 957.0 (M+H)4+, 1275.7 (M+H)3+ = Calculated (M+H)+ = 3822.9
Example 28
Nε37-(2-(2-(2-(tetradecanoylamino)ethoxy)ethoxy)acetyl)-[Aib8'22'35Lys37] GLP-1 H(7-37)- amide
Figure imgf000080_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT= 34,6 min LC-MS: m/z = 771 ,4 (M+5H)5+, 964,1 (M+4H)4+, 1284,9(M+H)3+ Calculated (M+H)+ = 3851 ,5
Example 29
Nε37-(2-(2-(2-(hexadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib8'22'35Lys37] GLP-1 (7-37)-amide
Figure imgf000080_0002
Prepared according to the methods in Example 1 and in "General Synthetic meth-ods". HPLC: (method B6): RT= 36,8 min
LC-MS: m/z = 970.7(M+4H)4+, 1294.3 (M+3H)3+ Calculated (M+H)+= 3879,6
Example 30 N" -(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetyl)-[AibB'^'3 Lys3/] GLP-1 (7-37)-amide
Figure imgf000081_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic meth-ods".
HPLC: (method B6): RT= 39,4 min LC-MS: m/z = 977,9 (M+4H)4+, 1303,7(M+H)3+ Calculated (M+H)+ = 3907,6
Example 31
,22,35, . „37η
N" -(2-(2-(2-(eicosanoylamino)ethoxy)ethoxy)acetyl)-[Aib°'^JOLys^] GLP-1 (7-37)-amide
Figure imgf000081_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods". HPLC: (method B6): RT= 42.7min
3+
LC-MS: m/z = 984.8 (M+4H) , 1312.8 (M+3H Calculated (M+H)+ = 3935.7
Example 32
N ,ε36 -(2-(2-(2-(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl))- [Aib8,Arg26'34,Lys36]GLP-1-(7-37)-OH
Figure imgf000082_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6) RT= 40.7min LC-MS: m/z = 792.3(M+5H)5+, 989.8(M+4H)4+, 1319.2(M+3H)3+ Calculated (M+H)+ = 3955.5
Example 33
N |E36 -(2-(2-(2-(2-(2-(2-
(octadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl))[Arg26,34,Lys36]GLP-
1 (7-37)-OH
Figure imgf000082_0002
The compound was prepared according to the methods in Example 1 and in "General Syn- thetic methods".
HPLC: (method B6) RT= 40.5min
LC-MS: m/z = 789.5 (M+5H)5+, 986.3 (M+4H)4+, 1314.8 (M+3H)3+ Calculated (M+H)+ =
3941.5
Example 34
Nε36-{2-(2-(2-(2-[2-(2-(octadecanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}- [Gly8,Arg26'34,Lys36]GLP-1-(7-37)-OH
Figure imgf000083_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6) RT= 38,3min LC-MS: m/z = 786.8 (M+5H)5+, 982.8 (M+4H)4+, 1310.1 (M+3H)3+ Calculated (M+H)+ = 3927,5
Example 35
Nε37-(2-(2-(2-(4-4(4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluorononanoylsulfamoyl- butyrylamino)ethoxy)ethoxy)acetyl))[Aib8,22'35,Lys37] GLP-1 -(7-37)-OH
Figure imgf000083_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6) RT= 32.4min LC-MS: m/z = 1042.7(M+4H)4+, 1389.9 (M+3H)3+ Calculated (M+H)+ = 4166.4
Example 36
Nε37-(2-(2-(2-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11 ,11 ,12,12,12-Heneicosafluoro- dodecyloxyacetylamino)ethoxy) ethoxy)acetyl)[Aib8'22,35,Lys37]GLP-1-(7-37)-OH
Figure imgf000084_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods". HPLC: (method B6) RT= 36.7 min
LC-MS: m/z = 1062.8 (M+4H)4+, 1416.9 (M+3H)3+ Calculated (M+H)+ = 4247.3
Example 37
Nε37-(2-(2-(2-(4-(hexadecanoylsulfamoyl)butyrylamino)ethoxy)ethoxy)acetyl)[Aib8'2 ,35,Lys37] GLP-1 -(7-37)-OH
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT= 37.4min LC-MS: m/z = 1008.8 (M+4H)4+ 1344.3 (M+3H)3+ Calculated (M+H)+ = 4030.7
Example 38
[Arg26'34]GLP-1 (7-37)Lys({2-(2-(2-(2-[2-(2- (octadecanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)})-OH
Figure imgf000085_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods". HPLC (method B6): RT= 38.5 min
3+ LCMS: m/z = (M+4H)4+ 025.1 (M+3Hr 1366.7 Calculated (M+H)1" = 4096.0
Example 39
[Arg26'34] GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-(4-(octadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000085_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC (method B6): RT= 37.7 min LCMS: m/z = (M+4H)4+ 1057.8 (M+3H)3+ 1410.2 Calculated (M+H)+ = 4235.9
Example 40
Nε20-{2-(2-(2-(2-[2-(2-(4-(hexadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy]acetyIamino)ethoxy)ethoxy)acetyl)}-exendin(1-39)
Figure imgf000086_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC (method B6): RT= 33.6 min LCMS: m/z = (M+4H)4+ 1205.3 (M+3H)3+ 1606.9 Calculated (M+H)+ = 4816.5
Example 41
[Ala8, Arg26'34]GLP-1 (7-37)Lys((2-[2-((2-oxalyIamino-3-carboxy-2-4,5,6,7-tetrahydro- benzo[b]thiophen-6-yl-acetylamino))ethoxy]ethoxyacetyl) amide
Figure imgf000086_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC (method B6): RT= 32.1 min HPLC (method A1): RT= 42.2 min LCMS: m/z = 1033.3 (M+4H)4+ 1376.6(M+3H)3+ Calculated (M+H)+ = 4126.7
Example 42
[Aib8'22'35]GLP-1 (7-37)Lys((2-[2-((2-oxalylamino-3-carboxy-2-4,5,6,7-tetrahydro- benzo[b]thiophen-6-yl-acetylamino))ethoxy]ethoxyacetyl) amide
Figure imgf000087_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC (method B1 ): RT= 37.4 min HPLC (method A1 ): RT= 35.5 min LCMS: m/z = 1002.5 (M+4H)4+ 1336.7 (M+3H)3+ Calculated (M+H)+ = 4007.5
Example 43
Nε36-(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl)-
[Aib8,Arg26'34,Lys36]GLP-1-(7-37)-OH
Figure imgf000087_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT= 39.0 min LC-MS: m/z = 1022.3 (M+4H)4+, 1362.3 (M+3H)3+, Calculated (M+H)+= 4084.6
Example 44
Nε36-(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl)-
[Gly8,Arg26'34,Lys36]GLP-1-(7-37)-OH
Figure imgf000088_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT= 38,6 min LC-MS: m/z = 1015.2 (M+4H)4+, 1353.4 (M+3H)3+, Calculated (M+H)+= 4056.6
Example 45
Nε37-2-(2-(2-(4-(4-(Heptadecanoylamino)-4-(S)-carboxybutyrylamino)-4-(S)- carboxybutyrylamino)ethoxy)ethoxy) acetyl-[Aib8'22'35,Lys37]GLP-1-(7-37)-NH2
Figure imgf000088_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B4): RT=10.72min LCMS: m/z = 1039.0 (M+4H)4+, 1385.0 (M+3H)3+ Calculated (M+H)+ = 4152.0
Example 46
Nε37-2-(2-[2-(2-[2-(4-[4-(Heptadecanoylamino)-4-(S) carboxybutyrylamino]-4-(S)-carboxybutyrylamino)ethoxy] ethoxy)acetylamino)ethoxy]ethoxy)acetyl-[Aib8,22'35,Lys37]GLP-1-(7-37)-NH2
Figure imgf000089_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods". HPLC: (method B4): RT=10.74 min
LCMS: m/z = 1074 (M+4H)4+, 1433 (M+3H)3+ Calculated (M+H)+ = 4297
Example 47
Nε26-(2-(2-(2-(4-(Hexadecanoylamino)-4(S)-carboxybutyrylamino) ethoxy)ethoxy)acetyl)-[Aib8,Arg34]GLP-1-(7-37)-
-OH
Figure imgf000089_0002
The compound was prepared according to the methods in Example 1 and in "General Syn- thetic methods".
HPLC: (method B4): RT=10.71 min
LCMS: m/z = 979.0 (M+4H)4+, 1304.0 (M+3H)3+ Calculated (M+H)+ = 3910.0
Example 48 Nε26-2-(2-2-(2-(2-(2-(4-(Octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl- [Aib8, Arg34]GLP-1-(7-37)-OH
Figure imgf000090_0001
The compound was prepared according to the methods in Example 1 and in "General Syn- thetic methods".
HPLC: (method B4): RT=11.32 min
LCMS: m/z = 1021 (M+4H)4+, 1362 (M+3H)3+ Calculated (M+H)+ = 4084
The peptide was synthesized on a chlorotrityl resin (Novabiochem) using the Fmoc strategy on an Advanced Chemtech 348 peptide synthesizer (0.5 mmol/g, 100 mg resin/hole and 10 holes were used). The couplings were mediated in Diisopropylcarbodiimide (DIC) (Fluka) and 1-hydroxybenzothazol (HOBt)/1-hydroxy-7-aza-benzotriazole (HOAt) (2:1 ) (Senn Chemicals) in 1-methyl-pyrrolidin-2-one (NMP) and 10 molar equivalents of amino acids and coupling reagents were applied. The used protected amino acid derivatives were standard Fmoc-amino acids (Advanced Chemtech) with the exception of the amino acids Fmoc- Lys(ivDde) (Novabiochem) and Fmoc-Glu-OtBu (Bachem). The resin was afterwards divided into 5 portions (0.1 mmol) and the N-terminal was then treated with (Boc)2O and DIEA (5 molar equivalent) in NMP.
The attachment of sidechains and linkers to specific lysine residues on the crude resin bound protected peptide was carried out in a specific position by incorporation of Fmoc- Lys(ivDde)-OH during automated synthesis followed by selective deprotection with hydrazine.
Procedure for removal of Dde-protection. The resin (0.1 mmol) was placed in a syringe and treated with 3% hydrazine and 3% piperidine in NMP (50 min at r.t.) to remove the Dde group and wash with NMP (4x5 ml).
Procedure for attachment of sidechains to Lysine residues. The OEG or amino acid (7 molar equivalents relative to resin) was dissolved in NMP. HOAt (7 molar equivalents relative to resin) and diisopropylcarbodiimide (7 molar equivalents relative to resin) was added and the solution was stirred for 15 min. Then, the solution was added to the resin. The resin was shaken overnight at room temperature. The resin was washed with NMP (3x5 ml).
Procedure for removal of Fmoc-protection: The resin (0.1 mmol) was placed in a syringe treated with a solution of 30% piperidine in NMP (5ml in 20 min). The resin was washed with NMP (2x5 ml) and methylene chloride (2x5 ml).
Procedure for cleaving the peptide off the resin:
The peptide was cleaved from the resin by stirring for 120 min at room temperature with a mixture of trifluoroacetic acid, water and triisopropylsilane (94:3:3). The cleavage mixture was filtered and the filtrate was concentrated to an oil by a stream of nitrogen. The crude peptide was precipitated from this oil with 10 ml diethyl ether and washed 2 times with 10 ml diethyl ether.
Example 49
[Gly8,Arg26,34]GLP-1 (7-37)Lys(2-(2-(19-(carboxy)nonadecanoylamino)ethoxy)ethoxy)acetyl)- OH
Figure imgf000091_0001
A chlorotrityl resin (0.5 mmol/g Novabiochem, 0.1 mmole) was used to produce the primary sequence on an Advanced Chemtech 348 machine. All protecting groups were acid labile with the exception of the residue used in position 37 (FmocLys(ivDde)-OH, Novabiochem) allowing specific deprotection of this lysine rather than any other lysine.
Procedure
The above prepared resin (0.1 mmole) containing the GLP-1 analogue amino acid sequence was placed in a syringe and treated with 3% hydrazine and 3% piperidine in N-methyl pyr- rolidone (50 min) to remove the Dde group. The resin was washed with NMP (4x5 ml). Fmoc-8-amino-3,6-dioxaoctanoic acid (Neosystem FA03202) (7 molar equivalents relative to resin) was dissolved in NMP. HOAt (7 molar equivalents relative to resin) and diisopropyl- carbodiimide (7 molar equivalents relative to resin) was added and the solution was stirred for 15 min. The solution was then added to the resin. The resin was shaken overnight at room temperature. The resin was washed with NMP (4x5 ml). A solution of 30% piperidine in NMP (5 ml, 20min) was added to the resin. The resin was washed with NMP (4x5 ml). The N-hydroxysuccinimide ester of C20 (6 molar equivalents relative to resin, KJ. Ross-Petersen A/S) and DIEA was dissolved in NMP and added to the resin. The resin was shaken overnight at room temperature. The resin was washed with NMP (3x5 ml) and methylene chloride (2x5 ml). The peptide was cleaved from the resin by stirring for 120 min at room temperature with a mixture of trifluoroacetic acid, water and triisopropylsilane (94:3:3, 3 ml). The cleavage mixture was filtered and the filtrate was concentrated to an oil in vacuum. The crude peptide was precipitated from this oil with 10 ml diethyl ether and washed 2 times with 10 ml diethyl ether.
Purification The crude peptide dissolved in DMSO at a concentration of 5-10 mg/200 μl and applied to a 7.8 x 300 mm X-Terra Prep MS C18 10 μm column running at 40°C. After 5 minutes at 30% CH3CN, 0.08% TFA, 4 ml/min, the column was eluted with a linear gradient of 30 to 65% CH3CN over 35 minutes. The main UV peaks were collected manually and the desired peak identified by MALDI-MS. The concentration of the peptide in the eluate was determined by measurement of the UV absorption at 280 nm assuming molar extinction coefficients of 1280 and 3690 for tyrosine and tryptophan respectively.
After the concentration determination the eluate was aliquotted into vials containing the desired amount and dried by vacuum centrifugation.
HPLC: elutes at 27.9 min = 52.9% CH3CN MALDI-MS: 3996 (MH+)
Example 50
[[GGllyy88,,AArrgg2266''3344]]GLP-1 (7-37)Lys((2-(2-(17 (carboxy)heptadecanoylamino)ethoxy)ethoxy)acetyl))-OH
Figure imgf000093_0001
The compound was prepared as in previous example and according to "Synthetic methods" except that octadecanedioic acid C18 was attached as a monoprotected tert-butyl ester (3 molar equivalents relative to resin) and the coupling was mediated with HOAt and DIC (also 3 molar equivalents relative to resin) in NMP. The crude peptide was dissolved in 22.5% CH3CN, 0.1 N NaOH for purification.
HPLC: elutes at 25.4 min = 50.4% CH3CN MALDI-MS: 3969 (MH+)
Example 51 [Gly8,Arg26'34]GLP-1 (7-37)Lys(2-(2-(2-(4-(19-(carboxy)nonadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy)acetyl)-OH
Figure imgf000093_0002
The compound was prepared as in the two previous examples and according to "Synthetic methods". The amino acid Fmoc-Glu(OtBu) (6 molar equivalents relative to resin) was coupled to the resin with HOAt and DIC (6 molar equivalents relative to resin). The crude peptide was dissolved in 22.5% CH3CN, 0.1 N NaOH for purification.
HPLC: elutes at 27.2 min = 52.2% CH3CN MALDI-MS: 4124 (MH+)
Example 52 [Gly8,Arg26'34]GLP-1 (7-37)Lys((2-(2-(2-(2-(2-(2-(2-(2-(2-
(hexadecanoylamino)ethoxy)ethoxy)acetyl)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)- acetyl)-OH
Figure imgf000094_0001
The compound was prepared as in the three previous examples and according to "Synthetic methods" except that additional two OEG was coupled to the side chain of Lys.
HPLC: elutes at 25.0 min = 50.0% CH3CN MALDI-MS: 4259 (MH+)
Example 53
[Gly8, Arg26'34]GLP-1 (7-37)Lys (2-(2-(2-(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)- acetylamino)ethoxy)ethoxy)acetyl) NH2
Figure imgf000094_0002
The compound was prepared as in Example 1 and in accord with "Synthetic methods"
HPLC (method B6): RT=38.8 min
LCMS: m/z = 1022.3 (M+4H)3+ Calculated (M+H)+ = 4081.7
Example 54
Nε20(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(4-(17-(carboxy)heptadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetylamino) ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl) [Lys20]exendin-4 (1-39)-NH2
Figure imgf000095_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic meth-ods".
HPLC (method A1 ): RT= 41.9 min HPLC (method B6): RT= 31.3 min LCMS: m/z = 1722.7 (M+3H)3+ Calculated (M+H)+ = 5164.9
Example 55 N ,ε36 -(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoy!amino)ethoxy)ethoxy)
26,3 , ,36, acetylamino)ethoxy)ethoxy)acetyl) [Aib°,Arg D' , Lys∞] GLP-1 (7-37)
Figure imgf000095_0002
The compound was prepared according to the methods in Example 1 and in "General Syn- thetic methods".
HPLC: (method B6): RT= 34,2 min
LC-MS: m/z = 997,2 (M+4H)4+, 1329,4 (M+3H)3+, 1993,2 (M+2H)2+, Calculated (M+H)+=
3985,5
Example 56 N-ε -(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy) acetylamino)ethoxy)ethoxy)acetyl) [ArgZb'd4, Lysd0] GLP-1 (7-37)
Figure imgf000096_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT= 34,2 min
LC-MS: m/z = 993.8 (M+4H)4+, 1324.6 (M+3H)3+, 1987.2 (M+2H) +, Calculated (M+H)+= 3971.5
Example 57
Nε36-(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy) acetylamino)ethoxy)ethoxy)acety[) [Gly8, Arg26'34, Lys36] GLP-1 (7-37)
Figure imgf000096_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT= 34,2 min LC-MS: m/z = 990.3 (M+4H)4+, 1320.3(M+3H)3+, Calculated (M+H)+= 3957.4 Example 58
Nε 0-(2-(2-(2-(2-(2-(2-(2-(2-(2-
(Octadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetylamino)ethoxy)- ethoxy)acetyl)[Lys20] Exendin-4 (1-39)amide
Figure imgf000097_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT= 37.7 min LC-MS: m/z = 1216.6 (M+4H)4+, 1621.4 (M+3H)3+, Calculated (M+H)+= 4861.5
Example 59
Nε36-(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl)-[Arg26,34,Lys36]GLP-1-
(7-37)
Figure imgf000097_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods". HPLC: (method B6): RT= 39.1 min LC-MS: m/z = 1018.8 (M+4H)4+, 1357.6 (M+3H)3+, Calculated (M+H)+= 4070.6
Example 60
Nε26-(2-[2-(2-[2-(2-[2-(17-Carboxyheptadecanoylamino)ethoxy] ethoxy)acetylamino]ethoxy)ethoxy]acetyl)[Arg34]GLP-1-(7-37)-OH
Figure imgf000098_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B4): RT= 12.1 min LCMS: m/z = 993.0 (M+4H)4+, 1325.0 (M+3H)3+ Calculated (M+H)+ = 3970.0
Example 61
Nε26-[2-(2-[2-(2-[2-(2-[4-(17-Carboxyheptadecanoylamino)-4(S)- carboxybutyryIamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Arg3 ]GLP-1-(7-37)-
OH
Figure imgf000098_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B4): RT= 11.8 min LCMS: m/z = 1026 (M+4H)4+, 1368 (M+3H)3+ Calculated (M+H)+ = 4100 Example 62
Nε20-(2-(2-(2-(2-(2-(2-(2-(2-(2-(17- Carboxyheptadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl- amino)ethoxy)ethoxy)acetyl)[Lys20] Exendin-4 (1-39) amide
Figure imgf000099_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT= 32,3 min LC-MS: m/z = 1223.9 (M+4H)4+, 1630.8 (M+3H)3+, Calculated (M+H)+= 4891.5
Example 63
[Gly8, Glu22'23'30, Arg18'26'34]GLP1 (7-37) Lys(2-(2-(2-(2-(2-(2-(17- carboxyheptadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy))ethoxy)acetyl)-NH2
Figure imgf000099_0002
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT= 32.0 min HPLC: (method A1): RT=43.4 min
3+
LCMS: m/z = 1438.7 (M+3H Calculated (M+H) = 4311.8 Example 64
[Imidazolylpropionic acid7, Asp16, Aib22'35 ]GLP1 (7-37)Lys NH((2-{[4-(17- carboxyheptadecanoylamino)butyIcarbamoyl]methoxy}ethoxy)ethoxy))
Figure imgf000100_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods". HPLC: (method B1): RT=32.5 min HPLC: (method A1 ): RT=43.5 min LCMS: m/z = 1028.8 (M+4H)4+ Calculated (M+H)+ = 4108.7
Example 65
[[IImmiiddaazzoollyyllpprrcopionic acid7, Aib22'35 ]GLP1 (7-37)Lys NH( (2-{[4-(17- carboxyheptadecanoyIamino)butylcarbamoyl]methoxy}ethoxy)ethoxy))
Figure imgf000101_0001
The compound was prepared according to the methods in Example 1 and in "General Synthetic methods".
HPLC: (method B6): RT=33.7 min HPLC: (method A1 ): RT=44.8 min LCMS: m/z = 1024.8 (M+4H)4+, 1365.4 (M+3H)3+ Calculated (M+H)+ = 4092.8
Example 66
[3-(5-lmidazoyl)propionyl7, Aib8, Arg26'34 ] GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-(17- carboxyheptanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000101_0002
The compound was prepared according to the methods in Example 1 and'in "General Synthetic methods". MALDI-MS: 4127 (MH+)
HPLC: elutes: 25.5 min = 50.6% CH3CN
BIOLOGICAL FINDINGS
Protraction of GLP-1 derivatives after i.v. or s.c. administration
The protraction of a number GLP-1 derivatives of the invention was determined by monitor- ing the concentration thereof in plasma after sc administration to healthy pigs, using the methods described below. For comparison also the concentration in plasma of GLP-1 (7-37) after sc. administration was followed. The protraction of other GLP-1 derivatives of the invention can be determined in the same way.
Pharmacokinetic testing of GLP-1 analogues in minipigs
The test substances were dissolved in a vehicle suitable for subcutaneous or intravenous administration. The concentration was adjusted so the dosing volume was approximately 1 ml.
The study was performed in 12 male Gόttingen minipigs from Ellegaard Gόttingen Minipigs ApS. An acclimatisation period of approximately 10 days was allowed before the animals entered the study. At start of the acclimatisation period the minipigs were about 5 months old and in the weight range of 8-10 kg. The study was conducted in a suitable animal room with a room temperature set at 21-23°C and the relative humidity to > 50%. The room was illuminated to give a cycle of 12 hours light and 12 hours darkness. Light was from 06.00 to 18.00 h.
The animals were housed in pens with straw as bedding, six together in each pen. The animals had free access to domestic quality drinking water during the study, but were fasted from approximately 4 pm the day before dosing until approximately 12 hours after dosing.
The animals were weighed on arrival and on the days of dosing.
The animals received a single intravenous or subcutaneous injection. The subcutaneous injection was given on the right side of the neck, approximately 5-7 cm from the ear and 7-9 cm from the middle of the neck. The injections were given with a stopper on the needle, allowing 0.5 cm of the needle to be introduced.
Each test substance was given to three animals. Each animal received a dose of 2 nmol/kg body weight. Six animals were dosed per week while the remaining six were rested.
A full plasma concentration-time profile was obtained from each animal. Blood samples were collected according to the following schedule:
After intravenous administration:
Predose (0), 0.17 (10 minutes), 0.5, 1 , 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after injection.
After subcutaneous administration: Predose (0), 0.5, 1 , 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours after injection.
At each sampling time, 2 ml of blood was drawn from each animal. The blood samples were taken from a jugular vein.
The blood samples were collected into test tubes containing a buffer for stabilisation in order to prevent enzymatic degradation of the GLP-1 analogues. Plasma was immediately transferred to Micronic-tubes. Approximately 200 μl plasma was transferred to each Micronic-tube. The plasma was stored at -20°C until assayed. The plasma samples were assayed for the content of GLP-1 analogues using a immunoassay.
The plasma concentration-time profiles were analysed by a non-compartmental pharmacoki- netic analysis. The following pharmacokinetic parameters were calculated at each occasion: AUC, AUC/Dose, AUC%Extrap, Cmax, tmax, λz, tκ> CL, CL/f, Vz, Vz/f and MRT.
Selected compounds of the invention were tested in Danish Landrace pigs.
Pharmacokinetic testing of GLP-1 analogues in pigs Pigs (50% Duroc, 25% Yorkshire, 25% Danish Landrace, app 40 kg) were fasted from the beginning of the experiment. To each pig 0.5 nmol of test compound per kg body weight was administered in a 50 μM isotonic solution (5 mM phosphate, pH 7.4, 0.02% Tween®-20 (Merck), 45 mg/ml mannitol (pyrogen free, Novo Nordisk). Blood samples were drawn from a catheter in vena jugularis. 5 ml of the blood samples were poured into chilled glasses con- taining 175 μl of the following solution: 0.18 M EDTA, 15000 KIE/ml aprotinin (Novo Nordisk) and 0.30 mM Valine-Pyrrolidide (Novo Nordisk), pH 7.4. Within 30 min, the samples were centrifuged for 10 min at 5-6000*g. Temperature was kept at 4°C. The supernatant was pipetted into different glasses and kept at minus 20°C until use.
The plasma concentrations of the peptides were determined in a sandwich ELISA or by RIA using different mono- or polyclonal antibodies. Choice of antibodies depends of the GLP-1 derivatives. The time at which the peak concentration in plasma is achieved varies within wide limits, depending on the particular GLP-1 derivative selected.
General assay protocol for sandwich ELISA in 96-wells microtiterplate Coating buffer (PBS) : Phosphate buffered saline, pH7.2
Wash-buffer (PBS-wash) : Phosphate buffered saline, 0.05 % v/v Tween 20, pH 7.2 Assay-buffer (BSA-buffer): Phosphate buffered saline, 10 g/l Bovin Serum Albumin
(Fluka 05477), 0.05 % v/v Tween 20, pH 7.2 Streptavidin-buffer : Phosphate buffered saline, 0.5 M NaCl, 0.05 % v/v Tween 20, pH 7.2 Standard : Individual compounds in a plasma-matrix
A-TNP : Nonsens antibody
AMDEX : Streptavin-horseradish-peroxodase (Amersham RPN4401V) TMB-substrate : 3,3',5,5'tetramethylbenzidine (<0.02 %), hydrogen peroxide
The assay was carried out as follows (volumen/well):
1.) coat with 100 μl catching antibody 5 μg/ml in PBS-buffer → incubate o/n , 4 °C
→ 5x PBS-wash → blocked with last wash in minimum 30 minute →then empty the plate 2.) 20 μl sample + 100 μl biotinylated detecting antibody 1 μg/ml in BSA-buffer with 10 μg/ml A-TNP → incubate 2 h, room temperature, on a shaker → 5x PBS-wash, then empty the plate
3.) 100 μl AMDEX 1 :8000 in Streptavidin-buffer
→ incubate 45-60 minute, room temperature, on a shaker → 5x PBS-wash, then empty the plate 4.) 100 μl TMB-substrate → incubate x minute at room temperature on a shaker
→ stop the reaction with 100 μl 4 M H3PO4 Read the absorbance at 450 nm with 620 nm as reference
The concentration in the samples was calculated from standard curves.
General assay protocol for RIA
DB-buffer : 80 mM phosphate buffer, 0.1 % Human serum albumin, 10 mM EDTA,
0.6 mM thiomersal, pH 7.5 FAM-buffer : 40 mM phosphate buffer, 0.1 % Human Serum Albumin,
0.6 mM thiomersal, pH 7.5 Charcoal : 40 mM phosphate buffer, 0.6 mM thiomersal, 16.7 % bovine plasma,
15 g/l activated carbon , pH 7.5 (mix the suspension minimum 1 h before use at 4 °C) Standard : Individual compounds in a plasma-matrix
The assay was carried out in minisorp tubes 12x75 mm (volumen/tube) as follows:
Figure imgf000105_0001
Mix - incubate 30 min at 4 °C - centrifuge at 3000 rpm, 30 min - immediately after transfer supernatants to new tubes, close with stopper and count on gamma-counter for 1 minute. The concentration in the samples was calculated from individual standard curves.
GLP-1 radio receptor assay (RRA):
The method is a radiometric-ligand binding assay using LEADsee/cer imaging particles. The assay is composed of membrane fragments containing the GLP-1 receptor, unlabeled GLP-1 analogues, human GLP-1 labelled with 125l and PS LEADsee/cer particles coated with wheat germ agglutinin (WGA). Cold and 125l-labelled GLP-1 will compete for the binding to the receptor. When the LEADsee/cer particles are added they will bind to carbohydrates residues on the membrane fragments via the WGA-residues. The proximity between the 125l-molecules and the LEADsee cer particles causes light emission from the particles. The LEADseeker will image the emitted light and it will be reversibly correlated to the amount of GLP-1 analogue present in the sample.
Reagents & Materials:
Pre treatment of animal plasma: Animal plasma was heat treated for 4 hrs at 56°C and centrifuged at 10.000 rpm for 10 minutes. Afterwards, Val-Pyr (10 μM) and aprotenin (500 KIE/mL) was added and stored at <-18°C until use. GLP-1 analogues calibrators: GLP-1 analogues were spiked into heat-treated plasma to produce dilution lines ranging from approximately 1 μM to 1 pM.
GLP-1 RRA assay buffer: 25 mM Na-HEPES (pH=7.5), 2.5 mM CaCI2, 1 mM MgCI2, 50 mM NaCl, 0.1 % ovalbumin, 0.003% tween 20, 0.005% bacitracin, 0.05% NaN3. GLP-1 receptor suspension: GLP-1 receptor membrane fragments were purified from baby hamster kidney (BHK) cells expressing the human pancreatic GLP-1 receptor. Stored <- 80°C until use.
WGA-coupled polystyrene LEADseeker imaging beads (RPNQ0260, Amersham): The beads were reconstituted with GLP-1 RRA assay buffer to a concentration of 13.3 mg/mL. The GLP-1 receptor membrane suspension was then added and incubated cold (2-8°C) at end- over-end for at least 1 hr prior to use.
[1z5l]-GLP-1(7-36)amide (Novo Nordisk A/S). Stored <-18°C until use. Ethanol 99.9% vol (De Dansk Spritfabrikker A/S): Stored <-18°C until use. Multiscreen® Solvinert 0.45pm hydrophobic PTFE plates (MSRPN0450, Millipore Corp.) Poly propylene plates (cat. no. 650201, Greiner Bio-One) White polystyrene 384-well plates (cat. no. 781075, Greiner Bio-One)
Apparatus:
Horizontal plate mixer
Centrifuge with a standard swinging-bucket microtitre plate rotor assembly UltraVap - Drydown Sample Concentrator (Porvair) LEADseeker™ Multimodality Imaging System (Amersham) Assay Procedure:
Sample preparation:
Mount the Multiscreen® Solvinert filter plate on a chemical-comparable receiver plate (i.e. poly propylene plates) to collect the filtrate. Add 150 μL ice-cold ethanol 99.9% into the empty wells of the Multiscreen® Solvinert filter plate followed by 50 μL calibrator or plasma sample. Place the storage lid on the filter plate. Incubate 15 minutes at 18-22°C on a horizontal plate mixer.
Place the assembled filter and receiver plate, with the lid, into a standard swinging-bucket microtitre plate rotor assembly. The filtrate is then collected in the empty wells of the receiver plate at 1500 rpm for 2 minutes.
Dry down the filtrate by using the UltraVap with heated (40°C) N2 for duration of 15 miuntes. Reconstitute the dry material by adding 100 μL GLP-1 RRA assay buffer into each well. Incubate for 5 minutes on a horizontal mixer.
GLP-1 radio receptor assay: Use the following pipetting scheme and white polystyrene 384-well plates:
• 35 μL GLP-1 RRA assay buffer
• 5 μL reconstituted filtrate.
• 10 μL [125l]-GLP-1 (7-36)amide. The stock solution was diluted in GLP-1 RRA assay buffer to 20.000 cpm/well prior to use. • 15 μL GLP-1 receptor membrane fragments (»0.5 μg/well) pre-coated to WGA- polystyrene LEADseeker imaging beads (0.2 mg/well)
Seal the plates and incubate over night at 18-22°C
The light emission from each wells are detected by using the LEADseeker™ Multimodality Imaging System for duration of 10 minutes.
Stimulation of cAMP formation in a cell line expressing the cloned human GLP-1 receptor.
Purified plasma membranes from a stable transfected cell line, BHK467-12A (tk-ts13), expressing the human GLP-1 receptor was stimulated with GLP-1 and peptide analogues, and the potency of cAMP production was measured using the AlphaScreen™ cAMP Assay Kit from Perkin Elmer Life Sciences.
A stable transfected cell line has been prepared at NN and a high expressing clone was selected for screening. The cells were grown at 5% CO2 in DMEM, 5% FCS, 1% Pen/Strep and 0.5 mg/ml G418.
Cells at approximate 80% confluence were washed 2X with PBS and harvested with Versene, centrifuged 5 min at 1000 rpm and the supernatant removed. The additional steps were all made on ice. The cell pellet was homogenized by the Ultrathurax for 20-30 sec. in 10 ml of Buffer 1 (20 mM Na-HEPES, 10 mM EDTA, pH=7.4), centrifuged 15 min at 20.000 rpm and the pellet resuspended in 10 ml of Buffer 2 (20 mM Na-HEPES, 0.1 mM EDTA, pH=7.4). The suspension was homogenized for 20-30 sec and centrifuged 15 min at 20.000 rpm. Suspension in Buffer 2, homogenization and centrifugation was repeated once and the membranes were resuspended in Buffer 2 and ready for further analysis or stored at -80°C. The functional receptor assay was carried out by measurering the peptide induced cAMP production by The AlphaScreen Technology. The basic principle of The AlphaScreen Technology is a competition between endogenous cAMP and exogenously added biotin-cAMP. The capture of cAMP is achieved by using a specific antibody conjugated to acceptor beads. Formed cAMP was counted and measured at a AlphaFusion Microplate Analyzer. The EC50 values was calculated using the Graph-Pad Prisme software.

Claims

1. A compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer.
2. A compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer -(CH2)|D[(CH2)nE]m(CH2)pQq-, wherein
I, m and n independently are 1-20 and p is 0-10,
Q is -Z-(CH2)|D[(CH2)nG]m(CH2)p-, q is an integer in the range from 0 to 5, each D, E, and G independently are selected from -O-, -NR3-, -N(COR4)-, -PR5(O)-, and -P(OR6)(O)-, wherein R3, R4, R5, and R6 independently represent hydrogen or
C1-6-alkyl,
Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH -, -C(O)NHCH2CH2-, -C(O)CH2-, -C(O)CH=CH-, -(CH2)S-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or
1 or a pharmaceutically acceptable salt or prodrug thereof.
3. A compound according to claim 2, which has the formula (I) : A— W — B — Y— therapeutic polypeptide (I) wherein
A is an albumin binding residue,
B is a hydrophilic spacer being -(CH2)|D[(CH2)nE]m(CH2)pQq-, wherein
I, m and n independently are 1-20 and p is 0-10, Q is -Z-(CH2),D[(CH2)nG]m(CH2)p-, q is an integer in the range from 0 to 5, each D, E, and G independently are selected from -O-, -NR3-, -N(COR4)-, -PR5(O)-, and -P(OR6)(O)-, wherein R3, R4, R5, and R6 independently represent hydrogen or
C .6-alkyl, Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH -, -C(O)NHCH2CH2-,
-C(O)CH2-, -C(O)CH=CH-, -(CH2)S-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or
1 , Y is a chemical group linking B and the therapeutic agent, and W is a chemical group linking A and B.
4. A compound according to claim 2, which has the formula (II)
A-W— B— Y-therapeutic polypeptide — Y'-B'-W — A' (II) wherein
A and A' are albumin binding residues, B and B' are hydrophilic spacers independently selected from -(CH2)|D [(CH2)nE]m(CH2)p-Qq-, wherein
I, m and n independently are 1-20 and p is 0-10,
Q is -Z-(CH2)|D[(CH2)nG]m(CH2)p-, q is an integer in the range from 0 to 5, each D, E, and G independently are selected from -O-, -NR3-, -N(COR4)-, -PR5(O)-, and -P(OR6)(O)-, wherein R3, R4, R5, and R6 independently represent hydrogen or
C1-6-alkyl,
Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH -, -C(O)NHCH2CH2-,
-C(O)CH2-, -C(O)CH=CH-, -(CH2)S-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or 1 ,
Y is a chemical group linking B and the therapeutic agent, and Y' is a chemical group linking B' and the therapeutic agent, and W is a chemical group linking A and B, and W' is a chemical group linking A' and B'.
5. A compound according to claim 4, wherein Y' is selected from the group consisting of - C(O)NH-, -NHC(O)-, -C(O)NHCH2-, -CH2NHC(O)-, -OC(O)NH -, -NHC(O)O-, -C(O)NHCH2-, CH2NHC(O)-, -C(O)CH2-, -CH2C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -(CH2)S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and -C(O)NH-, wherein s is 0 or 1.
6. A compound according to any one of claims 4-5, wherein W' is selected from the group consisting of -C(O)NH-, -NHC(O)-, -C(O)NHCH2-, -CH2NHC(O)-, -OC(O)NH -, -NHC(O)O-, -C(O)CH2-, -CH2C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -(CH2)S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and -C(O)NH-, wherein s is 0 or 1.
7. A compound according to claim 2, which has the formula (III)
A-W"-B— Y-therapeutic polypeptide (III) A' wherein
A and A' are albumin binding residues, B is a hydrophilic spacer selected from -(CH2)|D[(CH2)nE]m(CH2)p-Qq- wherein
I, m and n independently are 1-20 and p is 0-10,
Q is -Z-(CH2),D[(CH2)nG]m(CH2)p-, q is an integer in the range from 0 to 5, each D, E, and G are independently selected from -O-, -NR3-, -N(COR4)-, -PR5(O)-, and -P(OR6)(O)-, wherein R3, R4, R5, and R6 independently represent hydrogen or
C -6-alkyl,
Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH -, -C(O)NHCH2CH2-,
-C(O)CH2-, -C(O)CH=CH-, -(CH2)S-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or 1 ,
Y is a chemical group linking B and the therapeutic agent, and W" is a chemical group linking B with A and A'.
8. A compound according to claim 7, wherein W" is selected from the group consisting of -C(0)NHCH- , -C(0)CH- , -(CH2)SCH- , and -NHC(0)CNHC(0)CH20(CH2)20(CH2)2NH-
wherein s is 0, 1 or 2.
9. A compound according to any one of claims 3-8, wherein Y is selected from the group consisting of -C(O)NH-, -NHC(O)-, -C(O)NHCH2-, -CH2NHC(O)-, -OC(O)NH -, -NHC(O)O-, -C(O)NHCH2-, CH2NHC(O)-, -C(O)CH2-, -CH2C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -(CH2)S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and -C(O)NH-, wherein s is 0 or 1.
10. A compound according to any one of claims 3-9, wherein W is selected from the group consisting of -C(O)NH-, -NHC(O)-, -C(O)NHCH2-, -CH2NHC(O)-, -OC(O)NH -, -NHC(O)O-, -C(O)CH2-, -CH2C(O)-, -C(O)CH=CH-, -CH=CHC(O)-, -(CH2)S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)- and -C(O)NH-, wherein s is 0 or 1.
11. A compound according to any one of claims 2-10, wherein I is 1 or 2, n and m are independently 1-10 and p is 0-10.
12. A compound according to any one of claims 2-11 , wherein D is -O-.
13. A compound according to any one of claims 2-12, wherein E is -O-.
14. A compound according to any one of claims 2-10, wherein the hydrophilic spacer is CH2O[(CH2)2O]m(CH2)pQq-, where m is 1-10, p is 1-3, and Q is -Z-CH2O[(CH2)2O]m(CH2) p ■
15. A compound according to any of the previous claims, wherein q is 0 or 1.
16. A compound according to any of the previous claims, wherein q is 1.
17. A compound according to any one of claims 2-10 and 12-15, wherein G is -O-.
18. A compound according to any of the previous claims, wherein Z is selected from the group consisting of -C(O)NH-, -C(O)NHCH2-, and -OC(O)NH-.
19. A compound according to any one of claims 2-15, wherein q is 0.
20. A compound according to any one of claims 2-13, wherein I is 2.
21. A compound according to any of the previous claims, wherein n is 2.
22. A compound according to any one of claims 2-15, wherein the hydrophilic spacer B is
[CH2CH2θ]m+-| (CH2)pQq-.
23. A compound according to any one of claims 2-15, wherein the hydrophilic spacer B is -(CH2)|-O-[(CH2)n-O]m-(CH2)p-[C(O)NH-(CH2)rO-[(CH2)n-O]m-(CH2)p]q-, where I, m, n, and p independently are 1-5, and q is 0-5.
24. A compound according to any one of the preceding claims, wherein -W-B-Y- is selected from the group consisting of
Figure imgf000112_0001
w Y
Figure imgf000112_0002
Figure imgf000113_0001
25. A compound according to claim 7, wherein >W"-B-Y- is
Figure imgf000113_0002
26. A compound according to any one of the preceding claims, wherein A is selected from the group consisting of
Figure imgf000113_0003
Figure imgf000114_0001
Figure imgf000114_0002
Figure imgf000114_0003
where the chiral carbon atom is either R or S,
Figure imgf000114_0004
where the chiral carbon atom is either R or S,
Figure imgf000114_0005
where the chiral carbon atom is either R or S,
Figure imgf000114_0006
where the two chiral carbon atoms independently are either R or S,
Figure imgf000114_0007
where the two chiral carbon atoms independently are either R or S,
Figure imgf000115_0001
where the two chiral carbon atoms independently are either L or D,
Figure imgf000115_0002
where the chiral carbon atom is either R or S,
Figure imgf000115_0003
where the chiral carbon atom is either R or S,
Figure imgf000115_0004
where the two chiral carbon atoms independently are either R or S,
Figure imgf000115_0005
where the two chiral carbon atoms independently are either R or S,
Figure imgf000115_0006
Figure imgf000116_0001
Figure imgf000116_0002
Figure imgf000116_0003
Figure imgf000117_0001
Figure imgf000117_0002
27. A compound according to any of the previous claims, wherein the molar weight of said hy- drophilic spacer is in the range from 80D to 1000D or in the range from 80D to 300D.
28. A compound according to any of the previous claims, wherein said albumin binding residue is a lipophilic residue.
29. A compound according to any of the previous claims, wherein said albumin binding residue binds non-covalently to albumin.
30. A compound according to any of the previous claims, wherein said albumin binding residue is negatively charged at physiological pH.
31. A compound according to any of the previous claims, wherein said albumin binding residue has a binding affinity towards human serum albumin that is below about 10 μM or below about 1 μM.
32. A compound according to any of the previous claims, wherein said albumin binding residue is selected from a straight chain alkyl group, a branched alkyl group, a group which has an ω- carboxylic acid group, a partially or completely hydrogenated cyclopentanophenanthrene skeleton.
33. A compound according to any of the previous claims, wherein said albumin binding residue is a cibacronyl residue.
34. A compound according to any of the previous claims, wherein said albumin binding residue has from 6 to 40 carbon atoms, from 8 to 26 carbon atoms or from 8 to 20 carbon atoms.
35. A compound according to any of the previous claims, wherein said albumin binding residue is a peptide, such as a peptide comprising less than 40 amino acid residues.
36. A compound according to any one of the previous claims, wherein the albumin binding residue via spacer and linkers is attached to said therapeutic polypeptide via the ε-amino group of a lysine residue.
37. A compound according to any one of the previous claims, wherein the albumin binding residue via spacer and linkers is attached to said therapeutic polypeptide via a linker to an amino acid residue selected from cysteine, glutamate and aspartate.
38. A compound according to any of the previous claims, wherein said therapeutic polypeptide is a GLP-1 peptide.
39. A compound according to claim 34, wherein said polypeptide is a GLP-1 peptide comprising the amino acid sequence of the formula (IV):
Xaa7-Xaa8-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Xaa16-Ser-Xaa18-Xaa1g-Xaa20-Glu-Xaa22-Xaa23-Ala- Xaa25-Xaa26-Xaa27-Phe-lle-Xaa30-Trp-Leu-Xaa33-Xaa34-Xaa35-Xaa36-Xaa37-Xaa38-Xaa39- Xaa4o~Xaa4ι -Xaa42-Xaa43-Xaa44-Xaa 5-Xaa46
Formula (IV) (SEQ ID No: 2) wherein
Xaa7 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, Nα-acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3- pyridylalanine, 2-pyridylalanine or 4-pyridylalanine; Xaa8 is Ala, Gly, Val, Leu, lie, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1- aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid;
Xaa16 is Val or Leu;
Xaa-is is Ser, Lys or Arg;
Figure imgf000119_0001
Xaa20 is Leu or Met;
Xaa22 is Gly, Glu or Aib;
Xaa23 is Gin, Glu, Lys or Arg;
Xaa25 is Ala or Val;
Xaa28 is Lys, Glu or Arg;
Xaa27 is Glu or Leu;
Xaa30 is Ala, Glu or Arg;
Xaa33 is Val or Lys;
Xaa34 is Lys, Glu, Asn or Arg;
Xaa35 is Gly or Aib;
Xaa36 is Arg, Gly or Lys;
Xaa37 is Gly, Ala, Glu, Pro, Lys, amide or is absent;
Xaa38 is Lys, Ser, amide or is absent.
Xaa39 is Ser, Lys, amide or is absent;
Xaa40 is Gly, amide or is absent;
Xaa4 is Ala, amide or is absent;
Xaa42 is Pro, amide or is absent;
Xaa 3 is Pro, amide or is absent;
Xaa 4 is Pro, amide or is absent;
Xaa45 is Ser, amide or is absent;
Xaa46 is amide or is absent ; provided that if Xaa38, Xaa39, Xaa40, Xaa41, Xaa42, Xaa 3, Xaa4 , Xaa45 or Xaa46 is absent then each amino acid residue downstream is also absent.
40. A compound according to claim 39, wherein said polypeptide is a GLP-1 peptide comprising the amino acid sequence of formula (V):
Xaa7-Xaa8-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Xaa18-Tyr-Leu-Glu-Xaa22-Xaa23-Ala-Ala- Xaa26-Glu-Phe-lle-Xaa3o-Trp-Leu-Val-Xaa3 -Xaa35-Xaa36-Xaa37-Xaa38
Formula (V) (SEQ ID No: 3) wherein Xaa7 is L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, Nα-acetyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3- pyridylalanine, 2-pyridylalanine or 4-pyridylalanine;
Xaa8 is Ala, Gly, Val, Leu, lie, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1- aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid;
Xaa-|8 s Ser, Lys or Arg; Xaa22 s Gly, Glu or Aib; Xaa 3 s Gin, Glu, Lys or Arg; Xaa2@ s Lys, Glu or Arg;
Figure imgf000120_0001
Xaa84 s Lys, Glu or Arg; Xaa35 s Gly or Aib;
Figure imgf000120_0002
Xaa37 s Gly, Ala, Glu or Lys; Xaa38 s Lys, amide or is absent.
41. A compound according to any one of claims 38-40, wherein said GLP-1 peptide is selected from GLP-1 (7-35), GLP-1 (7-36), GLP-1 (7-36)-amide, GLP-1 (7-37), GLP-1 (7-38), GLP-1 (7-39), GLP-1 (7-40), GLP-1 (7-41) or an analogue thereof.
42. A compound according to any one of claims 38-41 , wherein said GLP-1 peptide comprises no more than fifteen amino acid residues which have been exchanged, added or deleted as compared to GLP-1 (7-37) (SEQ ID No. 1), or no more than ten amino acid residues which have been exchanged, added or deleted as compared to GLP-1 (7-37) (SEQ ID No. 1 ).
43. A compound according to claim 42, wherein said GLP-1 peptide comprises no more than six amino acid residues which have been exchanged, added or deleted as compared to GLP- 1 (7-37) (SEQ ID No. 1).
44. A compound according to any one of claims 42-43, wherein said GLP-1 peptide comprises no more than 4 amino acid residues which are not encoded by the genetic code.
45. A compound according to claim 38, wherein said GLP-1 peptide is a DPPIV protected GLP-1 peptide.
46. A compound according to claim 38, wherein said compound is DPPIV stabilised.
47. A compound according to any one of claims 38-46, wherein said GLP-1 peptide comprises an Aib residue in position 8.
48. A compound according to any one of claims 38-47, wherein the amino acid residue in position 7 of said GLP-1 peptide is selected from the group consisting of D-histidine, desamino- histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, Nα-acetyl-histidine , α- fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine and 4- pyridylalanine.
49. A compound according to any one of claims 38-48, wherein said GLP-1 peptide is selected from the group consisting of Arg34GLP-1(7-37),
Lys38Arg26'34GLP-1 (7-38), Lys38Arg26'34GLP-1 (7-38)-OH, Lys36Arg26'34GLP-1 (7-36), Aib8'22'35 GLP-1 (7-37), Aib8'35 GLP-1 (7-37), Aib8'22 GLP-1 (7-37),
Aib8'22,35 Arg26,34Lys38GLP-1 (7-38), Aib8'35 Arg26'34Lys38GLP-1 (7-38),
Aib8'22Arg26'34Lys38GLP-1 (7-38)> Aib8'22'35Arg26'34Lys38GLP-1(7-38),
Aib8'35 Arg26'34Lys38GLP-1 (7-38), Aib8'22'35 Arg26Lys38GLP-1 (7-38),
Aib8'35 Arg26Lys38GLP-1 (7-38), Aib8'22 Arg26Lys38GLP-1 (7-38), Aib8'22'35 Arg34Lys38GLP-1 (7-38), Aib8,35Arg34Lys38GLP-1 (7-38), Aib8'22Arg34Lys38GLP-1 (7-38),
Aib8'22'35Ala37Lys38GLP-1 (7-38), Aib8'35Ala37Lys38GLP-1 (7-38), Aib8'22Ala37Lys38GLP-1 (7-38),
Aib8'22'35 Lys37GLP-1 (7-37), Aib8'35Lys37GLP-1(7-37) and Aib8'22Lys37GLP-1(7-38).
50. A compound according to any one of claims 38-49, wherein said GLP-1 peptide is attached to said hydrophilic spacer via the amino acid residue in position 23, 26, 34, 36 or 38 relative to the amino acid sequence SEQ ID No:1.
51. A compound according to any one of claims 38-41 , wherein said GLP-1 peptide is exendin- 4.
52. A compound according to any one of claims 38-41 , wherein said GLP-1 peptide is ZP-10, i.e. HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-amide.
53. A compound according to any one of claims 38-52, wherein one albumin binding residue via said hydrophilic spacer is attached to the C-terminal amino acid residue of said GLP-1 peptide.
54. A compound according to claim 53, wherein a second albumin binding residue is attached to an amino acid residue which is not the C-terminal amino acid residue.
55. A compound according to any one of the previous claims, wherein said compound is selected from the group consisting of Nε37-(2-(2-(2-(dodecylamino)ethoxy)ethoxy)acetyl)-[Aib8'22'35Lys37]GLP-1 (7-37)amide
Figure imgf000122_0001
8,2 ,35
Nε37-(2-(2-(2-(17-sulphohexadecanoylamino)ethoxy)ethoxy)acetyl)-[Aiba' ∞,Lys ,3d7'-]. GLP-1 (7-
37)amide
Figure imgf000122_0002
N -{2-[2-(2-(15-carboxypentadecanoylamino)ethoxy)ethoxy]acetyl}-[Aibb'^'d&,Lys^] GLP-
1(7-37)amide
Figure imgf000122_0003
Nεi -(2-(2-(2-(17-carboxyheptadecanoylamino)ethoxy)ethoxy)acetyl)[Aib 80,'2"2,"3350, ,L .y.s-.Z°l'-]xGLP-1 (7 37)amide
Figure imgf000123_0001
Nε37-(2-(2-(2-(19-carboxynonadecanoylamino)ethoxy)ethoxy)acetyl)[Aib8'22'35,Lys37]GLP-1 (7.
37)amide
Figure imgf000123_0002
[AibB'^'Jϋ,Argzt5'HGLP-1-(7-37)Lys(4-(Hexadecanoylamino)-4(S)-carboxybutyryl)-OH
Figure imgf000123_0003
[Aiba' 3b,ArgΛ'd4]GLP-1-(7-37)Lys(2-(2-(2-(hexadecanoylamino)ethoxy)ethoxy)acetyl)-OH
Figure imgf000123_0004
Nε3 -(2-[2-(2,6-(S)-Bis-{2-[2-(2- (dodecanoylamino)ethoxy)ethoxy]acetylamino}hexanoylamino)ethoxy]ethoxy}) acetyl-[AibB' 2'3S]GLP-1(7-37)amide
Figure imgf000124_0001
Nε37-(2-[2-(2,6-(S)-Bis-{2-[2-(2-
(tetradecanoylamino)ethoxy)ethoxy]acetylamino}hexanoylamino)ethoxy]ethoxy}) acetyl-[Aib8'22'35]GLP-1(7-37)amide
Figure imgf000124_0002
[Aib8'22'35,Arg26'34]GLP-1-(7-37)Lys(2-(2-(2-(4-(Hexadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetyl)-OH
Figure imgf000124_0003
[Aib8'22'35]GLP-1(7-37)Lys((2-{2-[4-[4-(4-Amino-9,10-dioxo-3-sulfo-9,10-dihydro-anthracen-1- ylamino)-2-sulfo-phenylamino]-6-(2-sulfo-phenylamino)-[1 ,3,5]triazin-2-ylamino]-ethoxy}- ethoxy)-acetyl))amide
Figure imgf000125_0001
[Aib8'22,35]GLP-1(7-37)Lys(({2-[2-(2-{2-[2-(2-{2-[2-(15-carboxypentadecanoylamino)- ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl amino)ethoxy]ethoxy}acetyl))amide
Figure imgf000125_0002
Nε37-([2-(2-{3-[2,5-dioxo-3-(15-carboxypentadecylsulfanyl)-pyrrolidin-1-yl]- pprrooppiioonnyyllεamino}ethoxy)ethoxy)acetyl]-[D-Ala8,Lys37]-GLP-1-[7
37]amide
Figure imgf000125_0003
[Aib8'22'35Ala37]GLP-1 (7-37)Lys((2-(2-(2-(11- (oxalylamino)undecanoylamino)ethoxy)ethoxy)acetyl-)))amide
Figure imgf000126_0001
[Aib8' 2'35,Ala37]-GLP-1 (7-37)Lys({2-[2-(2-{2-[2-(2-(15-carboxy-pentadecanoylamino)- ethoxy]ethoxy}acetylamino)ethoxy]ethoxy}acetyl)amide
Figure imgf000126_0002
[Aib8'22'35,Ala37]-GLP-1 (7-37)Lys((2-{2-[11 -(5-Dimethylaminonaphthalene-1 - sulfonylamino)undecanoylamino]ethoxy}ethoxy)acetyl)amide
Figure imgf000126_0003
[Aib8'22'35,Ala37]-GLP-1 (7-37)Lys(([2-(2-{2-[1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1 H-indol- 3-yl]acetylamino}ethoxy)ethoxy]acetyl))amide
Figure imgf000127_0001
[Aib8,Arg26'34,Glu22,23'30]GLP-1 H(7-37)Lys(2-(2-(2- (octadecanoylamino)ethoxy)ethoxy)acetyl)amide
Figure imgf000127_0002
[Aib8,Arg26'34,Glu22'23'30]GLP-1 (7-37)Lys(2-(2-(2- (eicosanoylamino)ethoxy)ethoxy)acetyl)amide
Figure imgf000127_0003
[Gly8,Arg26'34] GLP-1 H-(7-37)Lys(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetyl)ethoxy)ethoxy)acetyl)-OH
Figure imgf000127_0004
„26,3 l
[Aib8,Arg26'34]GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2- (octadecanoylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000128_0001
[Aib8] -GLP-1 -(7-37)Lys (2-(2-(2-(4-(Hexadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetyl)-OH
Figure imgf000128_0002
[Aib8,Arg26'34] GLP-1 (7-37) Lys{2-(2-(2-(2-[2-(2-(4-(octadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000128_0003
[Aib8,Arg26'34] GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-(17- carboxyheptanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000129_0001
[Gly8, Arg26'34] GLP1-(7-37) Lys{2-(2-(2-(2-[2-(2-(17- carboxyheptadecanoylamino)ethoxy)ethoxy]acetyl)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000129_0002
[Aib8]GLP-1-(7-37)Lys(2-(2-(2-(2-(2-(2-(4-(Hexadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetylamino) ethoxy)ethoxy)acetyl)-OH
8,22,35, , ,„37τ N" -(2-(2-(2-(dodecanoylamino)ethoxy)ethoxy)acetyl)-[Aib°'^°LysJ'] GLP-1 H(7-37)-amide
Figure imgf000129_0004
Nε37-(2-(2-(2-(tetradecanoylamino)ethoxy)ethoxy)acetyl)-[Aib° i,"2i2,"3350,L .y,sa 37'n] GLP-1 H(7-37)- amide
Figure imgf000130_0001
Figure imgf000130_0002
GLP-1 (7-37)-amide
Figure imgf000130_0003
N" -(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetyl)-[Aib 8°,'22,'3∞5,Lys ,3J7'ι] GLP-1 (7-37)-amide
Figure imgf000130_0004
Figure imgf000130_0005
GLP-1 (7-37)-amide
Figure imgf000130_0006
Nε36-(2-(2-(2-(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl))- [Aib8,Arg26'34,Lys36]GLP-1-(7-37)-OH
Figure imgf000131_0001
N ,ε"36-(2-(2-(2-(2-(2-(2-
(octadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl))[Arg26,34,Lys36]GLP-
1 (7-37)-OH
Figure imgf000131_0002
Nε36-{2-(2-(2-(2-[2-(2-(octadecanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}- [Gly8,Arg26'34,Lys36]GLP-1-(7-37)-OH
Figure imgf000131_0003
N ,ε"37'_(2-(2-(2-(4-4(4,4,5,5,6,6,7,7,8,8,9,9,9-thdecafluorononanoyIsulfamoyl- butyrylamino)ethoxy)ethoxy)acetyl))[Aib8'22'35,Lys37] GLP-1-(7-37)-OH
Figure imgf000131_0004
■ε37
N" -(2-(2-(2-(3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11 ,11 ,12,12,12-Heneicosafluoro- dodecyloxyacetylamino)ethoxy) ethoxy)acetyl)[Aib8'22'35,Lys37]GLP-1-(7-37)-OH
Figure imgf000132_0001
■ε37
NM -(2-(2-(2-(4-(hexadecanoylsulfamoyl)butyrylamino)ethoxy)ethoxy)acetyl)[Aib """■ ,Lys3/] GLP-1 -(7-37)-OH
Figure imgf000132_0002
-26,3 l
[ArgΛHG P-1(7-37)Lys({2-(2-(2-(2-[2-(2- (octadecanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)})-OH
Figure imgf000132_0003
[Arg .26D,'3H4l GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-(4-(octadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000133_0001
Nεzu-{2-(2-(2-(2-[2-(2-(4-(hexadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-exendin(1-39)
Figure imgf000133_0002
[Ala8, Arg26'34]GLP-1 (7-37)Lys((2-[2-((2-oxalylamino-3-carboxy-2-4,5,6,7-tetrahydro- benzo[b]thiophen-6-yl-acetylamino))ethoxy]ethoxyacetyl) amide
Figure imgf000133_0003
[Aib8'22'35]GLP-1 (7-37)Lys((2-[2-((2-oxalylamino-3-carboxy-2-4,5,6,7-tetrahydro- benzo[b]thiophen-6-yl-acetylamino))ethoxy]ethoxyacetyl) amide
Figure imgf000133_0004
,ε36
N -(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl)-
[Aib8,Arg26'34,Lys36]GLP-1-(7-37)-OH
Figure imgf000134_0001
N -(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl)- [Gly8,Arg26'34,Lys36]GLP-1-(7-37)-OH
Figure imgf000134_0002
NεJ -2-(2-(2-(4-(4-(Heptadecanoylamino)-4-(S)-carboxybutyrylamino)-4-(S)- carboxybutyrylamino)ethoxy)ethoxy) acetyl-[Aib8'22'35,Lys37]GLP-1-(7-37)-NH2
Figure imgf000134_0003
NεJ7-2-(2-[2-(2-[2-(4-[4-(Heptadecanoylamino)-4-(S) carboxybutyrylamino]-4-(S)-carboxybutyrylamino)ethoxy] ethoxy)acetylamino)ethoxy]ethoxy)acetyl-[Aib8'22'35,Lys37]GLP-1-(7-37)-NH2
Figure imgf000135_0001
Nε26-(2-(2-(2-(4-(Hexadecanoylamino)-4(S)-carboxybutyrylamino) ethoxy)ethoxy)acetyl)-[Aib8,Arg34]GLP-1-(7-37)-
-OH
Figure imgf000135_0002
Nε26-2-(2-2-(2-(2-(2-(4-(Octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyI- [Aib8, Arg34]GLP-1-(7-37)-OH
Figure imgf000135_0003
[Gly8,Arg26'3 ]GLP-1 (7-37)Lys(2-(2-(19-(carboxy)nonadecanoylamino)ethoxy)ethoxy)acetyl)- OH
Figure imgf000136_0001
[Gly8,Arg26'34]GLP-1 (7-37)Lys((2-(2-(17- (carboxy)heptadecanoylamino)ethoxy)ethoxy)acetyl))-OH
Figure imgf000136_0002
[Gly8,Arg26,34]GLP-1 (7-37)Lys(2-(2-(2-(4-(19-(carboxy)nonadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy)acetyl)-OH
Figure imgf000136_0003
[Gly8,Arg26'34]GLP-1 (7-37)Lys((2-(2-(2-(2-(2-(2-(2-(2-(2-
(hexadecanoylamino)ethoxy)ethoxy)acetyl)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)- acetyl)-OH
Figure imgf000136_0004
[Gly8, Arg26'34]GLP-1 (7-37)Lys (2-(2-(2-(2-(2-(2-(octadecanoylamino)ethoxy)ethoxy)- acetylamino)ethoxy)ethoxy)acetyl) NH2
Figure imgf000137_0001
Nε20(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(4-(17-(carboxy)heptadecanoylamino)-4- carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetylamino) ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl) [Lys20]exendin-4 (1 -39)-NH2
Figure imgf000137_0002
N -(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy) acetylamino)ethoxy)ethoxy)acetyl) [Aib8,Arg26'34, Lys36] GLP-1 (7-37)
Figure imgf000137_0003
N- ε36 -(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy) acetylamino)ethoxy)ethoxy)acetyl) [Arg26'34, Lys36] GLP-1 (7-37)
Figure imgf000138_0001
Nε -(2-(2-(2-(2-(2-(2-(17-Carboxyheptadecanoylamino)ethoxy)ethoxy) acetylamino)ethoxy)ethoxy)acetyl) [Glya,Arg t>' ,LysJD] GLP-1 (7-37)
Figure imgf000138_0002
N ,εε20 -(2-(2-(2-(2-(2-(2-(2-(2-(2- (Octadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetylamino)ethoxy)- ethoxy)acetyl)[Lys20] Exendin-4 (1-39)amide
Figure imgf000138_0003
Nε36-(2-(2-(2-(2-(2-(2-(4-(octadecanoylamino)-4(S)- carboxybutyrylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl)-[Arg26,34,Lys36]GLP-1-
(7-37)
Figure imgf000139_0001
Nε2ύ-(2-[2-(2-[2-(2-[2-(17-Carboxyheptadecanoylamino)ethoxy] ethoxy)acetylamino]ethoxy)ethoxy]acetyl)[ArgJ4]GLP-1-(7-37)-OH
Figure imgf000139_0002
Nε2G-[2-(2-[2-(2-[2-(2-[4-(17-Carboxyheptadecanoylamino)-4(S)-
„34l carboxybutyrylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Arg ]GLP-1-(7-37)- OH
Figure imgf000139_0003
Nε u-(2-(2-(2-(2-(2-(2-(2-(2-(2-(17-
Carboxyheptadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy)ethoxy)acetyl- amino)ethoxy)ethoxy)acetyl)[Lys20] Exendin-4 (1-39) amide
EWL KNG-GPS
Figure imgf000140_0001
Figure imgf000140_0002
[Gly8, Glu22'23'30, Arg18'26'34]GLP1 (7-37) Lys(2-(2-(2-(2-(2-(2-(17- carboxyheptadecanoylamino)ethoxy)ethoxy)acetylamino)ethoxy))ethoxy)acetyl)-NHs
Figure imgf000140_0003
[Imidazolylpropionic acid7, Asp16, Aib22'35 ]GLP1 (7-37)Lys NH((2-{[4-(17- carboxyheptadecanoylamino)butylcarbamoyl]methoxy}ethoxy)ethoxy))
Figure imgf000140_0004
[Imidazolylpropionic acid7, Aib22'35 ]GLP1 (7-37)Lys NH( (2-{[4-(17- carboxyheptadecanoylamino)butylcarbamoyl]methoxy}ethoxy)ethoxy))
Figure imgf000141_0001
, and [[33--((55--llmidazoyl)propionyl7, Aib8, Arg26'34 ] GLP-1 (7-37)Lys{2-(2-(2-(2-[2-(2-(17- carboxyheptanoylamino)ethoxy)ethoxy]acetylamino)ethoxy)ethoxy)acetyl)}-OH
Figure imgf000141_0002
56. A compound according to any one of claims 1-37, wherein said therapeutic polypeptide is a GLP-2 peptide.
57. A compound according to claim 56, wherein said GLP-2 peptide is a DPPIV-protected GLP-2 peptide.
58. A compound according to claim 56, wherein said GLP-2 peptide is Gly -GLP-2(1-33).
59. A compound according to claim 56, wherein said GLP-2 peptide is Lys17Arg30-GLP-2(1- 33).
60. A compound according to any one of claims 1-37, wherein said therapeutic polypeptide is human insulin or an analogue thereof.
61. A compound according to claim 60, wherein said therapeutic polypeptide is selected from the group consisting of AspB28-human insulin, LysB28,ProB29-human insulin, LysB3,GluB29-human insulin, Gl A21,ArgB31,ArgB32-human insulin and des(B30) human insulin.
62. A compound according to any one of claims 1-37, wherein said therapeutic polypeptide is human growth hormone or an analogue thereof.
63. A compound according to any one of claims 1-37, wherein said therapeutic polypeptide is parathyroid hormone or an analogue thereof.
64. A compound according to any one of claims 1-37, wherein said therapeutic polypeptide is human follicle stimulating hormone or an analogue thereof.
65. A compound according to any one of claims 1-37, wherein said therapeutic polypeptide has a molar weight of less than 100 kDa, less than 50 kDa, or less than 10 kDa.
66. A compound according to any one of claims 1-37, wherein said therapeutic polypeptide is selected from the group consisting of a growth factor such as platelet-derived growth factor (PDGF), transforming growth factor α (TGF-α), transforming growth factor β (TGF-β), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), a somatomedin such as insulin growth factor I (IGF-I), insulin growth factor II (IFG-II), erythropoietin (EPO), thrombopoietin (TPO) or angiopoietin, interferon, pro-urokinase, urokinase, tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1 , plasminogen activator inhibitor 2, von Wille- brandt factor, a cytokine, e.g. an interleukin such as interleukin (IL) 1 , IL-1 Ra, IL-2, IL-4, IL-5, IL-6, IL-9, IL-11 , IL-12, IL-13, IL-15, IL-16, IL-17, IL-18, IL-20 or IL-21 , a colony stimulating factor (CFS) such as GM-CSF, stem cell factor, a tumor necrosis factor such as TNF-α, lymphotoxin-α, lymphotoxin-β, CD40L, or CD30L, a protease inhibitor e.g. aprotinin, an enzyme such as superoxide dismutase, asparaginase, arginase, arginine deaminase, adenosine deaminase, ribonuclease, catalase, uricase, bilirubin oxidase, trypsin, papain, alkaline phosphatase, β-glucoronidase, purine nucleoside phosphorylase or batroxobin, an opioid, e.g. en- dorphins, enkephalins or non-natural opioids, a hormone or neuropeptide, e.g. calcitonin, glucagon, gastrins, adrenocorticotropic hormone (ACTH), cholecystokinins, lutenizing hormone, gonadotropin-releassing hormone, chorionic gonadotropin, corticotrophin-releasing factor, vasopressin, oxytocin, antidiuretic hormones, thyroid-stimulating hormone, thyrotropin- releasing hormone, relaxin, prolactin, peptide YY, neuropeptide Y, pancreastic polypeptide, leptin, CART (cocaine and amphetamine regulated transcript), a CART related peptide, perilipin, melanocortins (melanocyte-stimulating hormones) such as MC-4, melanin-concentrating hormones, natriuretic peptides, adrenomedullin, endothelin, secretin, amylin, vasoactive intestinal peptide (VIP), pituary adenylate cyclase activating polypeptide (PACAP), bombesin, bombesin-like peptides, thymosin, heparin-binding protein, soluble CD4, hypothalmic releasing factor, melanotonins and analogues thereof.
67. A pharmaceutical composition comprising a compound according to any one of claims 1- 66, and a pharmaceutically acceptable excipient.
68. The pharmaceutical composition according to claim 67, which is suited for parenteral administration.
69. Use of a compound according to any one of the claims 1-66 for the preparation of a me- dicament.
70. Use of a compound according to any one of the claims 38-55 for the preparation of a medicament for the treatment or prevention of hyperglycemia, type 2 diabetes, impaired glucose tolerance, type 1 diabetes, obesity, hypertension, syndrome X, dyslipidemia, cognitive disor- ders, atheroschlerosis, myocardial infarction, coronary heart disease and other cardiovascular disorders, stroke, inflammatory bowel syndrome, dyspepsia and gastric ulcers.
71. Use of a compound according to any one of the claims 38-55 for the preparation of a medicament for delaying or preventing disease progression in type 2 diabetes.
72. Use of a compound according to any one of the claims 38-55 for the preparation of a medicament for decreasing food intake, decreasing β-cell apoptosis, increasing β-cell funtion and β-cell mass, and/or for restoring glucose sensitivity to β-cells.
73. Use of a compound according to any one of claims 56-59 for the preparation of a medicament for the treatment of small bowel syndrome, inflammatory bowel syndrome or Crohns disease.
74. Use of a compound according to any one of claims 60-61 for the preparation of a medicament for the treatment or prevention of hyperglycemia, type 1 diabetes, type 2 diabetes or β- cell deficiency.
PCT/DK2004/000624 2003-09-19 2004-09-17 Albumin-binding derivatives of therapeutic peptides WO2005027978A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
KR1020067005530A KR101241862B1 (en) 2003-09-19 2004-09-17 Novel glp-1 derivatives
AU2004273573A AU2004273573B2 (en) 2003-09-19 2004-09-17 Albumin-binding derivatives of therapeutic peptides
JP2006526519A JP4949838B2 (en) 2003-09-19 2004-09-17 New GLP-1 derivative
US10/572,348 US20070203058A1 (en) 2003-09-19 2004-09-17 Novel Glp-1 Derivatives
CA002539253A CA2539253A1 (en) 2003-09-19 2004-09-17 Albumin-binding derivatives of therapeutic peptides
BR122019021416A BR122019021416A2 (en) 2003-09-19 2004-09-17
BRPI0414539A BRPI0414539B8 (en) 2003-09-19 2004-09-17 compound, pharmaceutical composition, and use of a compound
EP04762844A EP1670515A2 (en) 2003-09-19 2004-09-17 Albumin-binding derivatives of therapeutic peptides
MXPA06002941A MXPA06002941A (en) 2003-09-19 2004-09-17 Albumin-binding derivatives of therapeutic peptides.
EP15152442.8A EP2932981B1 (en) 2003-09-19 2004-09-17 Albumin-binding derivatives of GLP-1
IL174154A IL174154A (en) 2003-09-19 2006-03-07 Glp-1 derivatives, pharmaceutical compositions comprising them and their use in manufacturing medicaments
NO20061722A NO343825B1 (en) 2003-09-19 2006-04-19 GLP-1 derivatives and pharmaceutical compositions and medical applications thereof.
US12/774,131 US20100305032A1 (en) 2003-09-19 2010-05-05 Novel GLP-1 Derivatives
AU2010203063A AU2010203063B2 (en) 2003-09-19 2010-07-19 Albumin-binding derivatives of therapeutic peptides
US13/427,791 US20130053315A1 (en) 2003-09-19 2012-03-22 Novel glp-1 derivatives
US13/427,667 US20130040884A1 (en) 2003-09-19 2012-03-22 Albumin-binding conjugates comprising fatty-acid and peg
US13/903,662 US20130244931A1 (en) 2003-09-19 2013-05-28 Novel GLP-1 Derivatives
US14/750,095 US20160108102A1 (en) 2003-09-19 2015-06-25 Novel GLP-1 Derivatives

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DKPA200301367 2003-09-19
DKPA200301367 2003-09-19
US50573903P 2003-09-25 2003-09-25
US60/505,739 2003-09-25
US52684703P 2003-12-04 2003-12-04
US60/526,847 2003-12-04
DKPA200301789 2003-12-04
DKPA200301789 2003-12-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/572,348 A-371-Of-International US20070203058A1 (en) 2003-09-19 2004-09-17 Novel Glp-1 Derivatives
US12/774,131 Continuation US20100305032A1 (en) 2003-09-19 2010-05-05 Novel GLP-1 Derivatives

Publications (2)

Publication Number Publication Date
WO2005027978A2 true WO2005027978A2 (en) 2005-03-31
WO2005027978A3 WO2005027978A3 (en) 2005-05-19

Family

ID=46045404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000624 WO2005027978A2 (en) 2003-09-19 2004-09-17 Albumin-binding derivatives of therapeutic peptides

Country Status (13)

Country Link
US (6) US20070203058A1 (en)
EP (2) EP2932981B1 (en)
JP (1) JP4949838B2 (en)
KR (1) KR101241862B1 (en)
AU (2) AU2004273573B2 (en)
BR (2) BR122019021416A2 (en)
CA (1) CA2539253A1 (en)
IL (1) IL174154A (en)
MX (1) MXPA06002941A (en)
NO (1) NO343825B1 (en)
SI (1) SI2932981T1 (en)
TW (1) TW200526254A (en)
WO (1) WO2005027978A2 (en)

Cited By (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006005667A2 (en) * 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
WO2006097537A3 (en) * 2005-03-18 2007-01-25 Novo Nordisk As Acylated glp-1 compounds
WO2007055728A1 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
WO2007068718A1 (en) 2005-12-14 2007-06-21 Novo Nordisk A/S Polypeptide protracting tags
WO2007090496A1 (en) * 2006-02-08 2007-08-16 Lonza Ag Synthesis of glucagon-like peptide
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2008023050A1 (en) * 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
WO2007104789A3 (en) * 2006-03-15 2008-03-13 Novo Nordisk As Amylin derivatives
WO2008056726A1 (en) * 2006-11-09 2008-05-15 Sanwa Kagaku Kenkyusho Co., Ltd. Glp-1 derivative and use thereof
DE102007005045A1 (en) 2007-01-26 2008-08-07 Sanofi-Aventis New phenothiazine derivative for use in preparing medicine for blood sugar lowering and for treatment of diabetes, nicotine dependence, alcohol dependence, central nervous system disorders, schizophrenia, and Alzheimer's disease
US7435720B2 (en) 2004-05-10 2008-10-14 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
JP2008539713A (en) * 2005-05-04 2008-11-20 ジーランド ファーマ アクティーゼルスカブ Glucagon-like peptide-2 (GLP-2) analog
JP2008542437A (en) * 2005-06-06 2008-11-27 カムルス エービー GLP-1 analog preparation
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2009030738A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030774A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
DE102007063671A1 (en) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh New crystalline diphenylazetidinone hydrates, medicaments containing these compounds and their use
WO2009121804A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
WO2009138511A1 (en) * 2008-05-16 2009-11-19 Novo Nordisk A/S Long-acting y2 and/or y4 receptor agonists
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010015668A1 (en) * 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010108937A2 (en) 2009-03-27 2010-09-30 Glaxo Group Limited Drug fusions and conjugates
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2010084169A3 (en) * 2009-01-23 2011-02-17 Novo Nordisk A/S Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
JP2011509077A (en) * 2007-12-28 2011-03-24 ノボ・ノルデイスク・エー／エス Semi-recombinant preparation of GLP-1 analog
WO2011033068A1 (en) * 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011039096A1 (en) 2009-09-30 2011-04-07 Glaxo Group Limited Drug fusions and conjugates with extended half life
WO2011058165A1 (en) * 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011073328A1 (en) 2009-12-16 2011-06-23 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
WO2011109787A1 (en) * 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011117416A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
WO2011136361A1 (en) 2010-04-30 2011-11-03 株式会社 三和化学研究所 Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
AU2007240313B2 (en) * 2006-04-20 2012-02-02 Amgen Inc. GLP-1 compounds
WO2011101261A3 (en) * 2010-02-16 2012-02-02 Novo Nordisk A/S Purification method
WO2012080471A1 (en) 2010-12-16 2012-06-21 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2012101124A1 (en) * 2011-01-26 2012-08-02 Novo Nordisk A/S Leptin derivatives
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
EP2565205A1 (en) * 2010-04-27 2013-03-06 Zhejiang Beta Pharma Inc. Glucagon-like peptide-1 analogue and use thereof
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013083826A2 (en) 2011-12-09 2013-06-13 Novo Nordisk A/S Glp-1 agonists
WO2013096939A1 (en) * 2011-12-23 2013-06-27 Sri International Selective binding compounds
WO2013098191A1 (en) 2011-12-29 2013-07-04 Novo Nordisk A/S Dipeptide comprising a non-proteogenic amino acid
EP2621519A2 (en) * 2010-09-28 2013-08-07 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action
US8513192B2 (en) 2009-01-22 2013-08-20 Novo Nordisk A/S Stable growth hormone compounds resistant to proteolytic degradation
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
WO2013171570A1 (en) 2012-05-16 2013-11-21 Glaxo Group Limited Polypeptide loaded poca nanoparticles for oral administration
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
WO2014005858A1 (en) 2012-07-01 2014-01-09 Novo Nordisk A/S Use of long-acting glp-1 peptides
US8642727B2 (en) 2006-11-08 2014-02-04 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
WO2014060472A1 (en) 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
US8779109B2 (en) 2010-01-22 2014-07-15 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
US20140235535A1 (en) * 2011-07-08 2014-08-21 Astrazeneca Pharmaceuticals Lp Engineered polypeptides having enhanced duration of action with reduced immunogenicity
EP2769990A2 (en) 2004-12-02 2014-08-27 Domantis Limited Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
US8895504B2 (en) 2008-10-21 2014-11-25 Novo Nordisk A/S Amylin derivatives
WO2014202727A1 (en) * 2013-06-20 2014-12-24 Novo Nordisk A/S Glp-1 derivatives and uses thereof
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
WO2014210029A1 (en) * 2013-06-24 2014-12-31 Riogin Corporation Double binding constructs
KR101496136B1 (en) 2011-03-30 2015-02-26 베타 파머수티컬 컴퍼니 리미티드 Glucagon-like peptide-1 analogue and use thereof
WO2015067791A1 (en) * 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
US9040660B2 (en) 2010-04-20 2015-05-26 Novo Nordisk A/S Long-acting gastrin derivatives
US9085637B2 (en) 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
US9266940B2 (en) 2011-04-12 2016-02-23 Novo Nordisk A/S Double-acylated GLP-1 derivatives
WO2016055550A1 (en) 2014-10-07 2016-04-14 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide or protein drugs
WO2016079302A1 (en) 2014-11-21 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Long-acting growth hormone dosage forms
CN105636979A (en) * 2013-10-07 2016-06-01 诺和诺德股份有限公司 Novel derivative of an insulin analogue
WO2016083499A1 (en) * 2014-11-27 2016-06-02 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2016097108A1 (en) * 2014-12-17 2016-06-23 Novo Nordisk A/S Glp-1 derivatives and uses thereof
US9453064B2 (en) 2012-05-03 2016-09-27 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
US9474790B2 (en) 2013-04-18 2016-10-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
WO2017060500A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2017083604A1 (en) * 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
US9655974B2 (en) 2010-07-20 2017-05-23 Novo Nordisk A/S N-terminal modified FGF21 compounds
US9708383B2 (en) 2010-11-09 2017-07-18 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US9744213B2 (en) 2014-12-23 2017-08-29 Novo Nordisk A/S FGF21 derivatives and uses thereof
WO2017148883A1 (en) 2016-03-01 2017-09-08 Ascendis Pharma Bone Diseases A/S Pth prodrugs
WO2018011266A1 (en) 2016-07-13 2018-01-18 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
US9879063B2 (en) 2011-07-08 2018-01-30 Aegerion Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
WO2018060312A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Pth compounds with low peak-to-trough ratios
WO2018060314A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release cnp agonists
WO2018060310A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
WO2018060311A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release pth compounds
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
US10005824B2 (en) 2015-06-12 2018-06-26 Novo Nordisk A/S Selective PYY compounds and uses thereof
US10016485B2 (en) 2011-05-13 2018-07-10 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
US10259856B2 (en) 2008-03-18 2019-04-16 Novo Nordisk A/S Protease stabilized acylated insulin analogues
US10265385B2 (en) 2016-12-16 2019-04-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US10266577B2 (en) 2013-08-15 2019-04-23 Novo Nordisk A/S GLP-1 derivatives, and uses thereof
US10302655B2 (en) 2008-12-05 2019-05-28 Glaxo Group Limited Methods for selecting protease resistant polypeptides
EP3488857A1 (en) 2012-03-22 2019-05-29 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
EP3542790A1 (en) 2012-03-22 2019-09-25 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
WO2019185706A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
WO2019185705A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Il-2 conjugates
WO2019193204A1 (en) 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
WO2019193576A1 (en) 2018-04-05 2019-10-10 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
WO2019215063A1 (en) 2018-05-07 2019-11-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2019219896A1 (en) 2018-05-18 2019-11-21 Ascendis Pharma Bone Diseases A/S Starting dose of pth conjugates
WO2019228510A1 (en) * 2018-05-31 2019-12-05 The Hong Kong Polytechnic University Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
WO2020165087A1 (en) 2019-02-11 2020-08-20 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
WO2020178273A1 (en) 2019-03-04 2020-09-10 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
US10905745B2 (en) 2016-12-09 2021-02-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
US11033499B2 (en) 2012-06-20 2021-06-15 Novo Nordisk A/S Tablet formulation comprising a GLP-1 peptide and a delivery agent
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
WO2021144249A1 (en) 2020-01-13 2021-07-22 Ascendis Pharma Bone Diseases A/S Hypoparathyroidism treatment
US11116816B2 (en) 2014-10-22 2021-09-14 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US11123296B2 (en) 2012-03-22 2021-09-21 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
WO2021219710A1 (en) 2020-04-29 2021-11-04 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
WO2021245130A1 (en) 2020-06-03 2021-12-09 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
EP3765061A4 (en) * 2018-03-16 2022-01-26 The General Hospital Corporation Parathyroid hormone polypeptide conjugates and methods of their use
WO2022043493A1 (en) 2020-08-28 2022-03-03 Ascendis Pharma Oncology Division A/S Glycosylated il-2 proteins and uses thereof
WO2022049310A1 (en) 2020-09-07 2022-03-10 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
WO2022064035A1 (en) 2020-09-28 2022-03-31 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
US11318191B2 (en) 2020-02-18 2022-05-03 Novo Nordisk A/S GLP-1 compositions and uses thereof
WO2022207798A1 (en) 2021-04-01 2022-10-06 Ascendis Pharma A/S Use of long-acting growth hormone for treating inflammation-induced diseases
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2023046732A1 (en) 2021-09-22 2023-03-30 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
US11752198B2 (en) 2017-08-24 2023-09-12 Novo Nordisk A/S GLP-1 compositions and uses thereof
WO2024094673A1 (en) 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
US12029779B2 (en) 2017-10-12 2024-07-09 Novo Nordisk A/S Semaglutide in medical therapy
US12054528B2 (en) 2020-12-18 2024-08-06 Novo Nordisk A/S Co-agonists of the GLP-1 and amylin receptors
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
RU2826185C2 (en) * 2018-05-31 2024-09-05 Дзе Хонг Конг Политекник Юниверсити Composition and use of arginine-depleting agents in cancer, obesity, metabolic disorders and related complications and comorbidities

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007537981A (en) * 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ Novel plasma protein affinity tag
ATE433746T1 (en) * 2004-03-12 2009-07-15 Biodel Inc INSULIN COMPOSITIONS WITH IMPROVED ACTIVE ABSORPTION
CN100429227C (en) * 2005-06-29 2008-10-29 常州制药厂有限公司 Exendin 4 polypeptide segment
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
RU2477286C2 (en) * 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн GLUCAGON ANALOGUES, HAVING HIGH SOLUBILITY IN PHYSIOLOGICAL pH BUFFERS
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
US20100268055A1 (en) * 2007-07-19 2010-10-21 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University Self-Anchoring MEMS Intrafascicular Neural Electrode
JP2010536341A (en) * 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド Compositions and methods for altering properties of biologically active polypeptides
EP2214691B1 (en) * 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
WO2009058662A2 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
KR101616995B1 (en) * 2007-12-03 2016-06-07 (주)아모레퍼시픽 Composition for slimming
CN101951957A (en) * 2008-01-04 2011-01-19 百达尔公司 Insulin discharges the insulin preparation as the function of the glucose level of tissue
WO2009099763A1 (en) * 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
MX2010010016A (en) * 2008-03-20 2010-09-30 Organon Nv Preparation of a pharmaceutical composition for increasing bone mineral density.
CL2009001424A1 (en) 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Glucagon-like peptide; dimer comprising two of said peptides; pharmaceutical composition comprising it; and its use to treat diabetes or induce weight loss.
EP2300035B1 (en) * 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
JP5753779B2 (en) * 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon analogs with improved solubility and stability in buffers at physiological pH
US8697632B2 (en) 2008-12-19 2014-04-15 Indiana University Research And Technology Corporation Amide based insulin prodrugs
WO2010071807A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
CA2747195A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
LT2393828T (en) 2009-02-03 2017-01-25 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
AU2010258898B8 (en) * 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
SG176858A1 (en) 2009-06-16 2012-02-28 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds
EP2470559B1 (en) * 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2011051312A1 (en) 2009-10-30 2011-05-05 Novo Nordisk A/S Derivatives of cgrp
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
JP6050746B2 (en) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Glucagon superfamily of peptides exhibiting G protein-coupled receptor activity
CA2802485C (en) 2010-06-16 2019-09-17 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US8946147B2 (en) 2010-06-24 2015-02-03 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
KR20130102470A (en) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Amide based glucagon superfamily peptide prodrugs
CN103458920B (en) 2010-12-22 2016-07-06 印第安那大学科技研究公司 Show the glucagon analogs of GIP receptor active
WO2012140647A2 (en) 2011-04-11 2012-10-18 Yeda Research And Development Co. Ltd Albumin binding probes and drug conjugates thereof
WO2012177443A2 (en) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
RU2014101697A (en) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon receptor coagonists / GLP-1
MX2014003579A (en) 2011-11-17 2015-04-10 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting glucocorticoid receptor activity.
BR112014015156A2 (en) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation ctp-based insulin analogues, their methods of production and use in the treatment of hyperglycemia, as well as nucleic acid and host cell sequences
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
RS63870B1 (en) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Factor viii compositions and methods of making and using same
CA2865578C (en) 2012-02-27 2023-01-17 Amunix Operating Inc. Xten conjugate compositions and methods of making same
CN104519902B (en) 2012-05-08 2017-10-27 诺和诺德股份有限公司 Double derivatives of acylated GLP 1
CN104411322B (en) * 2012-05-08 2017-05-24 诺和诺德股份有限公司 double-acylated GLP-1 derivatives
RU2015101697A (en) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн GLUCAGON ANALOGUES WITH GIP RECEPTOR ACTIVITY
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
KR20150131213A (en) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Insulin-incretin conjugates
CN103217522A (en) * 2013-03-18 2013-07-24 中国人民解放军第四军医大学 Method for digesting and extracting apoptosis rate in flow cytometry tissue by using digestion method
TWI667255B (en) 2013-08-14 2019-08-01 美商生物化學醫療公司 Factor viii-xten fusions and uses thereof
US10286078B2 (en) 2013-09-13 2019-05-14 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
JP6572497B2 (en) 2013-12-18 2019-09-11 ザ・スクリップス・リサーチ・インスティテュート Modified therapeutic agents, stapled peptide lipid complexes, and compositions thereof
CN103985909B (en) * 2014-05-14 2016-08-24 山东爱通工业机器人科技有限公司 A kind of lithium battery sheet group left and right sides tape sticking device
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3206710B1 (en) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Incretin-insulin conjugates
JP6701208B2 (en) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Lipidated amide insulin prodrug
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
UA126016C2 (en) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Factor ix fusion proteins and methods of making and using same
TWI744247B (en) 2015-08-28 2021-11-01 美商亞穆尼克斯製藥公司 Chimeric polypeptide assembly and methods of making and using the same
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
MX2018002514A (en) 2015-09-22 2018-08-15 Univ California Modified cytotoxins and their therapeutic use.
EP3393494A1 (en) 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10913952B2 (en) * 2016-10-26 2021-02-09 Salk Institute For Biological Studies Environmental stress response transcriptional regulatory network
KR20210008834A (en) 2018-03-23 2021-01-25 카모트 테라퓨틱스, 인크. Modulators of G-protein coupled receptors
TW202015723A (en) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 Methods of treating hemophilia a
US11492409B2 (en) 2018-06-01 2022-11-08 Novartis Ag Binding molecules against BCMA and uses thereof
JP2022513626A (en) 2018-11-26 2022-02-09 ノバルティス アーゲー LPL-GPIHBP1 fusion polypeptide
US20220098252A1 (en) 2019-01-25 2022-03-31 Ospedale San Raffaele S.R.L. Inhibitor of dux4 and uses thereof
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
CN112898406B (en) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 GLP-1 analogue peptide modified dimer with different configurations and application of preparation method thereof in treatment of type II diabetes
CN115260313B (en) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Fusion proteins of GLP-1 and GDF15 and conjugates thereof
CA3193453A1 (en) * 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
MX2023008330A (en) 2021-01-20 2024-01-18 Viking Therapeutics Inc Compositions and methods for the treatment of metabolic and liver disorders.
WO2022268213A1 (en) * 2021-06-25 2022-12-29 甘李药业股份有限公司 Pharmaceutical composition containing glp-1 compound
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008872A1 (en) * 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-2 derivatives
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043341A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999043361A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO2001004156A1 (en) * 1999-07-12 2001-01-18 Zealand Pharmaceuticals A/S Peptides that lower blood glucose levels
WO2001051071A2 (en) * 2000-01-11 2001-07-19 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
WO2002058725A2 (en) * 2001-01-23 2002-08-01 Pierre Fabre Medicament Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2003087139A2 (en) * 2002-04-10 2003-10-23 Eli Lilly And Company Treatment of gastroparesis
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP1498425A1 (en) 1986-05-05 2005-01-19 The General Hospital Corporation Use of glucagone-like-peptide 1 (GLP-1) derivatives for the preparation of pharmaceutical compositions
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
DE68929217T2 (en) 1989-03-20 2000-11-30 The General Hospital Corp., Boston INSULINOTROPES HORMON
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ES2113879T3 (en) 1990-01-24 1998-05-16 Douglas I Buckley GLP-1 ANALOGS USEFUL FOR THE TREATMENT OF DIABETES.
DK36492D0 (en) 1992-03-19 1992-03-19 Novo Nordisk As PREPARATION
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
KR20080085082A (en) * 2000-12-07 2008-09-22 일라이 릴리 앤드 캄파니 Glp-1 fusion proteins
EP1423136A4 (en) * 2001-08-10 2007-07-25 Epix Pharm Inc Polypeptide conjugates with extended circulating half-lives
JP2007537981A (en) * 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ Novel plasma protein affinity tag
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US8501693B2 (en) * 2006-08-04 2013-08-06 Amylin Pharmaceuticals, Llc Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
JP5591243B2 (en) * 2008-09-12 2014-09-17 ノボ・ノルデイスク・エー／エス Method for acylating peptides or proteins

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008872A1 (en) * 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-2 derivatives
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043341A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999043361A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO2001004156A1 (en) * 1999-07-12 2001-01-18 Zealand Pharmaceuticals A/S Peptides that lower blood glucose levels
WO2001051071A2 (en) * 2000-01-11 2001-07-19 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
WO2002058725A2 (en) * 2001-01-23 2002-08-01 Pierre Fabre Medicament Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2003087139A2 (en) * 2002-04-10 2003-10-23 Eli Lilly And Company Treatment of gastroparesis
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DEACON C F ET AL: "DIPEPTIDYL PEPTIDASE IV RESISTANT ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 WHICH HAVE EXTENDED METABOLIC STABILITY AND IMPROVED BIOLOGICAL ACTIVITY" DIABETOLOGIA, BERLIN, DE, vol. 41, 1998, pages 271-278, XP000917648 ISSN: 0012-186X *
HOLZ G G ET AL: "GLUCAGON-LIKE PEPTIDE-1 SYNTHETIC ANALOGS: NEW THERAPEUTIC AGENTS FOR USE IN THE TREATMENT OF DIABETES MELLITUS" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 10, no. 22, November 2003 (2003-11), pages 2471-2483, XP009035149 ISSN: 0929-8673 *
KNUDSEN LOTTE B ET AL: "Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 9, 4 May 2000 (2000-05-04), pages 1664-1669, XP002201014 ISSN: 0022-2623 *
KURTZHALS P ET AL: "ALBUMIN BINDING OF INSULINS ACYLATED WITH FATTY ACIDS: CHARACTERIZATION OF THE LIGAND-PROTEIN INTERACTION AND CORRELATION BETWEEN BINDING AFFINITY AND TIMING OF THE INSULIN EFFECT IN VIVO" BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 312, no. 3, 1995, pages 725-731, XP008005781 ISSN: 0264-6021 *
OSTROVSKII YU M: "COMPARATIVE CHARACTERISTICS OF THE HYDROPHOBIC NATURE OF CERTAIN PROTEINS BY THEIR INTERACTION WITH 2-P TOLUIDINO NAPHTHALENE-6-SULFONATE" UKRAYINS'KYI BIOKHIMICHNYI ZHURNAL, vol. 47, no. 6, 1975, pages 701-707, XP008039733 *
PICO G: "USE OF 1 ANILINO-8-NAPHTHALENESULFONATE AS A REPORTER MOLECULE TO STUDY THE BILE SALTS BOVINE SERUM ALBUMIN BINDING" STUDIA BIOPHYSICA, vol. 136, no. 1, 1990, pages 21-26, XP8039734 ISSN: 0081-6337 *
SHEFFIELD W P: "Modification of clearance of therapeutic and potentially therapeutic proteins" CURRENT DRUG TARGETS - CARDIOVASCULAR AND HAEMATOLOGICAL DISORDERS, vol. 1, no. 1, June 2001 (2001-06), pages 1-22, XP002310970 ISSN: 1568-0061 *

Cited By (282)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8602998B2 (en) 2004-03-18 2013-12-10 University of Pittsburgh—of the Commonwealth System of Higher Education Use of relaxin to increase arterial compliance
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US7435720B2 (en) 2004-05-10 2008-10-14 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
WO2006005667A3 (en) * 2004-07-08 2006-10-12 Novo Nordisk As Polypeptide protracting tags comprising a tetrazole moiety
US9061067B2 (en) 2004-07-08 2015-06-23 Novo Nordisk A/S Polypeptide protracting tags
WO2006005667A2 (en) * 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
US8772232B2 (en) 2004-10-07 2014-07-08 Novo Nordisk A/S Protracted exendin-4 compounds
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2769990A2 (en) 2004-12-02 2014-08-27 Domantis Limited Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
US8603972B2 (en) 2005-03-18 2013-12-10 Novo Nordisk A/S Extended GLP-1 compounds
US8129343B2 (en) 2005-03-18 2012-03-06 Novo Nordisk A/S Acylated GLP-1 compounds
WO2006097537A3 (en) * 2005-03-18 2007-01-25 Novo Nordisk As Acylated glp-1 compounds
EP2322546A1 (en) * 2005-03-18 2011-05-18 Novo Nordisk A/S Acylated GLP-1 compounds
US8536122B2 (en) 2005-03-18 2013-09-17 Novo Nordisk A/S Acylated GLP-1 compounds
US9580487B2 (en) 2005-05-04 2017-02-28 Zealand Pharma A/S Method of treating stomach or bowel-related disorders by administering glucagon-like-peptide-2 (GLP-2) analogues
US8163696B2 (en) 2005-05-04 2012-04-24 Zealand Pharma A/S Treatment of inflammatory bowel disease using glucagon-like-peptide-2 (GLP-2) analogues
JP2008539713A (en) * 2005-05-04 2008-11-20 ジーランド ファーマ アクティーゼルスカブ Glucagon-like peptide-2 (GLP-2) analog
US8263552B2 (en) 2005-05-04 2012-09-11 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
US9125882B2 (en) 2005-05-04 2015-09-08 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
JP2008542437A (en) * 2005-06-06 2008-11-27 カムルス エービー GLP-1 analog preparation
WO2007055728A1 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
WO2007068718A1 (en) 2005-12-14 2007-06-21 Novo Nordisk A/S Polypeptide protracting tags
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
US8580919B2 (en) 2005-12-16 2013-11-12 Nektar Therapeutics Polymer conjugates of GLP-1
WO2007090496A1 (en) * 2006-02-08 2007-08-16 Lonza Ag Synthesis of glucagon-like peptide
US8445433B2 (en) 2006-02-08 2013-05-21 Lonza Ag Synthesis of glucagon-like peptide
US8486890B2 (en) 2006-03-15 2013-07-16 Novo Nordisk A/S Amylin derivatives
JP2009530250A (en) * 2006-03-15 2009-08-27 ノボ・ノルデイスク・エー／エス Amylin derivatives
WO2007104789A3 (en) * 2006-03-15 2008-03-13 Novo Nordisk As Amylin derivatives
US8288339B2 (en) * 2006-04-20 2012-10-16 Amgen Inc. GLP-1 compounds
AU2007240313B2 (en) * 2006-04-20 2012-02-02 Amgen Inc. GLP-1 compounds
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2008023050A1 (en) * 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
US9012398B2 (en) 2006-08-25 2015-04-21 Novo Nordisk A/S Acylated exendin-4 compounds
US20090318353A1 (en) * 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
US10092648B2 (en) 2006-11-08 2018-10-09 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
US8642727B2 (en) 2006-11-08 2014-02-04 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
WO2008056726A1 (en) * 2006-11-09 2008-05-15 Sanwa Kagaku Kenkyusho Co., Ltd. Glp-1 derivative and use thereof
DE102007005045A1 (en) 2007-01-26 2008-08-07 Sanofi-Aventis New phenothiazine derivative for use in preparing medicine for blood sugar lowering and for treatment of diabetes, nicotine dependence, alcohol dependence, central nervous system disorders, schizophrenia, and Alzheimer's disease
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2009030738A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
JP2010538049A (en) * 2007-09-05 2010-12-09 ノボ・ノルデイスク・エー／エス Cleaved GLP-1 derivatives and therapeutic uses thereof
US8895694B2 (en) 2007-09-05 2014-11-25 Novo Nordisk A/S Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
WO2009030774A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
JP2010538048A (en) * 2007-09-05 2010-12-09 ノボ・ノルデイスク・エー／エス Peptides derivatized with ABCD and therapeutic uses thereof
US9657079B2 (en) 2007-09-05 2017-05-23 Novo Nordisk A/S Truncated GLP-1 derivatives and their therapeutical use
CN101868476A (en) * 2007-09-05 2010-10-20 诺沃-诺迪斯克有限公司 Glucagon-like peptide-1 derivatives and their pharmaceutical use
JP2010538042A (en) * 2007-09-05 2010-12-09 ノボ・ノルデイスク・エー／エス Glucagon-like peptide-1 derivatives and their pharmaceutical use
US9409966B2 (en) 2007-09-05 2016-08-09 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
EP2679597A1 (en) 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009034119A1 (en) * 2007-09-11 2009-03-19 Novo Nordisk A/S Improved derivatives of amylin
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
DE102007063671A1 (en) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh New crystalline diphenylazetidinone hydrates, medicaments containing these compounds and their use
JP2011509077A (en) * 2007-12-28 2011-03-24 ノボ・ノルデイスク・エー／エス Semi-recombinant preparation of GLP-1 analog
US9732137B2 (en) 2007-12-28 2017-08-15 Novo Nordisk A/S Semi-recombinant preparation of GLP-1 analogues
US10259856B2 (en) 2008-03-18 2019-04-16 Novo Nordisk A/S Protease stabilized acylated insulin analogues
WO2009121804A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
CN102027007A (en) * 2008-05-16 2011-04-20 诺沃-诺迪斯克有限公司 Long-acting Y2 and/or Y4 receptor agonists
US20110275559A1 (en) * 2008-05-16 2011-11-10 Novo Nordisk A/S Long-Acting Y2 and/or Y4 Receptor Agonists
WO2009138511A1 (en) * 2008-05-16 2009-11-19 Novo Nordisk A/S Long-acting y2 and/or y4 receptor agonists
AU2009248041B2 (en) * 2008-05-16 2013-10-03 Novo Nordisk A/S Long-acting Y2 and/or Y4 receptor agonists
RU2504550C2 (en) * 2008-05-16 2014-01-20 Ново Нордиск А/С Long-acting agonists of receptors y2 and(or) y4
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8865868B2 (en) 2008-08-06 2014-10-21 Novo Nordisk Healthcare Ag Conjugated proteins with prolonged in vivo efficacy
RU2526804C2 (en) * 2008-08-06 2014-08-27 Ново Нордиск Хелс Кеа Аг Conjugated proteins with prolonged action in vivo
WO2010015668A1 (en) * 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
US8895504B2 (en) 2008-10-21 2014-11-25 Novo Nordisk A/S Amylin derivatives
US10466252B2 (en) 2008-12-05 2019-11-05 Glaxo Group Limited Methods for selecting protease resistant polypeptides
US10302655B2 (en) 2008-12-05 2019-05-28 Glaxo Group Limited Methods for selecting protease resistant polypeptides
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8513192B2 (en) 2009-01-22 2013-08-20 Novo Nordisk A/S Stable growth hormone compounds resistant to proteolytic degradation
TWI494127B (en) * 2009-01-23 2015-08-01 Novo Nordisk As Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
US9480753B2 (en) 2009-01-23 2016-11-01 Novo Nordisk A/S FGF21 derivatives with albumin binder A-B-C-D-E- and their use
WO2010084169A3 (en) * 2009-01-23 2011-02-17 Novo Nordisk A/S Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
WO2010108937A2 (en) 2009-03-27 2010-09-30 Glaxo Group Limited Drug fusions and conjugates
US8779103B2 (en) 2009-03-27 2014-07-15 Glaxo Group Limited Drug fusions and conjugates
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US20130040877A1 (en) * 2009-09-18 2013-02-14 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011033068A1 (en) * 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011039096A1 (en) 2009-09-30 2011-04-07 Glaxo Group Limited Drug fusions and conjugates with extended half life
WO2011058165A1 (en) * 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
US20130096055A1 (en) * 2009-11-13 2013-04-18 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011073328A1 (en) 2009-12-16 2011-06-23 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
US8815802B2 (en) 2009-12-16 2014-08-26 Novo Nordisk A/S GLP-1 analogues and derivatives
WO2011080103A1 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2011080102A2 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Glp-1 analogues and derivatives
US8648041B2 (en) 2009-12-16 2014-02-11 Novo Nordisk A/S Double-acylated GLP-1 derivatives
EP3000482A1 (en) 2009-12-16 2016-03-30 Novo Nordisk A/S Double-acylated glp-1 derivatives
US9556250B2 (en) 2009-12-16 2017-01-31 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
US9695226B2 (en) 2010-01-22 2017-07-04 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy
US8779109B2 (en) 2010-01-22 2014-07-15 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011101261A3 (en) * 2010-02-16 2012-02-02 Novo Nordisk A/S Purification method
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011109787A1 (en) * 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
CN102918055B (en) * 2010-03-26 2017-03-29 诺沃—诺迪斯克有限公司 New glucagon analogs
CN102918055A (en) * 2010-03-26 2013-02-06 诺沃—诺迪斯克有限公司 Novel glucagon analogues
WO2011117415A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
WO2011117416A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
RU2559320C2 (en) * 2010-03-26 2015-08-10 Ново Нордиск А/С Novel glucagon analogues
AU2011231503B2 (en) * 2010-03-26 2014-11-06 Novo Nordisk A/S Novel glucagon analogues
AU2011231503C1 (en) * 2010-03-26 2016-03-03 Novo Nordisk A/S Novel glucagon analogues
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
US9040660B2 (en) 2010-04-20 2015-05-26 Novo Nordisk A/S Long-acting gastrin derivatives
EP2565205A1 (en) * 2010-04-27 2013-03-06 Zhejiang Beta Pharma Inc. Glucagon-like peptide-1 analogue and use thereof
EP2565205A4 (en) * 2010-04-27 2013-09-11 Zhejiang Beta Pharma Inc Glucagon-like peptide-1 analogue and use thereof
WO2011136361A1 (en) 2010-04-30 2011-11-03 株式会社 三和化学研究所 Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
US9655974B2 (en) 2010-07-20 2017-05-23 Novo Nordisk A/S N-terminal modified FGF21 compounds
EP3305315A1 (en) * 2010-09-28 2018-04-11 Aegerion Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
EP2621519A2 (en) * 2010-09-28 2013-08-07 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action
US10087228B2 (en) 2010-09-28 2018-10-02 Aegerion Pharmaceuticals, Inc. Chimeric leptin polypeptide and method of using the same
US11535659B2 (en) 2010-09-28 2022-12-27 Amryt Pharmaceuticals Inc. Engineered polypeptides having enhanced duration of action
EP2621519A4 (en) * 2010-09-28 2014-07-09 Amylin Pharmaceuticals Llc Engineered polypeptides having enhanced duration of action
US9708383B2 (en) 2010-11-09 2017-07-18 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US11382957B2 (en) 2010-12-16 2022-07-12 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
US10960052B2 (en) 2010-12-16 2021-03-30 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid
EP3326620A1 (en) 2010-12-16 2018-05-30 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
WO2012080471A1 (en) 2010-12-16 2012-06-21 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
EP3730127A1 (en) 2010-12-16 2020-10-28 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2012101124A1 (en) * 2011-01-26 2012-08-02 Novo Nordisk A/S Leptin derivatives
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
KR101496136B1 (en) 2011-03-30 2015-02-26 베타 파머수티컬 컴퍼니 리미티드 Glucagon-like peptide-1 analogue and use thereof
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
US11117947B2 (en) 2011-04-12 2021-09-14 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US11034746B2 (en) 2011-04-12 2021-06-15 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US9266940B2 (en) 2011-04-12 2016-02-23 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US10005827B2 (en) 2011-04-12 2018-06-26 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US9527900B2 (en) 2011-04-12 2016-12-27 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US10653752B2 (en) 2011-05-13 2020-05-19 Bolder Bio Technology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
US10016485B2 (en) 2011-05-13 2018-07-10 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
US9382304B2 (en) * 2011-07-08 2016-07-05 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action with reduced immunogenicity
US9879063B2 (en) 2011-07-08 2018-01-30 Aegerion Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
US20140235535A1 (en) * 2011-07-08 2014-08-21 Astrazeneca Pharmaceuticals Lp Engineered polypeptides having enhanced duration of action with reduced immunogenicity
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9486505B2 (en) 2011-09-23 2016-11-08 Novo Nordisk A/S Glucagon analogues
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013083826A2 (en) 2011-12-09 2013-06-13 Novo Nordisk A/S Glp-1 agonists
US9273092B2 (en) 2011-12-23 2016-03-01 RioGin LLC Selective binding compounds
WO2013096939A1 (en) * 2011-12-23 2013-06-27 Sri International Selective binding compounds
WO2013098191A1 (en) 2011-12-29 2013-07-04 Novo Nordisk A/S Dipeptide comprising a non-proteogenic amino acid
US10954267B2 (en) 2011-12-29 2021-03-23 Novo Nordisk A/S Dipeptide comprising a non-proteogenic amino acid
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
EP4331667A2 (en) 2012-03-22 2024-03-06 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
EP3542790A1 (en) 2012-03-22 2019-09-25 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
EP3488857A1 (en) 2012-03-22 2019-05-29 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
US11759503B2 (en) 2012-03-22 2023-09-19 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
US11123296B2 (en) 2012-03-22 2021-09-21 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
US11759501B2 (en) 2012-03-22 2023-09-19 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
US11759502B2 (en) 2012-03-22 2023-09-19 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
US10253080B2 (en) 2012-05-03 2019-04-09 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
US9969787B2 (en) 2012-05-03 2018-05-15 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
US9453064B2 (en) 2012-05-03 2016-09-27 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
WO2013171570A1 (en) 2012-05-16 2013-11-21 Glaxo Group Limited Polypeptide loaded poca nanoparticles for oral administration
US11033499B2 (en) 2012-06-20 2021-06-15 Novo Nordisk A/S Tablet formulation comprising a GLP-1 peptide and a delivery agent
EP3689365A1 (en) 2012-07-01 2020-08-05 Novo Nordisk A/S Use of long-acting glp-1 peptides
EP4406593A2 (en) 2012-07-01 2024-07-31 Novo Nordisk A/S Use of long-acting glp-1 peptides
WO2014005858A1 (en) 2012-07-01 2014-01-09 Novo Nordisk A/S Use of long-acting glp-1 peptides
WO2014060472A1 (en) 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
US9474790B2 (en) 2013-04-18 2016-10-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US9751927B2 (en) 2013-04-18 2017-09-05 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US10195255B2 (en) 2013-06-20 2019-02-05 Novo Nordisk A/S GLP-1 derivatives and uses thereof
WO2014202727A1 (en) * 2013-06-20 2014-12-24 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2014210029A1 (en) * 2013-06-24 2014-12-31 Riogin Corporation Double binding constructs
US10266577B2 (en) 2013-08-15 2019-04-23 Novo Nordisk A/S GLP-1 derivatives, and uses thereof
CN105636979A (en) * 2013-10-07 2016-06-01 诺和诺德股份有限公司 Novel derivative of an insulin analogue
CN105636979B (en) * 2013-10-07 2020-01-10 诺和诺德股份有限公司 Novel derivatives of insulin analogues
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
WO2015067791A1 (en) * 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
US9085637B2 (en) 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
US10246497B2 (en) 2013-11-15 2019-04-02 Novo Nordisk A/S Selective PYY compounds and uses thereof
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
WO2016055550A1 (en) 2014-10-07 2016-04-14 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide or protein drugs
US11116816B2 (en) 2014-10-22 2021-09-14 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US12076366B2 (en) 2014-10-22 2024-09-03 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016079302A1 (en) 2014-11-21 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Long-acting growth hormone dosage forms
US12016903B2 (en) 2014-11-21 2024-06-25 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone treatment
US11572398B2 (en) 2014-11-27 2023-02-07 Novo Nordisk A/S GLP-1 derivatives and uses thereof
US20170320927A1 (en) * 2014-11-27 2017-11-09 Novo Nordisk A/S GLP-1 Derivatives and Uses Thereof
WO2016083499A1 (en) * 2014-11-27 2016-06-02 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2016097108A1 (en) * 2014-12-17 2016-06-23 Novo Nordisk A/S Glp-1 derivatives and uses thereof
US10392428B2 (en) 2014-12-17 2019-08-27 Novo Nordisk A/S GLP-1 derivatives and uses thereof
US9895417B2 (en) 2014-12-23 2018-02-20 Novo Nordisk A/S FGF21 derivatives and uses thereof
US10124039B2 (en) 2014-12-23 2018-11-13 Novo Nordisk A/S FGF21 derivatives and uses thereof
US9744213B2 (en) 2014-12-23 2017-08-29 Novo Nordisk A/S FGF21 derivatives and uses thereof
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
US10005824B2 (en) 2015-06-12 2018-06-26 Novo Nordisk A/S Selective PYY compounds and uses thereof
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
WO2017060500A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2017083604A1 (en) * 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
US11793861B2 (en) 2016-03-01 2023-10-24 Ascendis Pharma Bone Diseases A/S PTH prodrugs
AU2022256158B2 (en) * 2016-03-01 2023-09-28 Ascendis Pharma Bone Diseases A/S PTH prodrugs
CN109069659A (en) * 2016-03-01 2018-12-21 阿森迪斯药物骨疾病股份有限公司 PTH prodrug
RU2747316C2 (en) * 2016-03-01 2021-05-04 Асцендис Фарма Боун Дизизис А/С Rtn prodrugs
AU2017227962C1 (en) * 2016-03-01 2021-05-13 Ascendis Pharma Bone Diseases A/S PTH prodrugs
IL260756B1 (en) * 2016-03-01 2023-05-01 Ascendis Pharma Bone Diseases As Pth prodrugs
AU2022256158A9 (en) * 2016-03-01 2023-09-28 Ascendis Pharma Bone Diseases A/S PTH prodrugs
AU2017227962B2 (en) * 2016-03-01 2020-11-12 Ascendis Pharma Bone Diseases A/S PTH prodrugs
IL260756B2 (en) * 2016-03-01 2023-09-01 Ascendis Pharma Bone Diseases As Pth prodrugs
WO2017148883A1 (en) 2016-03-01 2017-09-08 Ascendis Pharma Bone Diseases A/S Pth prodrugs
US11896671B2 (en) 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
WO2018011266A1 (en) 2016-07-13 2018-01-18 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
US11890326B2 (en) 2016-09-29 2024-02-06 Ascendis Pharma Bone Diseases A/S Controlled-release PTH compound
US11564974B2 (en) 2016-09-29 2023-01-31 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release CNP agonists
EP4275677A2 (en) 2016-09-29 2023-11-15 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
WO2018060311A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release pth compounds
WO2018060310A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
WO2018060314A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release cnp agonists
WO2018060312A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Pth compounds with low peak-to-trough ratios
US11918628B2 (en) 2016-09-29 2024-03-05 Ascendis Pharma Bone Diseases A/S Controlled-release PTH compound
US11759504B2 (en) 2016-09-29 2023-09-19 Ascendis Pharma Bone Diseases A/S PTH compounds with low peak-to-trough ratios
US11590207B2 (en) 2016-09-29 2023-02-28 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release PTH compound
US11857603B2 (en) 2016-09-29 2024-01-02 Ascendis Pharma Bone Diseases A/S PTH compounds with low peak-to-trough ratios
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
US10905745B2 (en) 2016-12-09 2021-02-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
US11395847B2 (en) 2016-12-09 2022-07-26 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
US10265385B2 (en) 2016-12-16 2019-04-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US10596231B2 (en) 2016-12-16 2020-03-24 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US11752198B2 (en) 2017-08-24 2023-09-12 Novo Nordisk A/S GLP-1 compositions and uses thereof
US12029779B2 (en) 2017-10-12 2024-07-09 Novo Nordisk A/S Semaglutide in medical therapy
US11833248B2 (en) 2018-02-02 2023-12-05 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
EP4299118A2 (en) 2018-02-02 2024-01-03 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
US11975050B2 (en) 2018-03-16 2024-05-07 The General Hospital Corporation Parathyroid hormone polypeptide conjugates and methods of their use
EP3765061A4 (en) * 2018-03-16 2022-01-26 The General Hospital Corporation Parathyroid hormone polypeptide conjugates and methods of their use
WO2019185705A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Il-2 conjugates
WO2019185706A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
EP4364751A2 (en) 2018-04-05 2024-05-08 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
US11866477B2 (en) 2018-04-05 2024-01-09 Sun Pharmaceutical Industries Limited GLP-1 analogues
US11242373B2 (en) 2018-04-05 2022-02-08 Sun Pharmaceutical Industries Limited GLP-1 analogues
EP4122954A1 (en) 2018-04-05 2023-01-25 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
WO2019193576A1 (en) 2018-04-05 2019-10-10 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
US11873328B2 (en) 2018-04-05 2024-01-16 Sun Pharmaceutical Industries Limited GLP-1 analogues
US11447535B2 (en) 2018-04-05 2022-09-20 Sun Pharmaceutical Industries Limited GLP-1 analogues
WO2019193204A1 (en) 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
WO2019215063A1 (en) 2018-05-07 2019-11-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2019219896A1 (en) 2018-05-18 2019-11-21 Ascendis Pharma Bone Diseases A/S Starting dose of pth conjugates
CN112513099A (en) * 2018-05-31 2021-03-16 香港理工大学 Compositions and uses of arginine depleting agents for cancer, obesity, metabolic disorders and related complications and complications
RU2826185C2 (en) * 2018-05-31 2024-09-05 Дзе Хонг Конг Политекник Юниверсити Composition and use of arginine-depleting agents in cancer, obesity, metabolic disorders and related complications and comorbidities
WO2019228510A1 (en) * 2018-05-31 2019-12-05 The Hong Kong Polytechnic University Composition and application of arginine-depleting agents for cancer, obesity, metabolic disorders, and related complications and comorbidities
WO2020165087A1 (en) 2019-02-11 2020-08-20 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
WO2020178273A1 (en) 2019-03-04 2020-09-10 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
WO2021144249A1 (en) 2020-01-13 2021-07-22 Ascendis Pharma Bone Diseases A/S Hypoparathyroidism treatment
US11318191B2 (en) 2020-02-18 2022-05-03 Novo Nordisk A/S GLP-1 compositions and uses thereof
WO2021219710A1 (en) 2020-04-29 2021-11-04 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
US11879001B2 (en) 2020-06-03 2024-01-23 Ascendis Pharma Oncology Division A/S Conjugate comprising an IL-2 moiety
WO2021245130A1 (en) 2020-06-03 2021-12-09 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
WO2022043493A1 (en) 2020-08-28 2022-03-03 Ascendis Pharma Oncology Division A/S Glycosylated il-2 proteins and uses thereof
WO2022049310A1 (en) 2020-09-07 2022-03-10 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
WO2022064035A1 (en) 2020-09-28 2022-03-31 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
US12054528B2 (en) 2020-12-18 2024-08-06 Novo Nordisk A/S Co-agonists of the GLP-1 and amylin receptors
WO2022207798A1 (en) 2021-04-01 2022-10-06 Ascendis Pharma A/S Use of long-acting growth hormone for treating inflammation-induced diseases
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2023046732A1 (en) 2021-09-22 2023-03-30 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
WO2024094673A1 (en) 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function

Also Published As

Publication number Publication date
MXPA06002941A (en) 2006-05-31
AU2010203063A1 (en) 2010-08-12
NO343825B1 (en) 2019-06-17
US20130053315A1 (en) 2013-02-28
EP2932981B1 (en) 2021-06-16
EP2932981A3 (en) 2016-02-24
US20130040884A1 (en) 2013-02-14
US20100305032A1 (en) 2010-12-02
KR101241862B1 (en) 2013-03-13
NO20061722L (en) 2006-06-12
US20070203058A1 (en) 2007-08-30
US20160108102A1 (en) 2016-04-21
BRPI0414539A (en) 2006-11-07
WO2005027978A3 (en) 2005-05-19
KR101241862B9 (en) 2022-12-09
AU2004273573B2 (en) 2010-04-22
JP4949838B2 (en) 2012-06-13
EP1670515A2 (en) 2006-06-21
KR20060096997A (en) 2006-09-13
SI2932981T1 (en) 2021-11-30
BR122019021416A2 (en) 2019-12-21
BRPI0414539B8 (en) 2021-05-25
JP2007505840A (en) 2007-03-15
TW200526254A (en) 2005-08-16
US20130244931A1 (en) 2013-09-19
IL174154A0 (en) 2006-08-01
EP2932981A2 (en) 2015-10-21
CA2539253A1 (en) 2005-03-31
AU2004273573A1 (en) 2005-03-31
BRPI0414539B1 (en) 2020-12-29
IL174154A (en) 2013-09-30
AU2010203063B2 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
EP2932981B1 (en) Albumin-binding derivatives of GLP-1
US7893017B2 (en) Protracted GLP-1 compounds
US9409966B2 (en) Glucagon-like peptide-1 derivatives and their pharmaceutical use
US8772232B2 (en) Protracted exendin-4 compounds
US9067977B2 (en) Peptides derivatized with A-B-C-D- and their therapeutical use
US20090005312A1 (en) Novel glp-1 analogues linked to albumin-like agents
US20090062192A1 (en) Dimeric Peptide Agonists of the Glp-1 Receptor
WO2009030774A1 (en) Truncated glp-1 derivatives and their therapeutical use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480030018.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 174154

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1313/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004273573

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006/02000

Country of ref document: ZA

Ref document number: 200602000

Country of ref document: ZA

Ref document number: 2004762844

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/002941

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2539253

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020067005530

Country of ref document: KR

Ref document number: 2006526519

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004273573

Country of ref document: AU

Date of ref document: 20040917

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004273573

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006107600

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004762844

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067005530

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0414539

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2007203058

Country of ref document: US

Ref document number: 10572348

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10572348

Country of ref document: US